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Abstract 
About 50% of patients with the clinical features of chronic heart failure suffer from heart 
failure with preserved ejection fraction (HfpEF); (1, 2) Previous data have demonstrated that 
patients with HfpEF had abnormal left ventricle (LV) relaxation and increased LV stiffness. 
Consequently the left ventricular diastolic pressure-volume relationship is shifted upwards 
and to the left. (1) In addition, enhanced left ventricular stiffness can result in increased 
end-diastolic pressure (EDP) during handgrip exercise. (2) Our studies demonstrate that 
patients with HfpEF have impaired myocardial energetics as indicated by the diminished in 
vivo myocardial PCr/ATP ratio. (3) Which might provide a scientific rationale for the 
potential use metabolic modulators such as perhexiline in HfpEF, which may improve 
cardiac energetics and therefore improve LV relaxation and exercise capacity. Data acquired 
during semi-supine cycling exercise indicates that patients with HfpEF had a dynamic 
impairment of LV active relaxation. (3) In addition, ventricular-vascular coupling ratio was 
unchanged during exercise in HfpEF patients in contrast to healthy controls where the ratio 
fell substantially during exercise, suggesting a failure of the normal increase in LV contractile 
function during exercise. In addition, we found in a group of HfpEF patients with normal LA 
dimensions that there was increased LA contribution during exercise in patients with HfpEF 
compared to matched controls. (4) This may be an attempt to compensate for the observed 
reduction in LV relaxation. Furthermore, we showed patients with HfpEF exhibits contractile 
inefficiency as well as systolic and diastolic dyssynchrony as measured by speckle tracking 
imaging (STI). And that the LV anterior wall appears to be the most delayed segment 
providing a probable target for a pacing site. 
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Another potential cause of exercise limitation is autonomic dysfunction. We studied a 
cohort of HfpEF patients who were not on heart rate (HR) limiting medication and found 
that patients with HfpEF exhibited chronotropic incompetence during peak exercise testing 
and abnormal HR recovery following exercise compared to age-gender-matched healthy 
controls and hypertensive patients. (5) In a separate study, we showed that changes in LV 
torsion, untwist and LV strain and strain rate in patients with HfpEF at rest were similar to 
changes found in normal aging. (6) Our studies suggest that the pathophysiology of the 
HfpEF is one of a dynamic process with complex interaction between various processes such 
as increased LV stiffness, abnormal myocardial energetic, increased central arterial tree 
stiffness, abnormal autonomic functions and other factors such as cardiac dyssynchrony and 
contractility inefficiency.  
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Introduction 
 
The prevalence of chronic heart failure (CHF) is increasing and it is a leading cause of 
morbidity and mortality in developed countries (7) and  an emerging one in the developing 
world. (8) The mortality of CHF at five years remains about 50%, which is similar to the 
prognosis for many cancers.(9) Heart failure is, therefore, a major clinical problem. 
Attention has focused mainly on those patients with left ventricular (LV) systolic 
dysfunction, as evidenced by a reduced LV ejection fraction (LVEF). The epidemiology and 
pathophysiology of such patients is well described, and treatment has improved 
substantially over the past 10-15 years. There is increasing consensus that about 50% of 
patients with the clinical features of chronic heart failure suffer from heart failure with 
preserved ejection fraction (HFpEF); (10, 11) epidemiological observations from different 
populations confirm that the prevalence of HFpEF is increasing, especially in obese 
hypertensive females. HFpEF causes as many hospitalizations and incurs as severe morbidity 
as heart failure with reduced LVEF. Finally, HFpEF portends a significant and un-improving 
mortality. (12) Recent epidemiological studies suggests that the leading cause of death in 
patients with HfpEF is non-cardiovascular whereas it is coronary artery disease in patients 
with systolic heart failure (SHF), and that the proportion of cardiovascular death reduced 
over time in patients with HfpEF. (13)  
 
The available epidemiological data suggests that these patients are, as a group, older, more 
commonly female, and more frequently have systolic hypertension (associated with stiff 
large arteries) than those patients with a reduced LVEF (14). Patients may present with 
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chronic symptoms of breathlessness and/or fatigue, and/or acutely in ‘flash’ pulmonary 
oedema (15).  
 
Diagnostic criteria 
Differentiation between systolic heart failure and HfpEF in patients presenting with chronic 
symptoms cannot be made at the bedside on the basis of the history, examination, ECG, or 
chest X-Ray alone (16). At present the epidemiology, pathophysiology and therapy of HFpEF 
is poorly understood, in part because of the absence of robust widely accepted diagnostic 
criteria. 
 
The European Society of Cardiology proposed the following criteria for the diagnosis of 
HFpEF (17): (a) signs or symptoms of heart failure, (b) presence of normal or mildly 
abnormal LV systolic function, and (c) evidence of abnormal LV relaxation, filling, diastolic 
distensibility, and diastolic stiffness. (Fig. 1) This was a consensus document and it has not 
been validated or used in clinical studies.  
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Figure 1: Flow chart from 2007 ESC guidelines ‘How to diagnose diastolic heart failure’. (17) 
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The Vasan and Levy criteria for ‘diastolic heart failure’ (DHF) proposed a few years earlier 
were also slightly similar but placed less emphasis on the presence of normal ejection 
fraction (EF) as this potentially could lead to underestimation of heart failure. (18) They 
proposed criteria of definite, probable and possible DHF. (Table 1) 
 
 
If all 3 criteria are met, the diagnosis of “definite” diastolic heart failure is made. In the 
absence of cardiac catheterization data, a diagnosis of “probable” diastolic heart failure is 
made. If the EF was not measured near the time of the heart failure and the patient 
presented with CHF and catheterization was not performed, then a diagnosis of “possible” 
diastolic heart failure is made. (Table from Yturralde and Gaasch (19)) 
 
One of the main differences between the Vasan and Levy criteria and the ESC guidelines was 
that in the ESC guidelines they accepted diastolic dysfunction as determined by either 
catheterization or echocardiography, whereas in the Vasan and Levy criteria, cardiac 
catheterization was required for a definite diagnosis of DHF.  
 
What both of these proposals have in common is that they require the evidence of 
abnormal LV relaxation, filling, diastolic dispensability, and diastolic stiffness.  However, 
whether it is necessary to have evidence of diastolic dysfunction to have HFpEF is 
Table 1: Vasan and Levy Criteria for Diastolic Heart Failure 
 
1. Reliable evidence of CHF (Framingham or Boston criteria) 
2. Objective evidence of normal LV EF (EF >50% within 72 h of CHF event) 
3. Evidence of LV diastolic dysfunction (cardiac catheterization is required) 
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controversial especially when measuring LV diastolic function is fraught with difficulties and 
most indices of diastolic function are load dependent. (20) To fully assess ventricular 
relaxation, high-fidelity measures of LV pressure must be obtained at cardiac 
catheterization. Because diastolic compliance falls in a curvilinear fashion with increasing 
pressure, assessment of passive diastolic stiffness requires measurement of end-diastolic 
pressure-volume relations over a variety of preloads (e.g. using IVC balloon occlusion) and is 
clearly impractical as a routine. Some believe that the measurements of relaxation rates 
have no diagnostic value. (21) Indeed, in a study of Zile et al (22), they showed that the 
diagnosis of HFpEF can be made without measurement of LV relaxation and passive stiffness 
and concluded that the measurement of LV diastolic dysfunction serves to confirm rather 
than establish the diagnosis of HFpEF. 
 
Several features of diastolic dysfunction can be assessed on echocardiography. The most 
commonly used is transmitral flow on pulse-wave Doppler analysis. A ‘delayed relaxation’ 
pattern (reversal of the E/A ratio) is often referred to as indicating ‘diastolic dysfunction’. 
However, resting diastolic abnormalities are frequently present in healthy elderly subjects 
(23) and it does not necessarily predicts clinical heart failure (24) nor exertional dyspnoea 
(25). When LV end-diastolic pressure rises, a ‘pseudo normal’ or ‘restrictive’ pattern may 
supervene (26). (Fig 2) 
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Figure 2: The abnormal relaxation pattern (mild diastolic dysfunction) is brought on by 
abnormally slow left ventricular relaxation, a reduced velocity of early filling (E wave), an 
increase in the velocity associated with atrial contraction (A wave), and a ratio of E to A that 
is lower than normal. In more advanced heart disease, when left atrial pressure has risen, 
the E-wave velocity and E:A ratio is similar to that in normal subjects (the pseudonormal 
pattern). In advanced disease, abnormalities in left ventricular compliance may supervene. 
In these latter two instances, the E wave of normal to high velocity is a result of high left 
atrial pressure and a high transmitral pressure gradient in early diastole. Therefore, the use 
of transmitral velocity patterns alone to estimate left ventricular filling pressures in patients 
with diastolic heart failure is problematic. Figure from Aurigemma and Gaasch. (27) 
 
In fact, despite this, the presence of a ‘delayed relaxation’ pattern at rest appears not to 
identify elderly subjects with ‘diastolic heart failure’, but rather is associated with a 
significantly greater exercise capacity than the presence of a ‘normal’ filling pattern. (28) In 
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the Strong Heart Study of elderly subjects, the presence of a ‘normal’ E/A profile was 
associated with an increased risk of developing heart failure and of subsequent mortality 
compared with the ‘delayed relaxation’ profile, presumably because a high proportion of 
patients with a ‘normal’ profile actually had a ‘pseudo normal’ pattern (29).  
 
Other echocardiographic measures include the deceleration time of the E wave, which is 
characteristically prolonged in patients with impaired relaxation, and IVRT (Isovolaemic 
relaxation time), which tends to parallel deceleration time. Assessment of pulmonary vein 
flow helps to differentiate between normal and ‘pseudo normal’ patterns (30). Tissue 
Doppler assessment of the mitral annulus during diastole provides a velocity profile of the 
movement of the mitral annulus, and is less preload-dependent than conventional indices of 
transmitral flow.   The mitral annular E wave velocity (Em) is related to the rate of active 
relaxation, and is less influenced by filling pressures than the E wave velocity on transmitral 
flow. The ratio of transmitral E/Em has been shown to correlate well with LVEDP (31, 32). 
Whilst a high E/Em ratio in a patient with symptoms of chronic heart failure but normal LVEF 
is strongly supportive of heart failure, many of these patients have normal or near normal 
estimated LVEDP at rest, and the negative predictive value of a normal E/Em ratio at rest for 
HFpEF may therefore be relatively low. Importantly, as discussed below, diastole is highly 
dynamic and load-dependent, therefore standard resting measures may provide little 
information about diastolic function during exercise. Consequently, even sophisticated 
resting measures of diastolic function may not accurately identify patients with HFpEF. 
 
Metabolic exercise testing can be useful to objectively measure exercise intolerance 
especially in patients with little evidence of congestion or physically deconditioned. As 
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argued by Coats in a recent review, metabolic exercise testing is the nearest one can 
achieve to a ‘’gold’’ standard for evaluating the mechanism of exercise limitation in patients 
with breathlessness on exertion, especially in patients in whom cardiac and respiratory 
disease co-exist. (33, 34) Patients undergo full resting assessment of respiratory function, 
including measurement of MVV (maximum voluntary ventilation) and Transfer Factor (DLCO 
– a measure of lung diffusion). Breath by breath assessment of gas exchange and finger 
oximetry is performed at rest and during incremental exercise. (33, 34) 
 
In the  Yturralde and Gaasch diagnostic criteria for diastolic heart failure (19) they 
incorporate the use of metabolic exercise testing and does not stipulate the presence of 
diastolic dysfunction as a major criteria. In the Yturralde and Gaasch criteria, emphasis is 
placed on clinical evidence of DHF and the presence of normal LVEF and LV chamber size. 
Confirmatory evidence such as the presence of LVH or LA enlargement or diastolic 
dysfunction (echocardiographic Doppler or catheterization) is then required to make a 
definite diagnosis of DHF. (Table 2) 
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Table 2: Yturralde and Gaasch diagnostic Criteria for diastolic heart failure 
 
Major criteria 
1. Clinical evidence of heart failure 
 Framingham or Boston criteria 
 Plasma BNP or chest x-ray 
 Cardiopulmonary exercise testing 
2. Normal LV EF and chamber size 
 Data are contemporary with item 1 
 
Confirmatory evidence 
1. LV hypertrophy or concentric remodeling 
2. Left atrial enlargement (in absence of atrial fibrillation) 
3. Echocardiographic Doppler or catheterization evidence of diastolic 
dysfunction 
 
If the 2 major criteria are met and there is evidence of LV hypertrophy or left atrial 
enlargement, the diagnosis of definite diastolic heart failure can be made. In the absence of 
hypertrophy or left atrial enlargement, it can be appropriate to make a tentative diagnosis 
of probable diastolic heart failure and require confirmatory evidence before making a 
diagnosis of definite diastolic heart failure. Valvular heart disease should be excluded. Table 
adapted from Yturralde and Gaasch for diastolic heart failure (19) 
 
Acute pulmonary oedema in HFpEF 
Patients with HFpEF often have markedly labile symptoms, and can present not only with 
chronic symptoms of breathlessness and/or fatigue, but also in pulmonary oedema, which 
may occur with very rapid onset (‘flash’ pulmonary oedema). Recent studies have shown 
that up to 30-40% of patients presenting to the emergency department with clear cut acute 
pulmonary oedema have normal LVEF measured within 2 hours of arrival, and Gandhi et al 
reported no significant difference between LVEF measured before and after stabilization 
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(35). This does not entirely exclude the possibility of transient systolic dysfunction that had 
fully recovered by the time of initial echocardiography. Some episodes of ‘flash’ pulmonary 
oedema in patients with HFpEF may be precipitated by acute myocardial ischaemia by one 
of three mechanisms: (a) transient systolic dysfunction, (b) ischaemia-mediated diastolic 
dysfunction, or (c) ischaemia-mediated mitral regurgitation (36, 37). Other precipitating 
factors may include arrhythmias (especially paroxysmal atrial fibrillation), and bilateral renal 
artery stenosis (38). However, many cases remain unexplained.  
 
A majority of patients with HFpEF often have normal LV end-diastolic volume (39) and LVEF 
with a low stroke volume and reduced cardiac output. (22) Studies have also found that LA 
volume indexed to body surface area was a stronger predictor of cardiovascular event in the 
elderly than LV mass index or LV diastolic dysfunction, (40) and that LA volume is a marker 
of LV diastolic dysfunction in patients with heart failure and normal LVEF. (41, 42) LA volume 
has also been shown to predict cardiovascular event in patients with diastolic dysfunction. 
(43, 44)   In a study of a predominantly African American cohort of patients with 
hypertensive left ventricular hypertrophy (LVH), it was shown that those with and without 
features of HFpEF had similar systolic, diastolic and vascular function, however the cohort 
with features of HFpEF differed predominantly because they had evidence of left atrial 
dilatation and left atrial ‘failure’.  (45) In a separate community study, LA fractional area 
change (a measure of LA emptying volume) was found to be reduced at rest in community 
older patients (≥65) with diastolic heart failure. (46)  
 
The problem with atrial dilatation is that it can contribute to alterations in LA pressure and 
therefore reduced early diastolic filling. (47) Furthermore LA dilatation in HFpEF is 
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associated with reduced LA function (45), reduced LA strain (during systole) and increased 
LA stiffness (48), the combination of which might compromise atrial contraction  and  
therefore might compromise or worsens diastolic filling. Indeed, when these HFpEF patients 
develops atrial fibrillation which is not uncommon (11, 12), the consequence is more severe 
diastolic dysfunction as well as increase hospitalization or death. (49) 
 
Systolic abnormalities in HFpEF 
Recently, the concept that diastolic dysfunction is responsible for HFpEF has been 
challenged. The term ‘diastolic’ heart failure is often used on the assumption that diastolic 
dysfunction underlies the pathophysiology, but more recently the term ‘heart failure with 
preserved ejection fraction’ (HFpEF) has become popular because it makes no presumptions 
about the pathophysiology. Many consider HFpEF to be a disorder of diastolic function (50), 
whilst others believe that it may be due to a combination of diastolic abnormalities with 
subtle disturbances of systolic function that are  insufficient to reduce LVEF (51). Whilst 
echocardiographic LVEF is preserved in these patients, regional wall motion abnormalities 
may be missed and abnormal ‘long axis’ systolic function has also been reported (52, 53) 
Impairment of long axis systolic function is initially compensated for by enhanced radial 
function, therefore global LVEF is preserved (52-55).  In addition, studies using tissue 
Doppler imaging (TDI) have demonstrated the presence of diastolic and/or systolic 
dyssynchrony in patients with HFpEF (56, 57). According to this paradigm, diastolic heart 
failure is a misnomer and represents a phase in the evolution of heart failure where the 
LVEF is still within the ‘normal’ range.  Advocates of this view argue that the increased 
diastolic LV stiffness reported in patients with HFpEF might be the result rather than the 
cause of the raised LVEDP, because compliance decreases as diastolic pressure increases. As 
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noted above, assessment of ‘passive’ LV stiffness requires the evaluation of LV pressure and 
volume across a wide range of filling conditions. ‘Passive’ LV stiffness is not consistently 
increased in patients with HfpEF (58). Table 3 summarises the similarities and differences 
between diastolic heart failure and systolic heart failure. 
 
 
* The clinical features of diastolic heart failure are similar to those of systolic heart failure, 
but left ventricular structure and function are distinctly different.  
† The descriptor of left ventricular geometry is the relative wall thickness, defined as the 
ratio of left ventricular wall thickness to the radius of the left ventricular cavity. (Table 
adapted from Aurigemma and Gaasch(27)). 
 
Left ventricular stiffness in HFpEF 
Diastolic function is influenced by passive elastic properties of the LV and by energy 
dependent process of active relaxation. Increased myocardial mass or changes in extra-
Table 3: Characteristics of Diastolic Heart Failure as Compared with Those of 
Systolic Heart Failure.* 
Characteristic Diastolic heart 
failure 
Systolic heart 
failure 
Clinical features   
Symptoms (e.g., dyspnea) Yes Yes 
Congestive state (e.g., edema) Yes Yes 
Neurohormonal activation (e.g., 
brain natriuretic peptide) 
Yes Yes 
Left ventricular structure and function 
Ejection fraction Normal Decreased 
Left ventricular mass Increased Increased 
Relative wall thickness† Increased Decreased 
End diastolic volume Normal Increased 
End diastolic pressure Increased Increased 
Left atrial size Increased Increased 
Exercise   
Exercise capacity Decreased Decreased 
Cardiac output augmentation Decreased Decreased 
End diastolic pressure Increased Increased 
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myocardial collagen (50) network can cause increased LV passive diastolic stiffness at rest 
(1). Recently there has been increased interest in the molecule titin which is a large 
cytoskeletal protein which contributes to resting stiffness of the myocardium. (59)Titin is a 
giant molecule which spans the entire half-sarcomere from the M-line to the Z-line. It is 
responsible for passive and restoring forces within the myofilament during sarcomere 
elongation and compression respectively (60). Titin appears to be the major determinant of 
passive force development at shorter slack length (61, 62). Titin also acts as a spring during 
shortening below slack length, generating a restoring force which opposes further 
shortening (61). It is expressed in two major isoforms via differential splicing. This results in 
two isoform transcripts; N2BA (long isoform) and N2B (short isoform), which may coexist 
within the same sarcomere (63). The expression ratio of these isoforms demonstrates 
interspecies variation, as well as variability in different locations within the heart (63). 
Changes in isoform expression have been demonstrated in certain pathological states. A 
recent study showed that in patients with dilated cardiomyopathy there was a shift towards 
increased expression of the longer N2BA isoform, which correlated with both lower LV 
stiffness and an improvement in diastolic function (64). 
 
In the canine rapid pacing heart failure model a change in isoform expression towards the 
shorter N2B isoform has been reported, which may account in part for the higher passive 
ventricular stiffness which develops in this model (65). Spontaneously hypertensive rats 
were shown to have a higher N2B/N2BA expression ratio than the normotensive WKY rat, 
potentially explaining the higher passive ventricular stiffness of the former. (66) A recent 
study by van Heerebeek et al examined shifts in titin isoform expression between patients 
with systolic and diastolic heart failure. (67) In this small, highly selected group (n=4 with 
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DHF, n=5 with SHF) they demonstrated a shift towards the stiffer N2B isoform in the DHF 
group and a shift towards the longer N2BA isoform in the SHF group when compared with 
previously publishes results from healthy controls (68). These healthy control samples were 
obtained from normal donor hearts. However, the authors do not state the mean age of this 
group, and it is unlikely that they were age-matched. Although invasive haemodynamic 
studies were performed in the group with DHF, there was no mentioned of measures of LV 
end-systolic elastance or arterial elastance, and their correlation to the titin isoform 
expression ratio.  
 
Cardiac myocytes that express predominantly N2BA have a longer extensible region and are 
predicted to develop less force than those that express predominantly N2B. Passive stiffness 
of cardiac myocytes is much higher in N2B-expressing myocytes than in N2BA myocytes, 
thus a change in titin isoform expression may (together with increased collagen content) 
contribute to the increase in passive LV diastolic and systolic stiffness in patients with 
HFpEF. A shift to expression of the shorter N2B isoform in response to increased arterial 
stiffness would increase ‘contractility’ (to compensate for increased aortic impedance) at 
the price of increased LV systolic stiffness (and leading in turn to dynamic impairment of LV 
active relaxation during acute increases in blood volume and/or exercise). 
 
When titin is phosphorylated by protein A, the LV stiffness is reduced which improves LV 
diastolic compliance and diastolic filling during sympathetic stimulation (i.e. during 
exercise).  (59, 69) In patients with HFpEF, van Heerebeek et al found a reduced ratio of 
N2BA to N2B titin isoforms because of the greater increased in the stiffer N2B which may 
contribute to the observed high diastolic stiffness in HFpEF. (67) Indeed, in patients with 
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dilated cardiomyopathy the converse has been observed that is increased levels of the less 
stiff N2BA isoform. (64)  
 
Zile et al studied 47 patients and 10 controls to assess LV diastolic function by means of 
cardiac catheterization to assess diastolic pressure-volume relationship. (1) They 
demonstrated that patients with HFpEF had abnormal LV relaxation and increased LV 
stiffness. The diastolic pressure-volume relationship was also shifted up and to the left. 
(Figure 3) 
 
Figure 3: Left Ventricular Pressure–Volume Loops in Systolic and Diastolic Dysfunction. 
In systolic dysfunction, left ventricular contractility is depressed, and the end-systolic 
pressure–volume line is displaced downward and to the right (Panel A, black arrow); as a 
result, there is a diminished capacity to eject blood into the high-pressure aorta. In diastolic 
dysfunction, the diastolic pressure–volume line is displaced upward and to the left (Panel C, 
black arrow); there is diminished capacity to fill at low left-atrial pressures. In systolic 
dysfunction, the ejection fraction is depressed, and the end-diastolic pressure is normal 
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(Panel A, open arrow); in diastolic dysfunction, the ejection fraction is normal and the end-
diastolic pressure is elevated (Panel C, open arrow). (Figure from Aurigemma and Gaasch  
(27)). 
A subsequent study by Westermann et al (2), involving  pressure-volume loop analyisis with 
and without atrial pacing in 70 HFpEF patients and 20 matched-controls, found that 
enhanced left ventricular stiffness can result in increased end-diastolic pressure (EDP) 
during handgrip exercise. In addition during atrial pacing, pacing with HFpEF displayed 
decreased stroke volume, bearing in mind that these patients were resting in supine 
position and thus to artificially increase HR by atrial pacing might not reflect true 
physiological exercise conditions. At the very least, these data suggest that left ventricular 
stiffness can modulate cardiac function in HFpEF patients. 
 
Systolic and diastolic function during exercise  
Diastolic abnormalities may involve active ventricular relaxation and/or passive ventricular 
filling. The physiological increase in the rate of LV active relaxation during exercise is a 
consequence of sympathetic activation, via cAMP-dependent protein kinase (PKA) mediated 
phosphorylation of key proteins including Troponin I, Sarco/Endoplasmic Reticulum Ca2+-
ATPase (SERCA) and Titin. (70-72) Consequently, in health even at high heart rates 
associated with maximal exercise, it has been shown that the rate of LV relaxation should 
not limit LV filling (73).  
 
Exercise data in HFpEF is scarce. In a small study by Kitzman et al 7 patients with HFpEF and 
10 matched controls underwent invasive cardiopulmonary exercise testing. HFpEF patients 
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had a shift of the LV end-diastolic pressure volume relation upward and to the left at rest, 
however during exercise increases in LV filling pressure during exercise were not 
accompanied by increases in end-diastolic volume index (EDVi), indicating limitation to LV 
filling during exercise and a failure of the Frank-Starling mechanism. (74) More recently a 
study conducted by Kawaguchi et al, reported in a relatively small number of HFpEF patients 
(n=10) a dynamic impairment of left ventricular active relaxation during isometric (handgrip) 
exercise. (58) This abnormal relaxation during dynamic exercise has previously been 
described in other related conditions. In a study of patients with asymptomatic essential 
hypertension, it was found that hypertensive patients (with LVEF either increased by <5% or 
decreased with exercise) had impaired diastolic filling during exercise. (75) In another study 
conducted by our group in patients with non-obstructive hypertrophic cardiomyopathy, a 
classic paradigm of diastolic heart failure, we found that exercise left ventricular diastolic 
filling characteristics were major determinant of peak exercise capacity. (76)  
 
In a study by Borlaug et al (77) , 17 HFpEF patients and 19 matched controls were studied at 
rest and during exercise using radionuclide ventriculography to assess chronotropic, 
systemic vasodilatation, and cardiac output responses to exercise. They found that HFpEF 
patients had impaired chronotropic and systemic vasodilatation responses to exercise 
compared to matched-controls. Ennezat et al (78), studied 25 HFpEF patient and 25 
hypertensive matched-controls using exercise echocardiography. They found that patients 
with HFpEF had reduced arterial elastance response to exercise which was accompanied by 
reduced systolic function as measured by LVEF, stroke volume and cardiac output. In 
another study by Ha et al (79), 141 patients with abnormal LV relaxation as defined by 
echocardiographic mitral inflow Doppler measurements (mitral E/A <0.75 and/or 
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deceleration time >240 ms) underwent exercise echocardiography with respiratory gas 
analysis. They found that patients with low LV diastolic function reserve index had higher 
ventricular elastance during exercise and reduced exercise capacity. 
 
Ventricular-vascular coupling  
The interaction between the heart and the systemic vasculature, termed ventricular-
vascular coupling (VVC) is essential for the heart to achieve maximal cardiac work, power 
and chamber efficiency while maintaining physiological blood pressures and cardiac 
outputs. (80, 81) Figure 4 demonstrates the relationship between stroke work and VVC 
coupling in isolated canine hearts. 
VVC is indexed by the ratio arterial elastance/end-systolic elastance. End-systolic elastance 
(Ees) is calculated from the slope of the end-systolic pressure-volume relation. Arterial 
elastance (Ea) is a measure of impedance and is determined by the ratio of end-systolic 
pressure/stroke volume. The VVC ratio in normal humans ranges between 0.7 and 1.0, the 
range of optimal function.(82, 83) In patients with chronic heart failure (CHF) this VVC ratio 
is typically high as Ees decreases (poor ventricular contractile function) and a rise in Ea 
(arterial resistance). Such high ratio leads to poor ventricular performance and metabolic 
efficiency. (82, 83) (Figure 4) 
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Figure 4:  Mean data obtained in isolated canine hearts, demonstrating the dependence of 
left ventricular stroke work on ventricular-vascular coupling (as indexed by the ratio of 
Ea/Ees). Over an Ea/Ees ratio spanning 0.3 to 1.3, left ventricular stroke work and cardiac 
metabolic efficiency is near optimal, whereas both decline at much higher or lower ratios. 
From De Tombe et al  (84) 
 
Aging is associated with increases in Ea (85) which in turn increases the load on the heart by 
increasing systolic wall stress. (86) Aging is also associated with increases in Ees which 
therefore preserve the VVC ratio and therefore preserving cardiac chamber power, stroke 
work and efficiency. (85) However, in women the VVC ratio declines modestly because of a 
disproportionate increase in Ees compared to Ea. (87) VVC ratio typically falls with exercise, 
as Ees (contractility) increases more than the increase in Ea (afterload) to augment cardiac 
output and blood pressure. (88) With aging, the exercise drop in VVC ratio becomes 
compromised, which in part contributes to the age-dependent reduction in aerobic capacity. 
(88) 
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However, there are consequences to an increased ventricular-vascular stiffness which 
includes reduced reserve mechanisms and hemodynamic instability. The hemodynamic 
consequences of an increased ventricular-vascular stiffness are reduced left-sided 
circulatory compliance which can lead to large changes in LV end-systolic pressure for a 
given change in ejected volume. This means for the heart, any modest rise in central blood 
volume (e.g. venoconstriction or increased blood volume) can result in exaggerated changes 
in systolic pressure. Furthermore, increased vascular stiffness can result in dramatic 
alterations in arterial pressures for a given change in cardiac output from the heart. (85) Ea 
usually rises because of increased heart rate and increased arterial pulsatility despite a fall 
in peripheral vascular resistance. (86) Elevated Ea can exacerbate systolic hypertension 
during exercise which increases energetic demand on the heart and raises myocardial 
oxygen consumption. (86) Enhanced LV contractility is reflected by a rise in Ees, however 
when there is elevated basal Ees and Ea there is consequently less reserve.  
Many patients with HFpEF are hypertensive, typically with isolated ‘systolic’ hypertension. 
Systolic hypertension is predominantly due to increased large artery stiffness and results in 
an increased pulsatile left ventricular afterload (impedance) often leading to left ventricular 
hypertrophy. A recent study showed that in older patients with ‘diastolic’ heart failure, 
impaired exercise tolerance correlated with aortic stiffness, which was significantly 
increased compared with age-matched controls (89). In a separate study, patients receiving 
verapamil was found to have increased exercise capacity, in association with a reduced 
resting pulse wave velocity and carotid pressure augmentation, implying improved large 
artery distensibility (90).  
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In patients with HFpEF, the VVC ratio falls compared to younger individuals (85) but similar 
to asymptomatic hypertensive elderly patients (45, 91) and falls within a range where 
cardiac work and efficiency are not compromised. (84) However, although the VVC ratio is 
preserved in patients with HFpEF, the absolute values of Ees and Ea are considerably 
elevated. HFpEF have increased vascular and ventricular stiffness in both systole and 
diastole. (1, 91) (Figure 5). Table 4 summarises the harmful hemodynamic effects of 
increased ventricular and vascular stiffness.  
 
Studies in healthy subjects have found that during exercise, VVC coupling decreases in both 
genders but to a lesser extent in older healthy subjects. (88) (Figure 6) This lead to the 
postulation that sub-optimal VVC coupling may be associated with blunting of maximal 
exercise ejection fraction. To date, no dynamic exercise data exists for VVC coupling in 
patients with HFpEF. However we can get some idea from a study that used hand grip 
exercise during invasive pressure-volume loop studies to derive the VVC coupling. 
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Figure 5: Increased Ees and Ea in a patient with Heart Failure normal Ejection Fraction (B) 
compared with an age matched healthy control (A). There is near matching of Ees and Ea in 
the control subject, compared with a disproportionate increase in Ees compared with Ea in 
the Heart Failure normal Ejection Fraction patient. (C) Group data showing the correlation 
between Ea and Ees (left) and the Ea/Ees coupling ratio for each subgroup (right). The HfpEF 
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patients show a lower coupling ratio compared with normotensive age-matched controls. 
Reproduced from Kawaguchi M et al (58)) 
 
Figure 6: Ventricular-vascular coupling at rest and during exercise in healthy subjects 
defined by age and gender. (Figure from Najjar SS et al   (88)) 
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Table 4: The pathophysiology of ventricular vascular stiffening 
Abnormality Hemodynamic consequences Clinical relevance 
Increased Ventricular 
Systolic Stiffness 
Exaggerated change in blood 
pressure for a given change in 
preload or afterload 
Hypotension and oliguria with 
slight over-diuresis or the 
addition of a new vasodilator 
agent 
 Lower contractile reserve Modest volume infusion leads to 
hypertension and/or acute 
pulmonary edema 
 Lower stroke volume reserve Impaired exercise tolerance and 
functional disability 
  Greater energetic cost to eject a 
given stroke volume 
Increased myocardial oxygen 
demand and ischemia  
Increased Arterial 
Stiffness 
Exaggerated change in blood 
pressure for a given change in 
preload or contractility 
Hypotension and oliguria with 
slight over-diuresis or the 
addition of a new vasodilator 
agent 
 Increased total afterload, wave 
reflections and late systolic load 
Modest volume infusion leads to 
hypertension and/or acute 
pulmonary edema 
 Greater dependence upon 
systolic pressure for coronary 
flow 
Impaired relaxation and 
decreased LV diastolic 
compliance, prolonged systole, 
abbreviated diastole 
 Abnormal endothelial 
mechanotransduction 
Increased ischemia and infarct 
size for a given drop in systolic 
blood pressure 
    Endothelial dysfunction, 
abnormal vasodilation response 
to stress 
 
Table adapted from Borlaug and Kass (92) 
 
In a recent invasive hemodynamic study (58), a small group of patients with HFpEF were 
compared with healthy age and gender matched controls. LV pressure volume loops were 
constructed before and during acute balloon occlusion of the inferior vena cava. Ees was 
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then calculated by measuring the slope of this pressure/volume relation. Ees is a measure of 
end-systolic LV elastance (∆P/∆V). Ea was calculated as the ratio of end-systolic 
pressure/stroke volume, and is a measure of impedance (being influenced by static and 
pulsatile afterload and by heart rate). In HFpEF patients both of these relations were 
considerably steeper than in controls (i.e. for a given increase in systolic volume these 
patients demonstrated much larger increases in LV end-systolic pressure (LVESP))(58). 
Active cardiac relaxation is slowed by large acute increases in LV ‘afterload’ (93), and, 
consistent with this, during handgrip exercise 
 
Patients with HfpEF demonstrated an increase in time constant of the left ventricular 
isovolemic pressure decline (Tau (τ)) (from resting values which were near normal) in 
contrast to healthy controls where τ had reduced as one would expect. This slowing of 
active relaxation resulted in an exercise-related impairment of LV filling in these patients, 
causing an upward displacement of the LV end-diastolic pressure-volume relation (Figure 7). 
Thus although passive chamber stiffness and τ were normal in some patients at rest, both 
became markedly abnormal during handgrip exercise, a finding that is supported by our 
previously performed non-invasive study during dynamic exercise (94). This small study 
provides a potentially attractive link between increased large artery stiffness and exercise-
induced diastolic dysfunction. It may also explain how small changes in fluid balance may 
precipitate ‘flash’ pulmonary oedema in patients with HFpEF. However, the study 
population was highly selected – a total of 10 patients over a four year period.  
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Figure 7: An example of pressure volume loops taken from patients with HfpEF at baseline 
and with acute increases in Ea induced by isometric handgrip (arrows). Because of elevated 
baseline stiffness, the “gain” is much greater with further increases, leading to severe 
hypertension. Note the greatly increased end-diastolic LV pressures during handgrip. (Figure 
from Kawaguchi et al (58)) 
 
Afterload and effects on LV active relaxation 
Animal studies have demonstrated that a large acute increase in afterload in the rabbit 
resulted in a marked slowing of active relaxation and impaired left ventricular LV diastolic 
filling (93). A key coupler of this load dependent LV relaxation is Troponin I – Protein Kinase 
A (TnI-PKA) phosphorylation (95). This energy dependent process of phosphorylation of 
Troponin I by PKA decreases myofibrillar calcium sensitivity (96) and increases the rate at 
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which calcium dissociates from Troponin C (97) which can lead to increase rate of LV 
relaxation by increasing the rate of thin filament deactivation. Indeed, in a study involving 
transgenic mice in which PKA phosphorylation sites on Troponin I were constitutively active, 
acute aortic constriction led to a lengthening of τ in the wild type mice but not in the 
transgenic mice. (95).  
 
Data from canine models suggests that the acute increase in afterload required to cause a 
slowing of active relaxation may be much less in a diseased compared with a healthy heart. 
Indeed in healthy hearts, modest elevations of afterload increase the rate of LV active 
relaxation, and a slowing of active relaxation is only observed with large acute increases in 
afterload. These findings can be explained by the concept of relative load, which represents 
the ratio of systolic LV pressure to isovolumetric LV pressure (98). A similar systolic LV 
pressure represents a higher relative load in the failing than in the normal heart. When 
relative load is low, afterload reserve is still available allowing the heart to face increased 
afterload without slowing of LV active relaxation. When relative load is high, afterload 
mismatch (99) occurs and a pronounced slowing of LV active relaxation is observed (98).  
 
Myocardial energetics and LV active relaxation 
The hypothesis that heart failure is due to energy-starvation has been around for decades. 
(100) Under aerobic condition the heart generates its energy primarily from free fatty acids 
(FFA) in particular long-chain fatty acids (LCFA), accounting from 60-90% of the energy 
generated. (101) Carbohydrate metabolism accounts for about 10-40% of energy generated 
by the heart, although the healthy heart is omnivorous – adapting its ‘diet’ as required 
(102). In contrast, the fetal heart utilizes predominantly glucose as its energy substrate and 
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the switch to free fatty acids metabolism occurs in the early postnatal period (103). During 
ischaemia there is a shift to relatively greater glucose metabolism. As noted below, FFA 
utilization requires more oxygen per unit of ATP generated than glucose utilization. Analysis 
of human biopsy specimens has shown a 25-30% reduction in [ATP] levels in the failing 
human heart. (104, 105) There is good evidence from cardiac magnetic resonance 
spectroscopy (MRS) studies of impaired myocardial energetic status in patients with systolic 
heart failure (106), and in patients with insulin resistance (107, 108). Hypertrophic 
cardiomyopathy (HCM), a paradigm of diastolic heart failure also displays impaired cardiac 
energetics as shown by a diminished resting PCr/ATP ratio. (109, 110) 
In the canine rapid pacing heart failure model a reduction in high energy phosphate status 
precedes objective evidence of impairment of LV systolic function (111). Furthermore, 
normal ageing is also associated with reduced mitochondrial function (112, 113) which may 
further exacerbate energy impairment in heart failure patients. Interestingly our group have 
previously shown that there is typically a dynamic abnormality of active relaxation during 
exercise in HCM, and that peak exercise rather than resting time to peak filling (TTPF, a 
measure of rate of LV active relaxation (114)) correlates strongly with VO2max in these 
patients (76). In a study by Smith CS et al (115) demonstrated in patients with left 
ventricular hypertrophy (LVH) and CHF (with no evidence of CAD) there was a 30% decrease 
in PCr/ATP ratio. Furthermore, there was a reduction in Kfor (which is effectively the fraction 
of the PCr pool that exchanges with ATP each second) by 50% and reduced ATP turnover 
through creatine kinase (CK) reaction (the product Kfor [Pcr]) by 65% compared with normal 
subjects ((P<.001). Interestingly, patients with LVH with normal EF and reduced EF heart 
failure had similar Kfor and cardiac CK flux, thus demonstrating a cardiac energetic deficit in 
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patients with HFpEF. This is supported by animal studies which have indicated that dogs 
with severe LVH exhibited reduced PCr/ATP ratio and that the degree of reduction was 
proportional to the extent of the LVH. (116) 
In the heart, the synthesis of ATP by means of oxidative phosphorylation matches the ATP 
demand demanded by contractile activity. However, when mitochondria become 
dysfunctional, FoF1 ATP synthase hydrolyses ATP rather than synthesizing it. This may 
provide a mechanism for reduced energy production under conditions of stress (including 
acute increases in LV afterload), leading to impaired LV relaxation due to reduced PKA-
mediated phosphorylation of Troponin I or potentially to reduced SERCA activity.  
 
Hypothesis 
Data from these previous studies has led us to hypothesize that in HfpEF there is a dynamic 
patho-physiological process that occurs during exercise which results from disturbances in 
the ventricular-vascular coupling ratio, abnormal LV active relaxation, and an underlying 
reduction in myocardial energetic reserves. This leads to impaired exercise tolerance and 
symptoms in patients with HfpEF particular during exertion. (Figure 8) 
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Figure 8: The paradigm 
 
 
 
Pathophysiology of HfpEF 
 
[39] 
 
 
 
Methods 
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 Methods  
Study Participants 
HfpEF patients 
A total of fifty patients were recruited or referred from heart failure specialist clinics for 
screening. 41 patients fulfilled the criteria for HfpEF and were prospectively and 
consecutively recruited. They had i) signs and/or symptoms of heart failure, ii) normal LVEF 
and chamber size iii) objective evidence of exercise limitation on cardiopulmonary exercise 
testing (peak VO2 <80% of predicted) with a pattern of gas exchange indicating a cardiac 
cause for limitation exercise capacity, and (iv) absence of objective evidence of lung disease 
on formal lung function testing and/or absence of arterial desaturation during exercise and 
with a ventilatory reserve at peak exercise ≥ 15L. This is consistent with Yturralde and 
Gaasch criteria for diastolic heart failure. (19) All study participants had clinical examination, 
12-lead electrocardiogram, pulmonary function test, echocardiogram and metabolic 
exercise test. Patients with severe pulmonary disease, significant valvular heart disease, 
atrial fibrillation, or evidence of hypertrophic cardiomyopathy were excluded similar to 
previous studies (77). Some patients were not involved in all the studies because of 
preferences or the presence of contraindications to for example magnetic resonance 
imaging.  
 
Healthy controls 
We studied 53 healthy controls with no cardiac history, hypertension or diabetes mellitus. 
Healthy controls were volunteers recruited prospectively from the community. All control 
subjects had a normal clinical cardiovascular examination, 12-lead electrocardiogram, 
echocardiogram and metabolic exercise test.  
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31P Magnetic Resonance Spectroscopy to Measure In Vivo Cardiac Energetics 
 
31P cardiac magnetic resonance spectroscopy was performed using a Phillips Achieva 3T 
scanner and a linearly polarized transmit and receive 31P coil with a diameter of 14 cm. 
Localization was achieved by ISIS (117) volume selection. The participants were positioned 
supine with the coil directly over the precordium. The coil was secured in place by straps 
wrapped around the upper body and coil. The participants were then positioned inside the 
magnet with the center of the coil at the isocenter of the magnet. Survey images were 
obtained to check the position of the coil (figure1). The subjects and/or the coil were 
repositioned if required to ensure that the distance between coil and septum and apex of 
the heart was minimized. 
 
Localized iterative 1st order shimming was performed including the entire heart using the 
unsuppressed water signal acquired with the body coil as reference. A short axis cine scan 
was acquired to calculate the trigger delay for ECG triggering and check quality of shimming 
and F0 determination. The trigger delay was calculated such that the spectra were acquired 
in the diastolic period. The 3-D voxel of acquisition was planned to include most of the 
septum and apex of the heart (Figure 1). Care was taken to minimize blood contamination 
from the right ventricle as much as possible. The voxel size was kept constant at 89.54ml 
(44x55x37mm3) so that comparisons could be made between different subjects and scans. 
Initially, 1H spectra were acquired from the same voxel without water suppression and 
repetition time of 2000 ms (total scan time of 16 sec). This helped to ensure adequate shim 
quality and correct F0 determination. F0 could be manually adjusted if necessary. Following 
this the 31 P spectrum was acquired with a repetition time of 10000 ms, 136 averages and 
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512 samples. A repetition time of 10000 ms was found to be optimal to adequately reduce 
saturation effects without increasing the scan time greatly. The spectral acquisition was ECG 
gated and the trigger delay was set to acquire spectra mainly in diastole. The trigger delay 
was measured by subtracting 250-300 from the total length of the cardiac cycle which 
allowed 250-300 msec of the cardiac cycle left for spectral acquisition (acquisition time is 
170 msec). The total scan time was 23 minutes. The spectra were analysed and quantified 
on jMRUI software using AMARES a time domain fitting program(118). Post-processing was 
performed with 15Hz Gaussian line broadening and Fourier transformation. Phase 
correction was performed with PCr peak as the reference peak. Quantification was 
performed with AMARES using a prior knowledge file to preselect the peaks. The 
concentrations of PCr, ATP and 2,3-Diphosphoglycerate (2,3-DPG) were calculated as the 
area under the peaks (Figure 2). PCr/ATP ratio was determined after correcting the ATP 
peak for blood contamination as described previously. (119) 
Figure 1: Survey images showing the position of voxel of acquisition and centre of the 31P 
coil.  
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Figure 2: A typical cardiac spectra  
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate;  PDE - Phosphodiesters; ATP - 
Adenosine triphosphate. 
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Exercise Radionuclide Ventriculography 
 
Left ventricular ejection fraction and diastolic filling were assessed by equilibrium R-wave gated 
blood pool scintigraphy using a standard technique at rest and during graded semi erect 
exercise on a cycle ergometer as previously described in detail by our group (76).  Twenty 
minutes after an intravenous injection of 0.03 mg/kg stannous pyrophosphate, 5 mL of blood 
was drawn into a heparinised syringe and incubated for 10 minutes with 750 MBq of 99mTc 
pertechnetate before re-injection. Studies were acquired on a small-field-of-view gamma 
camera fitted with a low-energy, general-purpose, parallel-hole collimator and interfaced to a 
dedicated minicomputer. With the patient on the cycle ergometer (Figure 3), the detector was 
adjusted for the left anterior oblique view with the best ventricular separation and 10° to 15° 
of caudal tilt. A 20% tolerance window was set about the patient's heart rate, and each RR 
interval was divided into 28 equal frames throughout. A constant number of frames per RR 
interval ensure constant temporal resolution during diastole at all heart rates. Three minutes 
of data were acquired at rest and at each level of exercise after a 30-second period for 
stabilisation of heart rate at the commencement of each stage. Exercise was performed at 50% 
workloads of heart rate reserve. In the study of atrial function, exercise was performed at 35% 
of heart rate reserve in order to adequately delineate the early and late filling component of 
diastolic filling because exercise at higher heart rates the early and late peaks of the first-
derivative time-activity-curve are more likely to fuse. The composite cycle derived from each 
stage was spatially and temporally filtered. Left ventricular end-diastolic counts corrected for 
background gamma activity were obtained by means of a semi-automated edge detection 
algorithm. Data were analysed using LinkMedical MAPS software, Sun Microsystems (Figure 4). 
Peak left ventricular filling rate in terms of end-diastolic count per second (EDC/s) and time to 
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peak filling (normalised for heart rate) in milliseconds after end systole were calculated from 
the first derivative of the diastolic activity-time curve. Venous blood samples (≈ 5.0 mL) were 
obtained for weighing and for counting of blood gamma activity during each scan in order to 
correct for physical and physiological decay as well as for determination of relative volume 
changes. (120)  The validity of these radionuclide measures of diastolic filling at high heart rates 
has been established previously. (121, 122)  
 
Rest and exercise systolic (SBP) and diastolic blood pressure (DBP) were determined by cuff 
sphygmomanometry. Pulse pressure (PP) was calculated as the difference between SBP and 
DBP and mean arterial pressure as (2*DBP + SBP)/3. End-systolic pressure (ESP) 
approximated by (2*SBP + DBP)/3. This non-invasive assessment of ESP accurately predicts 
LV pressure-volume loop measurements of ESP. (123) All gated blood pool scan-derived 
volumes were normalized to body surface area, yielding their respective indexes: end-
diastolic volume index, end-systolic volume index (ESVI), stroke volume index (SVI), and 
cardiac index. The following indexes were calculated: a) arterial elastance index (EaI) = 
ESP/SVI; b) LV systolic elastance index (ELVI) = ESP/ESVI and c) arterial-ventricular coupling 
index = EaI/ELVI = (1/EF) – 1. (88)  EaI/ELVI ratio is independent of BP measurements and is 
therefore relatively accurate.   
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Figure 3: A photo of the gamma camera and the cycle ergometer used during the studies. 
Figure 4: An example of a radionuclide ventriculography image and results 
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Metabolic Exercise Testing 
The metabolic exercise testing was performed on a Schiller CS-200 Ergo-Spiro exercise 
machine which was calibrated before every study. Subjects underwent spirometry and this 
was followed by symptom-limited erect treadmill exercise testing using incremental ramp 
protocol (speed and inclination was increased every minute) as described previously by our 
group (124) with simultaneous respiratory gas analysis (125, 126). Samplings of expired 
gases were performed continuously, and data were expressed as 30-second means.  The 
minute ventilation − carbon dioxide production relationship (VE/VCO2 slope), maximal 
oxygen consumption, carbon dioxide production, and respiratory exchange ratio (RER) was 
used to verify objective effort adequacy.  Maximal oxygen consumption (V02max) was 
defined as highest value of oxygen consumption measured during the exercise period. Blood 
pressure and ECG were monitored throughout.  Subjects were encouraged to exercise to 
exhaustion with a minimal requirement of RER > 1.  
 
Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position with 
a Vivid 7 echocardiographic machine and a 2.5-MHz transducer.  Resting scans were 
acquired in standard apical 4-chamber and apical 2-chamber. LV volumes were obtained by 
biplane echocardiography, and LVEF was derived from a modified Simpson’s formula (127). 
Pulse wave Doppler sample volume was placed at the mitral valve tips to record 3 cardiac 
cycles. Mitral annulus velocities by pulse wave Tissue Doppler imaging (PW-TDI) were 
recorded from basal antero-lateral and basal Inferoseptum. LA volumes were measured by 
area length method from apical 2 and 4 chambers as previously described (127).  
Assessment of LV end-systolic elastance (Ees) was determined using the noninvasive single-
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beat technique. (128) Arterial elastance (Ea) was calculated as the ratio of systolic 
pressure/stroke volume. Studies were stored digitally and analyzed off-line.  
 
Speckle Tacking Echocardiography (STE) 
 
STE was measured using a commercially available speckle tracking system in an ECHOPAC 
workstation.  Myocardial deformation measurements were performed using tissue speckle 
tracking. In this speckle tacking system, the displacement of speckles of myocardium in each 
spot were analyzed and tracked from frame to frame.  We selected the best-quality digital 
two-dimensional image cardiac cycle  and the left ventricle endocardium was traced at end-
systole.(129).  The region of interest width was adjusted as required to fit the wall thickness.  
The software package then automatically tracked the motion through the rest of the cardiac 
cycle (Figure 5).  The onset of QRS complex was taken as the beginning of systole. Adequate 
tracking was verified in real time.  A frame rate between 70-100 Hz was used.  For each 
subject, longitudinal strain values for all LV myocardial segments in each of the apical 4 and 
2 chamber views were measured and averaged to derive the global LV longitudinal strain, 
strain rates and velocity. Circumferential strain values were obtained in all 18 segments of 
the three short-axis views. The average of peak systolic circumferential strain values from 
the three short-axis views was calculated to derive the global LV circumferential strain and 
strain rates. Similarly, peak radial strain values were measured in all 18 segments at the 
three short-axis views and averaged to derive the global radial strain and strain rates.  
 
In addition, cardiac rotation was computed using speckle tracking. Counter-clockwise 
rotation was marked as a positive value and clockwise rotation as a negative value when 
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viewed from the apex. In order to calculate LV torsion, LV untwist and untwist rates, the 
rotation traces of the basal and apical LV cross-sections were exported into DPlot graph 
software (Version 2.2.1.4, HydeSoft Computing, LLC, Vicksburg, USA). The LV twist curve was 
generated by calculating the difference between apical and basal rotations at each 
corresponding time point. LV twist rates were derived from the first derivative of the LV 
twist curve. Peak LV torsion was derived from LV twist divided by LV diastolic longitudinal 
length. (130) Rotational deformation delay was also determined and defined as the 
magnitude of the time difference between time to peak basal rotation and time to peak 
apical rotation. To adjust for intra- and inter-subject differences in heart rate, all time 
measurements were normalized to R-R interval.  
Figure 5: An example of speckle tracking derived longitudinal strain rate curves 
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Chapter I 
 
31P Magnetic Resonance Spectroscopy to Measure In Vivo Cardiac Energetics 
in Normal Myocardium and Hypertrophic Cardiomyopathy: 
Experiences at 3 Tesla 
 
Background 
Phosphorus Spectroscopy is a non-invasive method of studying cardiac in vivo high energy 
phosphate kinetics (131). It allows for determination of PCr, ATP, Adenosine Diphosphate 
(ADP) and inorganic phosphate (Pi) concentrations in the myocardium. The concentrations 
of these substances and the ratio of PCr/ATP are measures of the cardiac energetic status.  
PCr is an important short-term reserve energy source that maintains a high phosphorylation 
potential under conditions of increased energy demand like exercise and ischaemia. The 
conversion of ADP to ATP by transfer of a phosphoryl group from PCr is catalysed by 
creatine kinase. This reaction occurs 10 times faster than ATP production via oxidative 
phosphorylation(132). In patients with mild to moderate heart failure, cardiac ATP flux 
mediated by creatine kinase is reduced by approximately 50%(133). Animal and human 
studies have demonstrated that a progressive reduction of the creatine pool is directly 
related to the severity of heart failure (134). This is largely due to a decrease in the number 
of creatine transporters at sites of energy production and utilisation(135). In normal 
myocardium two thirds of the creatine pool is phosphorylated via creatine kinase reaction 
to form PCr(136) and the expression and activity of this enzyme is reduced in heart failure 
(115, 137). Therefore in heart failure the available PCr is markedly diminished. The depletion 
Pathophysiology of HfpEF 
 
[53] 
 
of PCr occurs to a greater extent compared to ATP resulting in reduced PCr/ATP ratio in 
heart failure as measured by MRS (138). Reduced PCr/ATP ratio is associated with increased 
mortality in heart failure patients (139). 31P cardiac spectroscopy can also be used to 
monitor disease progress in heart failure patients. It has been used as an objective marker 
to show benefits of various treatments such as metabolic modulators (140).  
 
Reduced PCr/ATP ratio is also seen in other conditions including ischaemic heart 
disease(141), left ventricular hypertrophy secondary to hypertension (142), valvular heart 
disease (mitral regurgitation and aortic valve disease) (119, 143), diabetes (144) and HCM  
(109). Interestingly, patients with genotypic HCM who do not yet have hypertrophy have a 
similar degree of impairment of cardiac PCr/ATP ratio as do patients with marked 
hypertrophy, implying that the disturbance may be an early feature of the disease and is not 
simply due to the hypertrophy (145). 
 
Traditionally cardiac spectroscopy in humans has been performed using 1.5 Tesla magnets.  
Previous studies in animals(146) and humans demonstrated that higher field strength such 
as 3T (147) or 4.7T offer higher SNR. The increased sensitivity can be traded for either 
increased spatial resolution or improved quantification precision and hence might improve 
specificity of 31P cardiac MRS as a diagnostic tool. Hence it is desirable to perform cardiac 
MRS at 3T MR scanners. However, higher field strength also result in inhomogeneities of the 
transmit and receive B1 field along with restrictions of the maximum achievable B1 field 
strength that result in larger chemical shift displacements. Furthermore susceptibility 
differences between adjacent tissues have a greater effect on B0 homogeneity, which results 
in line broadening. Hence in this study we test the feasibility and reliability of 31P cardiac 
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spectroscopy at 3 Tesla for clinical diagnostics using standard methods pre-implemented on 
a clinical MR scanner.  
 
Methods: 
37 Controls (22-males) and 26 HCM patients (21-males) with symptomatic non-obstructive 
cardiomyopathy who provided written informed consent, were included in the study.  The 
experiment was approved by the Regional Ethics Committee at Birmingham, UK.  All healthy 
volunteers were screened with history, echocardiography and metabolic exercise testing to 
rule out any structural heart diseases. All patients were recruited from cardiomyopathy 
clinics and had clinically proven diagnosis of non-obstructive hypertrophic cardiomyopathy. 
The subject characteristics are presented in table-1. The mean age of the healthy volunteers 
was 48 ± 16 years and that of HCM patients was 55±13 (P=ns).  The mean ejection fraction 
on echocardiography was 64±6% in controls and 64±9% (P=ns) in HCM patients. None of the 
healthy volunteers had any structural heart disease or ECG abnormalities. 31P cardiac 
spectroscopy was performed eight times in one participant both - on the same and on 
different days - to test the reproducibility and coefficient of variation of the test.  
 
31P cardiac magnetic resonance spectroscopy was performed using a Phillips Achieva 3T 
scanner and a linearly polarized transmit and receive 31P coil with a diameter of 14 cm. 
Localization was achieved by ISIS (117) volume selection. The participants were positioned 
supine with the coil directly over the precordium. The coil was secured in place by straps 
wrapped around the upper body of the subject and the coil. The participants were then 
positioned inside the magnet with the center of the coil at the isocenter of the magnet. 
Survey images were obtained to check the position of the coil (figure1). The subjects and/or 
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the coil were repositioned if required to ensure that the distance between coil and septum 
and apex of the heart was minimized.  
 
The standard phosphorus spectroscopy sequence provided by the manufacturer was used. It 
was based on hyperbolic secant pulses for slice selective inversion and adiabatic half 
passage RF pulse for non-selective excitation. In contrast to the standard procedure manual 
fine adjustment of F0 was performed if the automatic F0 determination was not correct in 
order to ensure the correct voxel position. In contrast to the default iterative or FASTERMAP 
based shimming algorithm, which was based on the selected spectroscopy VOI, an image 
guided shim volume was selected that included the entire myocardium. A short axis cine 
scan was acquired to calculate the trigger delay for ECG triggering and check quality of 
shimming and F0 determination. The trigger delay was calculated such that the spectra were 
acquired in the diastolic period. The 3-D voxel of acquisition was planned to include most of 
the septum and apex of the heart. Care was taken to minimize blood contamination from 
the right ventricle as much as possible. The voxel size was kept constant at 89.54ml 
(44x55x37mm3) so that comparisons could be made between different subjects and scans. 
Initially, 1H spectra were acquired from the same voxel without water suppression and 
repetition time of 2000 ms (total scan time of 16 sec). This helped to ensure adequate shim 
quality and correct F0 determination. F0 could be manually adjusted if necessary. Following 
this the 31 P spectrum was acquired with a repetition time of 10000 ms, 136 averages and 
512 samples. A repetition time of 10000 ms was found to be optimal to adequately reduce 
saturation effects without increasing the scan time greatly. The spectral acquisition was ECG 
gated and the trigger delay was set to acquire spectra mainly in diastole. The trigger delay 
was measured by subtracting 250-300 from the total length of the cardiac cycle which 
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allowed 250-300 msec of the cardiac cycle left for spectral acquisition (acquisition time is 
170 msec). The total scan time was 23 minutes.  
 
Increased chemical shift artefacts are present at 3T. In order to minimise this, slice selective 
inversion for ISIS encoding was based on adiabatic hyperbolic secant pulses, which achieved 
a pulse bandwidth between 1300 Hz (at a distance of 9 cm from the surface coil) to 2000 Hz 
(at a distance of 3 cm from the surface coil). This corresponds to a chemical shift 
displacement of 6-10% for the investigated metabolites PCr and gamma-ATP for volumes of 
interest that were between 3 and 9 cm away from the coil. When subjects where scanned 
the distance from the coil to the ROI averaged about 7.5cm and no subjects were beyond 
9.0 cm. Therefore all subjects would have a chemical shift displacement less than 10% which 
is acceptable. 
 
Analysis: 
The spectra were analysed and quantified on jMRUI software using AMARES a time domain 
fitting program(118). Post-processing was performed with 15Hz Gaussian line broadening 
and Fourier transformation. Phase correction was performed with PCr peak as the reference 
peak. Quantification was performed with AMARES using a prior knowledge file to preselect 
the peaks. The concentrations of PCr, ATP and 2,3-Diphosphoglycerate (2,3-DPG) were 
calculated as the area under the peaks. Cramer Rao lower bounds (148) were then 
calculated. PCr/ATP ratio was determined after correcting the ATP peak for blood 
contamination as described previously(149).  
 
Results: 
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A typical cardiac spectrum in healthy volunteer as compared to hypertrophic 
cardiomyopathy is shown in Figure 2.  The PCR/ATP ratio was significantly lower in 
hypertrophic cardiomyopathy (1.42 ± 0.51) as compared to healthy controls (2.11 ± 0.57, 
P<0.0001) (Figure 3). The mean PCr/ATP ratio for the one participant with eight 
measurements was 2.11 ± 0.25 (Table-2). Bland Altman plots were used as a test of 
reproducibility (Figure 4). The distribution of all the data points showed a good 
reproducibility with a coefficient of variation of 12% in the measurement of PCr/ATP ratios 
which is within limits of agreement of repeated measurements. We also measured the line 
width of PCr peaks in the one participant who had 8 repeated scans. The mean line width 
was 1.363±0.204 ppm (Figure 5). The standard deviation of the line width was low which 
again confirmed the fact that the spectra were of good reproducible quality. As a further 
measure of the quality of spectra we calculated the Cramer Rao lower bounds (148), which 
were 6 ± 1% for the PCr peak and 10 ± 1% for the gamma ATP peak. Cramer Rao lower 
bounds were calculated for the whole group, which was 12 ± 6% for the PCr peak and 17 ± 
9% for the gamma ATP peak (Table-3). 
Due to an increase of susceptibility differences between heart muscle tissue, blood and air 
in the lungs at high field strength shim quality was slightly decreased at 3T in comparison to 
values reported for 1.5T cardiac spectroscopy. Hence multiple splitting of the ATP 
resonances due to J-coupling is hardly visible. 
 
Discussion 
Here we demonstrate that in-vivo cardiac 31P MRS at 3T is a reliable method of measuring 
high energy phosphate kinetics in the myocardium. We also show reduced PCr/ATP ratio in 
HCM patients known to have impaired cardiac energetics as measured in 1.5T systems (145, 
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150). The spectra show good reproducibility indicating that 31P cardiac MR spectroscopy is 
feasible on a clinical 3T MR system. The standard deviation for the PCr/ATP ratio for the 
whole group was low and comparable to previous published data on cardiac spectroscopy at 
1.5 Tesla(151). This basic method of acquiring 31P spectra at 3T using pre-implemented 
methods such as ISIS volume localisation and iterative shimming promises to be an 
important diagnostic and research tool. Possible applications are the comparison of PCr/ATP 
ratios in conditions like heart failure, ischaemic heart disease and valvular heart disease. It 
might also be used to monitor disease progression and study effects of medications like 
metabolic modulators in heart disease.  
Cardiac spectroscopy at 3T continues to face some challenges which are present at 1.5T as 
well, but some of them are even more pronounced at high field strength. One main 
drawback of cardiac spectroscopy is the effect of respiratory motion and movement of the 
heart itself. This can result in contamination from liver and skeletal muscle of the chest wall. 
Careful localization of the voxel ensures minimal contamination. We particularly paid 
attention to this aspect while planning our voxel of acquisition. Provided the voxel is 
positioned carefully, no significant advantages to the quality of spectra acquired with 
multiple outer volume suppression bands was observed.  None of our spectra show any 
significant contamination with skeletal muscle or liver. It is also important to ensure that the 
spectral acquisition is done when the heart motion is at its minimum. This is during diastole 
and we set the trigger delay such that all of the spectral acquisition happened during 
diastole. One other problem is the respiratory motion. This could be partially negated by 
acquiring the spectra with respiratory gating as well as cardiac gating (double triggered) and 
volume tracking (152, 153). Further developments in these techniques should improve 
quality of cardiac spectra and reduce the contamination from surrounding structures. 
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Higher field strength of 3T offers better spatial resolution and signal to noise ratio. These 
effects have been particularly noted in proton spectroscopy of the human brain (154). 
However, increasing susceptibility differences between muscle tissue, blood and air in the 
lungs cause increased B0 field inhomogeneities and hence problems with shim convergence. 
Various shimming techniques like iterative and FASTMAP based (155) higher order 
shimming were compared. Localized iterative 1st order shimming based on a volume 
including the entire heart offered the best and most reproducible shim quality. However, 
there is definitely scope for further improvement in shimming techniques. One possibility 
might be localized shimming based on cardiac triggered B0-mapping as reported earlier for 
cardiac imaging at 3T(156). Another problem is the shortened transverse relaxation times 
(T2) at 3T in comparison to 1.5T. This causes an additional increase in line width of the 
various peaks. 
 
No significant advantages to the quality of spectral acquisition using proton decoupling or 
Nuclear Overhauser Enhancement (NOE) were found. Therefore these techniques were not 
used. Although NOE can increase the SNR by up to 40%, this is not useful for experiments 
were quantification is required. NOE in particular imparts different amount of energy to 
phosphates in ATP and PCr which can result in altered PCr/ATP ratio. This is particularly 
important as the effect of NOE is different for distinct molecules and depends on conditions 
as the pH which might be changed in the diseased myocardium.  
 
Due to a decrease of the maximum achievable B1 field strength at 3T together with an 
increase in spectral separation compared to 1.5T, the bandwidth of the excitation pulse was 
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limited and hardly sufficient to excite the entire frequency range of interest. Using a simple 
surface coil this is especially a problem in large penetration depth. In addition, the excitation 
profile was not homogeneous. Hence different flip angles were applied to spins with 
different offset frequencies. This resulted in a frequency dependent weighting of peak 
intensities. Hence, the intensity of the beta ATP peak, which has a large frequency offset 
compared to PCr, was always significantly decreased (Figure 1) or even lost in obese 
subjects, where the distance between coil and VOI is large. However the determined 
PCr/gamma-ATP ratios were not affected, because the frequency difference between both 
resonances is small and the pulse frequency offset was chosen to be in-between of both.  
 
Conclusions 
31P magnetic resonance spectroscopy of the myocardium at 3T is feasible and allows for 
reliable determination of high energy phosphate kinetics. Our reproducibility data suggests 
that the suggested method is robust and might be used for clinical diagnostics as well as for 
clinical studies. However, to take full advantage of increased SNR and spectral separation at 
3T advances in shimming, coil and RF pulse design are necessary.  
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Figure 1: Survey images showing the position of voxel of acquisition and centre of the 31P 
coil.  
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Figure 2: A typical cardiac spectra in control and HCM 
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate;  PDE - Phosphodiesters; ATP - 
Adenosine triphosphate. 
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Figure 3: Box-plots of PCr/ATP ratios in controls and HCM patients  
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Figure 4: Bland-Altman plots of 31P cardiac MRS measurements from the healthy volunteer 
who had 8 repeated scans. Graph plotted as difference in two measurements against mean 
of the same two measurements. 
 
 
 
Figure 5:  Line width of PCr peaks from the healthy volunteer who had 8  
repeated scans expressed as parts per million (ppm)  
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Table 1:  Baseline Characteristics 
Parameter Controls 
(N=37) 
HCM 
(N=26) 
P Value 
Age 48 ± 16 55 ± 13 ns 
Male sex –no(%) 22 (59) 21 (81) ns 
EF(%) 64 ± 6 64 ± 9 ns 
VO2 max 39 ± 8 24 ± 6 <0.0001 
RER 1.2 ± 0.2 1.1 ± 0.1 ns 
Heart rate 79.5 ± 11.7 67.5 ± 12.5 <0.01 
QTc interval 421.8 ± 16.0 455.9 ± 35.0 <0.01 
Systolic Blood Pressure 127.0 ± 20.4 126.1 ± 20.1 ns 
Diastolic Blood Pressure  79.5 ± 9.6 75.6 ± 10.7 ns 
 
EF- Ejection Fraction, VO2 max- Maximal oxygen consumption at peak exercise, RER – Respiratory exchange 
ratio, QTc- Corrected QT interval. 
 
 
 
 
 
 
 
Pathophysiology of HfpEF 
 
[66] 
 
Table 2: Table depicting the concentrations of 2,3-DPG, ATP and PCr and the calculated PCr/ATP 
ratios from these measurements in the subject with eight measurements. 
 
Subject No 
2,3 DPG 
sum 
PCr Gamma 
ATP 
Gamma 
ATP (C) 
PCr/Gamm
a ATP Ratio 
PCr/Gamm
a ATP Ratio 
(C) 
Subject 1A 6.72 x10
-4
 4.90 x10
-4
 3.57 x10
-4
 2.45 x10
-4
 1.37 2.00 
Subject 1B 4.27 x10
-4
 4.32 x10
-4
 3.21 x10
-4
 2.50 x10
-4
 1.34 1.72 
Subject 1C 7.32 x10
-4
 6.53 x10
-4
 4.77 x10
-4
 3.55 x10
-4
 1.36 1.83 
Subject 1D 1.00 x10
-3
 8.52 x10
-4
 5.12 x10
-4
 3.45 x10
-4
 1.66 2.47 
Subject 1E 9.39 x10
-4
 5.53 x10
-4
 3.86 x10
-4
 2.30 x10
-4
 1.43 2.40 
Subject 1F 8.29 x10
-4
 6.34 x10
-4
 4.26 x10
-4
 2.88 x10
-4
 1.48 2.20 
Subject 1G 8.66 x10
-4
 5.36 x10
-4
 3.90 x10
-4
 2.46 x10
-4
 1.37 2.18 
Subject 1H 8.32 x10
-4
 5.55 x10
-4
 4.05 x10
-4
 2.66 x10
-4
 1.37 2.08 
 
PCr- Phosphocreatine; 2,3-DPG- 2,3 Diphosphoglycerate; ATP- Adenosine triphosphate; (C)- Corrected for 
blood contamination 
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Table 3:  Cramer Rao Lower bounds measured to test the quality of spectra 
 PCr peak Gamma ATP Peak 
Healthy control (8 Measurements) 6% ± 1 10% ± 1 
Whole group( Controls + HCM) 12% ± 6 17% ± 9 
Controls 11% ± 5 16% ± 8 
HCM 12% ± 6 17% ± 9 
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Heart Failure with Preserved Ejection Fraction is characterized by dynamic 
impairment of active relaxation and contraction of the left ventricle on 
exercise and associated with myocardial energy deficiency 
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Chapter II 
 
Heart Failure with Preserved Ejection Fraction is characterized by dynamic 
impairment of active relaxation and contraction of the left ventricle on 
exercise, associated with myocardial energy deficiency 
 
Introduction 
There is increasing consensus that ≈50% of patients with the clinical features of chronic 
heart failure suffer from heart failure with preserved ejection fraction (HfpEF). (10) 
Epidemiological observations from different populations confirm that the prevalence of 
HfpEF is increasing as it tracks the demographic transition, especially in obese hypertensive 
females. HfpEF causes as many hospitalizations and incurs as severe morbidity as heart 
failure with reduced LVEF. Finally, HfpEF portends a significant and unimproving mortality. 
(12) Nonetheless, despite its unarguable clinical significance, HfpEF’s pathophysiology 
remains controversial with some investigators proposing that diastolic abnormalities (1) and 
others that systolic abnormalities play a dominant role. (157) However most studies have 
focussed on resting parameters yet symptoms predominantly occur on exercise. One study 
reported a dynamic impairment of left ventricular active relaxation during isometric 
(handgrip) exercise (58) but the relevance of this observation to dynamic leg exercise that 
usually provokes breathlessness during everyday life is unclear. 
 
The present study was designed to test the hypothesis that exercise limitation in HfpEF is 
due to a dynamic impairment of both LV active relaxation and of LV contractile performance 
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during exercise, both of which may be due to an underlying impaired myocardial energetic 
reserve. We used radionuclide ventriculography to measure LV active relaxation, LV 
contractile function and vasculo-ventricular coupling, at rest and during exercise. 
Furthermore, 31P Cardiac Magnetic Resonance Spectroscopy (MRS) at 3-Tesla was used to 
measure in vivo myocardial energetics. 
 
Methods 
Patients 
We studied 37 HfpEF patients prospectively recruited from heart failure clinics. We also 
studied twenty healthy controls with no cardiac history or diabetes mellitus. Study 
participants had clinical examination, 12-lead electrocardiogram, pulmonary function test, 
echocardiogram, metabolic exercise test, radionuclide ventriculography studies and a 
subgroup underwent cardiac 31P MRS studies to assess cardiac energetic status. All controls 
had a normal cardiovascular examination, 12-lead electrocardiogram and echocardiogram. 
HfpEF patients were defined in accordance with ACC/AHA recommendation (158): i) 
symptoms and signs of heart failure, ii) EF ≥50%, iii) no valvular abnormalities. In addition 
we stipulated that patients should have iv) VO2max <80% of age and gender predicted 
values with a pattern of gas exchange on metabolic exercise testing indicating a cardiac 
cause for limitation, v) absence of objective evidence of lung disease on formal lung 
function testing and/or absence of arterial desaturation during exercise and with a 
ventilatory reserve at peak exercise ≥15L. We chose to use such a definition as advocated by 
Coats and others (33) in order to have robust evidence that patients had exercise limitation 
that was cardiac rather than non cardiac  in origin and so as not to prejudge the underlying 
pathophysiology by stipulating the presence of resting diastolic abnormalities because 
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diastolic abnormalities are frequently present in healthy elderly subjects (23) and it does not 
necessarily predict clinical heart failure (24) nor exertional dyspnoea (25). Patients with 
rhythm other than sinus were excluded. The investigations were performed at The 
University of Birmingham with approval of the Research Ethics Committee. Informed 
consent was obtained from all patients and controls.  
 
Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position with 
a Vivid 7 echocardiographic machine using a 2.5-MHz transducer.  Cardiac quantifications 
were determined in accordance with European Association of Echocardiography. (127) LV 
end-systolic elastance (Ees), a relatively load independent measure of LV contractility, was 
determined using the non-invasive single-beat technique. (128) Arterial elastance (Ea), a 
measure of the stiffness of the entire arterial tree, was calculated as the ratio of LV end-
systolic pressure/stroke volume. Studies were stored digitally and analyzed off-line.  
 
31P Cardiac Magnetic Resonance Spectroscopy (MRS) 
In vivo myocardial energetics was measured by MRS at 3-Tesla as previously validated and 
described in detail by our group. (110) 31P cardiac magnetic resonance spectroscopy was 
performed using a Phillips Achieva 3T scanner and a linearly polarized transmitter and 
receiver 31P coil with a diameter of 14 cm.  The repetition time was 10000 ms with 136 
averages and 512 samples. Acquisition was ECG gated and the trigger delay was set to 
acquire in diastole. Total scan time was 23 minutes.  Java magnetic resonance user interface 
v3.0 (jMRUI) was used for analysis. (159) PCr and γ-ATP was used to determine the PCr/ATP 
ratio which is a measure of cardiac energetic state (160). Patients with ischemic heart 
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disease and diabetes (N=7) were excluded from the MRS studies because these conditions 
are known to have impaired cardiac energetics. (144, 160) Patients with contraindications 
were also excluded from the MRS study (N=5). One patient’s spectra was excluded from the 
analysis due to poor quality. Three controls had contraindication to MRS study. Data were 
analysed separately by an investigator unaware of participants’ clinical status.  
 
Radionuclide Ventriculography 
LV ejection fraction and diastolic filling were assessed by radionuclide ventriculography 
at rest and during graded semi erect exercise on a cycle ergometer as previously described 
in detail by our group. (76, 94)  Three minutes of data were acquired at rest and during 
exercise after a 30-second period for stabilisation of heart rate at the commencement of 
each stage. Exercise was performed at 50% workloads of heart rate reserve. Data were 
analysed using LinkMedical MAPS software, Sun Microsystems (Hampshire, UK). Peak left 
ventricular filling rate in terms of end-diastolic count per second (EDC/s) and time to peak 
filling normalised for R-R interval (nTTPF) in milliseconds after end systole were calculated 
from the first derivative of the diastolic activity-time curve. Venous blood samples were 
obtained for weighing and for counting of blood gamma activity during each scan in order to 
correct for physical and physiological decay as well as for determination of relative volume 
changes. (120)  The validity of these radionuclide measures of diastolic filling at high heart 
rates has been established previously. (121) 
 
All gated blood pool scan-derived volumes were normalized to body surface area, yielding 
their respective indexes: end-diastolic volume index (EDVI), end-systolic volume index 
(ESVI), stroke volume index (SVI), and cardiac index. The following indexes were calculated: 
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a) arterial elastance index (EaI) = ESP/SVI; b) LV end-systolic elastance index (ELVI) = ESP/ESVI 
and c) vasculo-ventricular coupling ratio (VVC) = EaI/ELVI = (1/EF)–1. (88)   
 
Metabolic Exercise Test  
All participants underwent a symptom-limited erect treadmill exercise with simultaneous 
respiratory gas analysis. The incremental ramp protocol was such that the speed and 
inclination increased in a stepwise manner every minute. Exercise was terminated at the 
subject’s request because of fatigue or breathlessness. VO2max was obtained during peak 
exercise. 
Statistics 
Continuous variables are expressed as means ± SD. Unpaired Student’s t-test (2-tail) was 
used to assess differences between mean values. Categorical variables were compared with 
Pearson Chi-Square test. All reported P values were calculated on the basis of two-sided 
tests and a P value of <0.05 was considered to indicate statistical significance. Variances of 
data sets were determined using Levene's test. SPSS (v15.0) was used to perform the 
statistical operations. 
 
Results 
Characteristics of the Patients 
HfpEF patients were generally females, overweight, aged 67±9 years old with a history of 
hypertension, however blood pressure was well treated (systolic BP 138±19mmHg vs. 
131±23mmHg; p=0.23, in patients vs. controls) (Table 1).  The tissue Doppler E/E’ at the 
basal anterior-lateral (a measure of left ventricular end-diastolic pressure) (161), was 
significantly higher in patients than controls. There was also a trend (non-significant) to 
Pathophysiology of HfpEF 
 
[74] 
 
higher Ees in patients than in the control group. HfpEF patients also had significantly 
reduced VO2max and reduced peak HR on metabolic exercise testing. During semi-erect 
cycle exercise the relative stroke volume (SVi EXERCISE /SVi REST) was lower in patients 
compared to controls (0.99±0.34 vs. 1.25±0.47; P=0.04), and relative cardiac output 
(COiEXERCISE/COiREST) was also lower (1.36±0.45 vs 2.13±0.72; p<0.001). (Table 2) 
 
Left Ventricular Active Relaxation  
 nTTPF is determined by the rate of LV active relaxation (114) and by transmitral pressure 
gradient at the time of mitral valve opening. nTTPF was similar at rest in HfpEF patients and 
controls. During exercise it shortened in controls, but lengthened in patients (Table 2). 
Furthermore, peak filling rates during exercise were significantly reduced in patients 
compared to controls. (Table 2)  
 
Left ventricular contractile function and Vasculo-Ventricular Coupling 
VVC was similar at rest in HfpEF patients and controls. During exercise, LV arterial elastance, 
a measure of the stiffness of the entire arterial tree increased in both patients and controls 
but tended to increase more in patients. LV end systolic elastance, a measure of LV 
contractile function, markedly increased on exercise in controls but increased substantially 
less in patients. Accordingly the VVC ratio was essentially unchanged on exercise in patients 
but fell substantially on exercise in healthy controls. Furthermore whilst resting LVEF and 
peak emptying rate were similar in patients and controls, during exercise both were lower in 
patients. (Table 2)  
 
In vivo Myocardial Energetic State 
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At rest, cardiac PCr/ATP ratio in HfpEF patients was significantly reduced compared to 
healthy controls, 1.57±0.52 and 2.14±0.63, respectively, P=0.003 (Figure 1). 
 
Discussion 
The principal findings of this study are: a) HfpEF patients manifest a significant reduction in 
PCr/ATP ratio at rest, indicating impairment of myocardial energy ‘reserves’. b) As a 
corollary, during exercise, the energetically demanding active relaxation stage of diastole 
lengthened in patients (vs. a shortening in controls) and there was also a failure of the 
normal increase in contractile function on exercise in patients. These combined dynamic 
abnormalities of both diastolic and contractile function together resulted in a lower stroke 
volume during exercise. c) Consistent with previous studies, HfpEF patients demonstrated 
chronotropic incompetence on exercise. (77) These findings underline the importance of a  
dynamic (rather than resting) assessment of cardiac function to comprehensively 
characterise patients with HfpEF. 
 
The pathophysiology of HfpEF has been the subject of considerable controversy. These 
patients are typically hypertensive and exhibit impaired LV active relaxation and/or 
increased passive left ventricular diastolic stiffness at rest. (1) This has led many to conclude 
that exercise limitation is primarily a result of impaired LV diastolic filling and to the use of 
the term ‘diastolic heart failure’. (50) However, diastolic dysfunction is also a common 
finding at rest in healthy elderly subjects. (23) Furthermore, ‘subtle’ abnormalities of systolic 
function, in particular long axis systolic function, are also almost universally observed in 
HfpEF patients despite normal LV ejection fraction. (157) This has led others to propose that 
HfpEF is predominantly a disorder of contractile function. (162)  In order to compare both of 
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these possibilities, we specifically chose to define the syndrome on the basis of a limitation 
of exercise capacity with a cardiac basis for this limitation rather than by using resting 
parameter of diastolic function in order not to prejudge the role of diastolic vs. systolic 
mechanisms . 
 
Little attention has been directed to changes in systolic and diastolic function during 
dynamic exercise, which is when the majority of patients experience their symptoms. In one 
study, ten patients with HfpEF were assessed with invasive pressure-volume loops and 
compared with age-matched controls. (58) The former had increased arterial elastance (a 
measure of the stiffness of the entire arterial tree), and increased LV end-systolic elastance 
(a measure of the stiffness of the ventricle during systole and a relatively load independent 
measure of the contractile state of the left ventricle (163)). Whilst diastolic abnormalities 
were not universally present in patients at rest, marked differences appeared during 
handgrip exercise. The rate of LV active relaxation increased in healthy subjects but it 
slowed in patients. (58)  In another study from the same group, exercise-related symptoms 
in Afro-Caribbean hypertensive patients appeared to be strongly associated with 
chronotropic incompetence and an inadequate vasodilator reserve on exercise. (77)  
 
The present study examined the patho-physiological mechanisms in HfpEF and found 
marked dynamic (exercise induced) abnormalities in both contractile and diastolic function 
of the left ventricle, and a lower peak exercise HR in patients.  It is possible for an impaired 
HR response during exercise to cause a reduction in exercise capacity as measured by 
VO2max, which is largely determined by cardiac output on exercise and the latter is simply 
the product of HR and SV. However, in the setting of a profound slowing of active relaxation 
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and increased LV passive diastolic stiffness, a larger diastolic filling period might be expected 
to be beneficial.  In this study, despite a longer diastolic filling time, the relative change in SV 
was lower in patients during sub-maximal exercise. Impaired HR response may be a 
consequence of the heart failure as an impaired chronotropic response (associated with 
slow HR recovery following exercise) is typically present in systolic heart failure and is in part 
a manifestation of impaired vagal tone; (164) or it may be an adaptation to improve 
diastolic filling. The latter seems at least plausible, since increasing heart rate by atrial 
pacing has been shown to reduce supine resting stroke volume and cardiac output in 
patients with HfpEF. (2)  It will be important to undertake further studies to assess whether 
heart rate plays a causal role in exercise limitation in HfpEF, because if so this may be 
amenable to rate responsive pacing. 
 
The patients in this study had a history of hypertension but were well treated with anti-
hypertensives (in most cases including vasodilators) therefore resting blood pressure and 
arterial elastance were not significantly higher than in the control group. Consistent with 
prior studies (58), at rest,  LV end-systolic elastance (a measure of contractility or systolic 
stiffness) tended to be higher in patients although this did not reach significance.  The 
increase in arterial elastance during exercise tended to be greater in patients vs. controls 
(presumably reflecting a greater increase in large artery stiffness). However, whilst left 
ventricular end-systolic elastance almost doubled during exercise in controls, the increase 
was only 35% in patients; hence VVC reduced by 33% during exercise in controls but was 
unchanged in patients. These findings indicate a blunting of the physiological increase in the 
contractile state of the left ventricle on exercise. 
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The physiological increase in the rate of LV active relaxation during exercise is a 
consequence of sympathetic activation, via cAMP-dependent protein kinase (PKA) mediated 
phosphorylation of key proteins including Troponin I, Sarco/Endoplasmic Reticulum Ca2+-
ATPase (SERCA) and Titin. (70-72) In experimental models, large acute increases in afterload 
resulted in an acute impairment of LV active relaxation (93), with the threshold for this 
phenomenon being lower in the diseased heart, leading to the concept of ‘relative load’ as a 
determinant of afterload related impairment of LV active relaxation. (165) In the study of 
HfpEF patients described earlier (58), handgrip exercise was associated with a substantially 
greater increase in LV end-systolic pressure than in controls, potentially explaining the 
observed slowing of LV active relaxation.  A key coupler of this load dependent LV relaxation 
is Troponin I – Protein Kinase A (TnI-PKA) phosphorylation (95). It is known that the energy 
dependent process of phosphorylation of Troponin I by PKA decreases myofibrillar calcium 
sensitivity (96) and increases the rate at which calcium dissociates from Troponin C (97) 
which can lead to increase rate of LV relaxation. Indeed, in a study involving transgenic mice 
in which PKA phosphorylation sites on Troponin I were constitutively active, acute aortic 
constriction led to a lengthening of Tau (an invasive measure of active relaxation) in the wild 
type mice but not in the transgenic mice. (95).  
 
Integrating these observations, we speculate that dynamic energy impairment may account 
for the slowing of LV active relaxation on exercise as well as the failure of LV contractile 
function to increase. To increase the generalisability of this hypothesis, we avoided 
positively biasing our study by excluding patients with established causes of cardiac energy 
deficiency (ischemic heart disease and diabetes) (144, 160). Nevertheless, the PCr/ATP ratio 
was still substantially reduced in HfpEF patients vs. controls at rest. The lower PCr/ATP ratio 
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in patients indicates a reduction of high energy phosphates reserve at rest. (115, 166) 
Although the time required for acquisition of Cardiac MRS signals precluded the 
measurement of high energy phosphate status during exercise, it is likely that any basal 
energetic impairment will be exacerbated dynamically. This exacerbation of dynamic 
energetic impairment would explain the prolongation of the energy demanding active 
relaxation as manifest by nTTPF. Moreover, the lower hearts rates and lesser increases in LV 
end-systolic elastance may represent strategies to limit dynamic cardiac energy demands. 
The cause for this resting energy deficit may relate to insulin resistance(108), to impaired 
mitochondrial function as a result of ageing (113), and to neuro-endocrine activation and 
aberrant substrate metabolism. (167)  In addition, increased myocardial fibrosis, as 
previously reported serologically in patients with diastolic heart failure (168), may also lead 
to reduced PCr/ATP ratio in HfpEF patients. This is relevant because in patients with HCM, 
reduced PCr/ATP has been shown to correlate with the presence of fibrotic area in the 
myocardium of the LV. (169) 
 
From a clinical perspective, this study have shown that patients with HfpEF have reduced 
myocardial energetic status which provides the rationale to assess the therapeutic value of 
‘metabolic agents’ (e.g. perhexiline and trimatazidine) that increase cardiac  energetic status 
by altering cardiac substrate use (170). Indeed, trimetazidine and perhexiline have both 
been shown to be beneficial in systolic heart failure (124, 170) Importantly we have shown 
that patients with HfpEF have a dynamic pathophysiological process whereby resting 
parameters may  be comparable to controls however during exercise HfpEF patients have 
impaired LV active relaxation and to a failure of LV end-systolic elastance to increase. This 
suggests that in detecting patients with HfpEF we cannot solely rely on resting parameters 
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and that we perhaps need to consider some form of exercise testing such as metabolic 
exercise testing as advocated by Coats and others (33) or exercise radionuclide 
ventriculography scans to detect abnormal LV relaxation during exercise. 
 
Study limitations 
Our radionuclide exercise protocol involved asking subjects to maintain a HR which was 50% 
of HR reserve above their resting HR. Since this HR reserve was calibrated to peak HR rate, 
the absolute workload in patients was lower. To have compared patients at the same 
workload would be inappropriate since this would represent a higher relative workload in 
patients. Moreover, most changes in SV occur in the first part of exercise with subsequent 
increases in cardiac output being principally due to increases in HR. (171) A small proportion 
of patients were on beta-blockers which may have affected their cardiovascular response to 
exercise, however when these patients were excluded from the analysis the findings and the 
level of significance remained unchanged. In addition, some patients were on calcium 
blockers however these were all peripherally acting (dihydropyridines for hypertension) and 
therefore are not expected to affect the myocardium directly. Ideally we would have liked 
to measure cardiac energetics during exercise however cardiac MRS studies during exercise 
is currently quite challenging more so if we tried to replicate the same dynamic leg exercise 
in the confinement of a MR scanner. A number of problems like acquisition at higher heart 
rates, shorter acquisition times, voxel specificity, pulse design, shorter repetition times etc 
are currently being addressed by our group and other groups around the world. MRS and 
Radionuclide studies also require a regular rhythm, thus patients with atrial fibrillation were 
excluded from the study. In contrast, the strength of radionuclide studies is their increasing 
temporal resolution at higher heart rates. This obviates the confounding E:A fusion as is 
Pathophysiology of HfpEF 
 
[81] 
 
frequently experienced with exercise echocardiography. Radionuclide studies are thus not 
subject to systematically biasing mechanistic HfpEF towards a subgroup of patients without 
E:A fusion on exercise.  
 
Conclusion 
HfpEF Patients have reduced cardiac energetic reserves which when exacerbated 
dynamically may contribute to the abnormal LV active relaxation during exercise and to a 
failure of LV end-systolic elastance to increase. In addition chronotropic response was 
markedly impaired during exercise in these patients.  
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Table 1. Baseline Characteristics of the Subjects 
Variable Patient Control P Value 
(N = 37) (N = 20) 
Age - yr 67±9 63±7 0.51 
Female sex - no. (%) 28 (76) 10 (50) 0.05 
Body Mass Index 30±4 26±5 <0.01 
Left Ventricular Hypertrophy - no. (%) 19 (51) 5 (25) 0.05 
Diabetes mellitus - no. (%) 4 (11) 0 - 
Hypertension - no. (%) 27 (73) 0 - 
Ischemic Heart Disease - no. (%) 4 (11) 0 - 
NYHA functional class – no.    
II 29 0 - 
III 8 0 - 
Drug therapy – no. (%)    
Diuretic 10 (27) 0 - 
ACE inhibitor 20 (54) 0 - 
ARB 6 (16) 0 - 
Beta-blocker 8 (22) 0 - 
Calcium blocker 10 (27) 0 - 
Alpha Blocker 4 (11) 0 - 
Spironolactone 2 (5) 0 - 
Nitrate 3 (8) 0 - 
Statins 21 (57) 0  
    
Metabolic exercise testing    
VO2max (ml/kg/min) 19±4 36±8 <0.001 
Respiratory Exchange Ratio (RER) 1.06±0.07 1.13±0.10 0.003 
Breathing Reserve - L/min 36±15 43±18 0.16 
HR - beats/min    
Rest 74±14 83±17 0.03 
Peak Exercise 127±20 166±11 <0.001 
∆HR  52±16  81±14 <0.001 
SBP (mmHg)    
Rest 138±19 131±23 0.23 
Peak Exercise 182±26 190±30 0.30 
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DBP (mmHg)    
Rest 81±11 81±12 0.98 
Peak Exercise 81±13 84±10 0.36 
    
Echocardiography    
Left ventricular ejection fraction - % 64±14 63±6 0.77 
Mitral E-wave velocity - m/sec 0.72±0.19 0.61±0.12 0.02 
Mitral A-wave velocity - m/sec 0.80±0.20 0.59±0.17 <0.001 
Ratio of E-wave: A-wave velocity 0.96±0.35 1.03±0.32 0.47 
Mitral E-wave deceleration - msec 274±70 269±73 0.82 
E/E' (lateral) 12±4 8±2 <0.001 
Ees 3.07±1.07 2.60±.53 0.09 
Ea 2.22±0.63 2.28±0.48 0.69 
 
Plus-minus values are means ± SD. When patients on beta blockers were excluded from 
analysis, the level of significance were similar apart from resting HR (P=0.14). NYHA denotes 
New York Heart Association, ACE angiotensin-converting enzyme, ARB angiotensin II 
receptor blockers, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood 
pressure, MABP mean arterial blood pressure, LA left atrium, E/E’  mitral E-wave velocity-E’ 
tissue velocity (PW-TDI) at basal anterior-lateral wall ratio, Ees denotes Left Ventricular End-
Systolic Elastance and Ea is Arterial elastance. The body-mass index is the weight in 
kilograms divided by the square of the height in meters. 
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Table 2. Radionuclide ventriculography at Rest and on Exercise: Diastolic Filling 
Characteristics, Systolic Function, Relaxation, Stiffness, and Vasculo-ventricular 
coupling 
Variable Patient Control P Value 
(N = 37) (N = 20) 
HR (beats/min)    
Exercise 97±14 114±11 <0.001 
Exercise SBP (mm/Hg) 204±26 198±27 0.45 
Exercise DBP (mmHg) 95±15 97±7 0.56 
Exercise MABP (mmHg) 132±15 131±9 0.85 
Ejection fraction (%)    
Rest 65±9 64±9 0.61 
Exercise 66±9 72±8 0.05 
Peak emptying rates (EDC/sec)    
Rest 382±106 400±90 0.56 
Exercise 477±123 563±144 0.04 
Peak filling rates (EDC/sec)    
Rest 342±120 321±111 0.54 
Exercise 504±127 602±163 0.02 
Time to peak filling (RR)    
Rest 0.18±0.08 0.18±0.09 0.84 
Exercise 0.25±0.09 0.16±0.08 0.001 
∆ nTTPF +0.07±0.11 -0.03±0.12 <0.005 
Vasculo-Ventricular Coupling ratio 
(VVC) (EaI/ELVI)  
   
Rest 0.57±0.20 0.62±0.22 0.36 
Exercise 0.55±0.19 0.41±0.15 0.01 
∆ VVC -0.01±0.15 -0.25±0.19 <0.001 
Relative ∆ Stroke Volume Index     
Exercise 0.99±0.34 1.25±0.47 0.04 
Relative ∆ Cardiac Output  Index    
Exercise 1.36±0.45 2.13±0.72 <0.001 
Relative ∆ ELVI     
Exercise 1.35±0.50 1.85±0.63 0.01 
Relative ∆ EaI     
Exercise 1.52±0.48 1.28±0.44 0.17 
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Plus-minus values are means ± SD.  When patients on beta blockers were excluded from 
analysis, the level of significance were similar apart from peak filling rates during exercise 
(P=0.08). RR – values normalised for R-R interval, EDC end diastolic count. SBP systolic blood 
pressure, DBP diastolic blood pressure, MABP mean arterial blood pressure. Relative ∆ 
Stroke Volume Index is SVi EXERCISE / SVi REST, Relative ∆ Cardiac Output Index is COi EXERCISE / 
COi REST. Relative ∆ ELVI is ELVIEXERCISE / ELVIREST.  Relative ∆ EaI is EaIEXERCISE / EaIREST. ∆ Vasculo-
ventricular coupling ratio is (EaI/ELVI)EXERCISE - (EaI/ELVI)REST.  
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Figure 1. Panel A shows cardiac MR images of a patient with HfpEF and the corresponding 
localized 31P MR spectra from the left ventricle is shown in panel B. The corresponding peaks 
of PCr and the γ-, α-, and β-phosphate (resonances of the ATP) are labeled. Panel C shows 
individual PCr/ γ-ATP ratio in patients with HfpEF and Controls. The PCr/ γ-ATP ratio was 
significantly reduced in patients with HfpEF compared to healthy controls, P= 0.003 
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Chapter III 
Increased atrial contribution to left ventricular filling compensates for 
impaired early filling during exercise in Heart Failure with Preserved Ejection 
Fraction 
 
Introduction 
HfpEF accounts for approximately half of patients with clinical features of chronic heart 
failure (10) These patients are typically elderly women who frequently have associated 
hypertension, diabetes, and/or coronary artery disease. (14) They have similar hospital 
length of stay, admission rates (11, 12) and mortality rate to that of patients with systolic 
heart failure (12). The prevalence of HfpEF appears to be increasing and in contrast to 
systolic heart failure the mortality rate of this disorder is not declining. (11) 
 
Many patients with HfpEF have slow active relaxation and/or increased LV passive diastolic 
stiffness at rest. (1) In addition, there is a dynamic impairment of left ventricular active 
relaxation during isometric (handgrip) exercise in HfpEF. (58) However, the role of LA 
function during exercise remains poorly understood in HfpEF despite its key role in 
optimizing LV end diastolic volume, especially in the context of a possible slowing of LV 
active relaxation and increased LV stiffness. (1, 58) Previous studies have primarily focussed 
on how well geometrical aspects of the LA predicts diastolic LV dysfunction (42) and 
cardiovascular event (43, 44) but these observations provide little insights on how LA 
function plays a role in the pathophysiology of HfpEF especially during exercise when the 
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majority of patients experience breathlessness. In this study, using radionuclide 
ventriculography, we evaluated the role of LA function in the pathophysiology of HfpEF by 
investigating both LA and LV function at rest and during exercise. 
 
Method 
Study Participants 
We studied Twenty-five HfpEF patients prospectively recruited from heart failure clinics. 
Fifteen healthy age-matched-controls (volunteers) with no cardiac history, hypertension or 
diabetes mellitus were also studied. All study participants had clinical examination, 12-lead 
electrocardiogram, pulmonary function test, echocardiogram, metabolic exercise test and 
radionuclide ventriculography (rest and exercise). All patients had signs and/or symptoms of 
heart failure with a LV ejection fraction >50% by transthoracic echocardiography and met 
the criteria of Yturralde and Gaasch for diastolic heart failure (19). All healthy controls had a 
normal clinical cardiovascular examination, 12-lead electrocardiogram, echocardiogram and 
a metabolic exercise test. Patients with severe pulmonary disease, significant valvular heart 
disease, atrial fibrillation, or evidence of hypertrophic cardiomyopathy were excluded. The 
investigations were performed at The University of Birmingham with approval of the 
Research Ethics Committee. Informed consent was obtained from all subjects. 
 
Metabolic Exercise Testing 
The metabolic exercise testing was performed on a Schiller CS-200 Ergo-Spiro exercise 
machine which was calibrated before every study. Subjects underwent spirometry and this 
was followed by symptom-limited erect treadmill exercise testing using incremental ramp 
protocol (speed and inclination was increased every minute) with simultaneous respiratory 
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gas analysis (125, 126). Samplings of expired gases were performed continuously, and data 
were expressed as 10-second means.  Minute ventilation (VE), oxygen consumption (VO2), 
carbon dioxide production (VCO2) and respiratory exchange ratio (RER) were obtained. 10-
second-averaged VE and VCO2, from the initiation of exercise to anaerobic threshold, were 
placed in to an excel worksheet (Microsoft Excel 2003, Microsoft Corp, Bellevue, WA) to 
calculate the VE/VCO2 slope via a linear regression (y= Ax + B, A = slope) as previously 
described. (172) Peak oxygen consumption (peak VO2) was defined as highest value of 
oxygen consumption measured during the exercise period. Blood pressure and ECG were 
monitored throughout.  Subjects were encouraged to exercise to exhaustion with a minimal 
requirement of RER > 1. 
 
Resting Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position with 
a Vivid 7 echocardiographic machine (GE Healthcare) and a 2.5-MHz transducer.  Resting 
scans were acquired in standard apical 4-chamber and apical 2-chamber. LV volumes were 
obtained by biplane echocardiography, and LVEF was derived from a modified Simpson’s 
formula (127). Pulse wave Doppler sample volume was placed at the mitral valve tips to 
record 3 cardiac cycles. Mitral annulus velocities by pulse wave Tissue Doppler imaging (PW-
TDI) were recorded from basal antero-lateral segment. LA volumes were measured by the 
area length method from apical 2 and 4 chambers as previously described (127).  Left 
ventricular hypertrophy was defined as a left ventricular mass indexed to body surface area 
that exceeded 88 g/m2 for women and 102 g/m2 for men. (127) Studies were stored digitally 
and analyzed off-line.  
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Radionuclide Ventriculography  
Left ventricular ejection fraction and diastolic filling were assessed by radionuclide 
ventriculography using a standard technique at rest and during graded semi erect exercise 
on a cycle ergometer as previously described in detail by our group (173).  Twenty minutes 
after an intravenous injection of 0.03 mg/kg stannous pyrophosphate, 5 mL of blood was 
drawn into a heparinised syringe and incubated for 10 minutes with 750 MBq of 99mTc 
pertechnetate before re-injection. Studies were acquired on a small-field-of-view gamma 
camera fitted with a low-energy, general-purpose, parallel-hole collimator and interfaced to 
a dedicated minicomputer. With the patient on the cycle ergometer, the detector was 
adjusted for the left anterior oblique view with the best ventricular separation and 10° to 
15° of caudal tilt. A 20% tolerance window was set about the patient's heart rate, and each 
RR interval was divided into 28 equal frames throughout. A constant number of frames per 
RR interval ensure constant temporal resolution during diastole at all heart rates. Three 
minutes of data were acquired at rest and during exercise after a 30-second period for 
stabilization of heart rate. Exercise was performed at 35% workloads of heart rate reserve 
because at HR above >100-110/ min, the early and late LV filling curves begin to merge. The 
composite cycle derived from each stage was spatially and temporally filtered. Left 
ventricular end-diastolic counts corrected for background gamma activity were obtained by 
means of a semi-automated edge detection algorithm. Venous blood samples (≈ 5.0 mL) 
were obtained for weighing and for counting of blood gamma activity during each scan in 
order to correct for physical and physiological decay as well as for determination of relative 
volume changes..  (120)  The validity of these radionuclide measures of diastolic filling at 
high heart rates has been established previously (121, 122). All gated blood pool scan-
derived volumes were normalized to body surface area, yielding their respective indexes: 
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end-diastolic volume index (EDVi), end-systolic volume index (ESVi), stroke volume index 
(SVi), and cardiac output index (COi). In order calculate changes in these volumes during 
exercise, relative volume changes were determined as follows: relative change in EDVi is 
defined as EDVi EXERCISE / EDVi REST; relative change in ESVi is defined as ESVi EXERCISE / ESVi REST; 
relative change in SVi is defined as SVi EXERCISE / SVi REST; relative change in cardiac output 
Index is COi EXERCISE / COi REST. 
 
The activity-time curve (ATC) (figure 1) was exported from LinkMedical MAPS software, Sun 
Microsystems into DPlot graph software (Version 2.2.1.4, HydeSoft Computing, LLC, Vicksburg, 
USA). The first derivative of the ATC curve was computed to represents the rate of LV volume 
changes. End-systole (ES) is defined as the lowest ATC point. Stroke volume (SV) is defined as 
the difference between end-diastolic count (EDC) and end-systolic count. Peak emptying rate 
(PER) was defined as the negative peak of the first derivative curve during systole and was 
expressed in EDC/sec. Likewise, peak early filling rate (PEFR) was defined as the early positive 
deflection of the first derivative curve during diastole, expressed in EDC/sec. The early LV filling 
was measured from the corresponding ATC segment and was expressed as percentage of 
stroke volume (%SV). The interval from ES to the time when PEFR occurred was defined as time 
to peak early filling rate (TTPEF), expressed in msec. The late positive deflection of the first 
derivative curve during diastole is attributed to the atrial contraction, this peak defines the 
peak ventricular filling rate during atrial contraction (PAFR).  We used the late positive 
deflection of the first derivative curve as a measure of ‘atrial function’ however strictly this part 
of the curve is also determined by ventricular properties. The atrial contribution to LV filling 
was measured from the corresponding ATC segment and expressed as percentage of stroke 
volume (%SV).  
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The interval from end of early filling to the time when PAFR occurred was defined as time to 
peak atrial filling rate (TTPAF), expressed in msec. The diastolic period was expressed as a 
percentage of R-R interval. The atrial component of diastolic period was defined as the 
percentage of the diastolic period that was spent in atrial contraction. All these parameters for 
diastolic function assessment have been previously described (174, 175). The early and atrial 
contribution of diastolic filling were fused on the activity-time curve during exercise in three 
patients and three healthy controls, thus these exercise data were excluded in the final 
analysis.  
 
Statistics 
Continuous variables are expressed as means ± SD. Unpaired Student’s t-test (2-tail) was 
used to assess differences between mean values. ANCOVA with baseline values as 
covariates was performed to test for the significance of differences in between patients and 
controls during exercise. Categorical variables were compared with Pearson Chi-Square test. 
All reported P values were calculated on the basis of two-sided tests and a P value of <0.05 
was considered to indicate statistical significance. Variances of data sets were determined 
using F-test. Pearson correlation coefficient (r) was used to describe the relationship 
between variables. All subjects were included in the model. SPSS (v15.0) was used to 
perform the statistical operations. 
 
Results 
Characteristics of Patients 
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HfpEF Patients were generally females, overweight, aged 66±11 years old with a history of 
hypertension consistent with previous large epidemiological studies (12) (Table 1).  Blood 
pressure was well treated (systolic BP 138±17mmHg vs. 130±25mmHg; p=0.24, in patients 
vs. controls). The tissue Doppler E/E’ at the basal anterior-lateral segment (a measure of left 
ventricular end-diastolic pressure) (161), was significantly higher in patients than controls 
(11±4 vs. 8±3, p=0.01).  Left ventricular end-diastolic volume indexed for body surface area 
(EDVi) was significantly smaller in patients with HfpEF than controls. Patients with HfpEF 
also had significantly reduced peak VO2 compared to controls (20±5 ml/Kg/min vs. 35±8 
ml/Kg/min, p<0.001). The VE/VCO2 slope was also higher in patients with HfpEF than 
controls (33±5 vs. 28±3, p=0.002). Resting E/E’ correlated negatively with peak VO2 (r=-
0.389, P=0.019).  (Table 2) 
 
Left ventricular systolic and diastolic characteristics 
At Rest 
Peak emptying rate (PER), peak early filling rate (PEFR) and time to peak early filling (TTPEF) 
were similar in patients and controls. (Table 3) 
 
During exercise 
LVEF was significantly lower in patients compared to controls (69 ± 9 % vs. 73 ± 10 %, 
p<0.05). Peak early filling rate was significantly lower in patients compared to controls 
(387±109 EDC/sec vs. 561±156 EDC/sec, p<0.001). Peak early filling rate correlated 
positively with peak VO2 (r=0.485, P=0.004) and negatively with VE/VCO2 (r=-0.423, P=0.013) 
during exercise but not at rest (p=0.399 and p= 0.320, respectively). 
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Atrial contribution to diastolic filling 
At rest 
Peak atrial filling rate (PAFR) and time to peak atrial filling (TTPAF) were similar in patients 
and controls.  The atrial contribution to LV filling was similar in patients and controls. The 
total diastolic period and atrial component of diastolic period were both similar in patients 
and controls. (Table 3) 
 
During exercise 
The atrial contribution to LV filling was significantly higher in patients than controls (46 ± 11 
%SV vs. 30 ± 9 %SV, p<0.001). In addition, the atrial contribution to LV filling correlated 
negatively with peak early filling rate during exercise (r=-0.6, P<0.001) but not at rest 
(r=0.04, P<0.83). The total diastolic period and atrial component of diastolic period were 
both similar in patients and controls. (Table 3)  
 
The effects of LVH on LV filling 
 
When patients with and without LVH were analyzed separately the findings of this study 
remained significant for both group of patients. In patients with LVH, during exercise, 
patients had lower peak early filling rate (415±117 EDC/sec vs. 561±156 EDC/sec, p=0.029), 
the atrial contribution to LV filling was significantly higher in patients than controls (44 ± 
11% vs. 30 ± 9%, p=0.004). At rest the two groups were no different. In patients without 
LVH, during exercise, patients had lower peak early filling rate (369±104 EDC/sec vs. 
561±156 EDC/sec, p=0.001), the atrial contribution to LV filling was significantly higher in 
patients than controls (48 ± 11% vs. 30 ± 9%, p<0.001). At rest the two groups were no 
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different. When we compared patients with LVH to patients without LVH, there were no 
significant differences between peak early filling rate and atrial contribution to LV filling 
during exercise. 
 
Discussion 
Whilst there has been a considerable literature examining the role of atrial contribution to 
LV filling at rest in patients with HfpEF this is to the best of our knowledge, the first study to 
investigate LA function during exercise in patients with HfpEF and provides new insights on 
the role of LA function in the pathophysiology of HfpEF. The principal findings are: a) At rest, 
LV and atrial functions were similar in HfpEF and controls. b) During exercise, HfpEF patients 
showed markedly reduced early LV filling. c) HfpEF patients have increased LA contribution 
to LV filling during exercise. d) HfpEF patients have reduced systolic reserve. 
 
The atrium contributes about 20-30% of total LV stroke volume. In dilated cardiomyopathy, 
there is a compensatory increase in the LA contribution to LV filling in patients with 
asymptomatic or mildly symptomatic dilated cardiomyopathy. (176) However, in patients 
with more advanced heart failure or highly symptomatic dilated cardiomyopathy, this 
compensatory response of LA contraction is reduced and attributed to elevated LV filling 
pressure. (177)  In a study of a predominantly African American cohort of patients with 
hypertensive left ventricular hypertrophy (LVH), it was shown that those with and without 
features of HfpEF had similar systolic, diastolic and vascular function, however the cohort 
with features of HfpEF differed predominantly because they had evidence of left atrial 
dilatation and left atrial ‘failure’.  (45) In a separate community study, LA fractional area 
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change (a measure of LA emptying volume) was found to be reduced at rest in community 
older patients (≥65) with diastolic heart failure. (46)  
 
Previous studies have also found that LA volume indexed to body surface area was a 
stronger predictor of cardiovascular event in the elderly than LV mass index or LV diastolic 
dysfunction, (40) and that LA volume is a marker of LV diastolic dysfunction in patients with 
heart failure and normal LVEF. (41) Our cohort of patients had similar LA volume to controls. 
This may be because patients with atrial fibrillation (AF), a common feature in HfpEF (11, 12) 
which is strongly associated with LA enlargement (178) were excluded from the study 
because  radionuclide studies requires a regular rhythm and also this study’s aim was to 
evaluate LA function. In addition, our cohort of patients were well characterized all of whom 
met Yturralde and Gaasch criteria for diastolic heart failure (19) and are objectively very 
limited in their exercise capacity as indicated by their reduced peak VO2 and higher minute 
ventilation (VE/CO2 slope) than controls, which is prognostic in diastolic heart failure. (179) 
The use of metabolic exercise testing as a mean to show objective exercise limitation may 
have potentially identified patients with HfpEF at an early stage of the condition before the 
development of LA dilatation. 
 
Although, previous studies have revealed the importance of LA function and LA volume in 
heart failure, they provide little insight into the pathophysiology of HfpEF and even less so 
to what happen to LA contribution to LV filling during exercise. In this study we have 
demonstrated that during patients with HfpEF has an increased atrial contribution to LV 
filling during exercise (compared to controls). The reason for this we believe is maybe 
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secondary to an impaired early LV filling as previous studies have indicated that left 
ventricular filling impairment can modulate LA function. (180) 
 
We found that patients with HfpEF had significantly lower peak early filling rates during 
exercise which suggests impairment in early LV filling and relaxation during exercise. (181) 
Our findings are supported by previous studies which looked at patients with asymptomatic 
essential hypertension, and found that hypertensive patients (with LVEF either increased by 
<5% or decreased with exercise) had impaired diastolic filling during exercise. (75) With 
respect to HfpEF, some studies have alluded to the presence of profound slowing of active 
relaxation and increased LV passive diastolic stiffness (1) at rest.  
 
In this study the relative change in EDVi during exercise was non-significantly lower in HfpEF 
compared to controls (1% vs 10%), however this was in the context that in HfpEF, the atrial 
contribution to LV filling increased from 34% to 46% during exercise compared to controls 
where atrial contribution to LV filling remained essentially unchanged. Thus we believe that 
the increase in LA contribution to LV filling might represent a compensatory response to the 
observed abnormal early LV filling during exercise in order to maintain EDVi, and therefore 
we do not see a significant difference in the relative change in EDVi between the 2 groups 
during exercise.  Furthermore, this trend towards a lesser relative increase in EDVi during 
exercise in patients with HfpEF coupled with the observed smaller resting EDVi might result 
in a substantially reduced absolute EDVi (and probably stroke volume) during exercise in 
these patients with HfpEF. 
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When patients with and without LVH were analysed separately the findings were similar.  
 
Previous studies conducted by our group in patients with non-obstructive hypertrophic 
cardiomyopathy, a classic paradigm of diastolic heart failure, found that exercise left 
ventricular diastolic filling characteristics were a major determinant of peak exercise 
capacity. (76). In this study we found that during exercise and not at rest, the peak early 
filling rate had a significantly positive correlation with peak exercise capacity (peak VO2) and 
a significantly negative correlation with VE/VCO2 slope. Thus this impairment in early filling 
during exercise might in part explain why patient with HfpEF have poor exercise capacity. 
Furthermore, VE/VCO2 slope has been shown to have prognostic value in patients with 
diastolic heart failure with respect to mortality and hospitalization. (179) 
 
These studies were performed during sub-maximal exercise. It is possible that during more 
intense levels of exercise the dynamic impairment in early LV filling may worsen and that 
the LA compensatory response may then become insufficient or might even fail, the net 
result being a poor stroke volume response during exercise resulting in exercise limitation in 
HfpEF. Interestingly also, we observed this impairment in early LV filling during exercise in a 
cohort of patients with relatively normal LA volume. It is possible that this impairment in 
early LV filling can be further exacerbated when the LA is dilated because previous studies 
have shown that atrial dilatation can contribute to alterations in LA pressure and therefore 
reduced early diastolic filling. (47) Furthermore LA dilatation in HfpEF is associated with 
reduced LA function (45), reduced LA strain (during systole) and increased LA stiffness (182), 
the combination of which might compromise atrial kick and  therefore might diminish LA 
compensatory response for any poor early LV filling during exercise. Furthermore when 
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these patients with HfpEF lose their atrial function completely (i.e. atrial fibrillation) not 
surprisingly the result is more severe diastolic dysfunction as well as increase hospitalization 
or death. (49) 
 
We also found that at rest contractility appeared normal in HfpEF, consistent with recent 
data. (183) However during exercise, systolic function appear diminished as indicated by the 
significantly lower LVEF and a trend (non-significant) to lower peak emptying rates in 
patients than controls. This observation is supported by previous studies in subjects with 
LVH. (184) Perhaps this is not surprising because we know from previous studies that 
despite EF being normal, at rest, early LV longitudinal dysfunction  has been detected by 
tissue doppler imaging (157), as well as the presence of systolic and diastolic dyssynchrony 
in HfpEF (56, 57), which could further exacerbate systolic reserve in HfpEF. Another factor 
that can limit cardiovascular reserve is chronotropic response. The metabolic exercise data 
reveals that HfpEF patients have significantly lower heart rate during peak exercise 
compared to controls indicating the presence of chronotropic incompetence as previously 
reported (77). This remained significant even when patients on beta-blockers were excluded 
from the analysis (p<0.001).  
 
What we have learnt from this study which has not previously been described in HfpEF is 
that there is a dynamic pathophysiological process whereby early LV filling is impaired 
during exercise which correlates with peak exercise capacity and minute ventilation. As a 
result there is a compensatory increase in LA contribution to LV filling. Furthermore, there is 
a reduction in systolic reserve during exercise. We believe these findings play an important 
part in the pathophysiology of HfpEF. 
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Study limitations 
Our radionuclide exercise protocol involved asking subjects to maintain a HR which was 35% 
of HR reserve above their resting HR. Since this HR reserve was calibrated to peak HR rate 
on metabolic exercise testing, the absolute workload and heart rate was lower in patients. 
Comparison of patients at the same workload would be inappropriate because this would 
represent a higher relative workload in patients. Furthermore, most of the changes in SV 
occur in the first part of exercise with subsequent increases in cardiac output being 
principally due to increases in HR. (171)  
 
A minority of patients were on beta-blockers which may have some negative lusotropic 
effect on the myocardium however, if anything one would expect the net effect of beta-
blockers would be less atrial contribution to LV filling as early LV filling is improved. To stop 
the beta blockers would have been unethical and could also result in rebound tachycardia. 
Besides, when patients on beta blocker were removed from the analysis the findings of 
enhanced atrial contribution to LV filling and reduced peak early filling rates during exercise 
remained significant (p<0.001 and p<0.001, respectively). In addition, some patients were 
on calcium blockers however these were all peripherally acting (dihyodropyridines for 
hypertension) and therefore are not expected to affect the myocardium.    
 
Conclusion 
Patients with HfpEF have increase left atrial contribution to LV filling as a compensatory 
response to impaired early LV filling during cycle exercise. 
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Table 1: Baseline characteristics 
  Patient Control P value 
N 25 15  
Females no. (%) 16 (64) 9 (60)  
Age (years) 66 ± 11 63 ± 7 0.33 
BMI 30 ± 4 27 ± 5 0.03 
Left ventricular hypertrophy no.  12  4 - 
Hypertension no.  17 0 - 
Ischaemic heart disease no.  4 0 - 
Diabetes no.  3 0 - 
NHYA functional class no.     
II 21 0 - 
III 4 0 - 
Medications no.     
Diuretic 7 0 - 
ACE inhibitor 17 0 - 
ARB 2 0 - 
Beta-blocker 7 0 - 
Calcium blocker 7 0 - 
Alpha Blocker 3 0 - 
Nitrate 3 0 - 
Plus-minus values are means ± SD. NYHA denotes New York Heart Association, ACE 
angiotensin-converting enzyme, ARB angiotensin II receptor blockers. 
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Table 2: Metabolic exercise test and Echocardiographic parameters 
  Patient Control P value 
Metabolic exercise test    
peak VO2 (ml/Kg/min) 20 ± 5 35 ± 8 <0.001 
RER 1.07 ± 0.08 1.15 ± 0.11 0.017 
% Predicted peak VO2 58 ± 12 97 ± 17 <0.001 
VE/VCO2 33 ± 5 28 ± 3 0.002 
Breathing Reserve (L/min) 40 ± 16 41 ± 16 0.92 
Heart rate (beats/min)    
Rest 72 ± 15 80 ± 15 0.13 
Peak 123 ± 22 164 ± 11 <0.001 
Systolic blood pressure (mmHg)    
Rest  138 ± 17 130 ± 25 0.24 
Peak 185 ± 29 188 ± 28 0.72 
Diastolic blood pressure (mmHg)    
Rest 81 ± 11 80 ± 13 0.83 
Peak 81 ± 14 83 ± 9 0.57 
Echocardiography    
    
Ejection fraction (%) 64 ± 16 64 ± 6 0.93 
EDVi (mL/m2) 30 ± 8 40 ± 12 0.02 
ESVi (mL/m2) 10 ± 5 14 ± 4 0.02 
LA Volume Index (mL/m2) 21 ± 4 19 ± 5 0.41 
MV E Vel 0.72 ± 0.18 0.63 ± 0.12 0.09 
MV A Vel (m/s) 0.75 ± 0.16 0.58 ± 0.19 0.004 
MV E/A Ratio 0.99 ± 0.30 1.05 ± 0.32 0.56 
MV DecT (ms) 279 ± 57 265 ± 77 0.51 
E/E' Antlat 11 ± 4 8 ± 3 0.01 
 
Plus-minus values are means ± SD. LA - left atrium, E/E’ - mitral E-wave velocity-E’- tissue 
velocity (PW-TDI) at basal anterior-lateral ratio, EDVi –end diastolic volume indexed for body 
surface area, ESVi - end systolic volume indexed for body surface area. MV DecT - mitral 
valve deceleration time. The body-mass index is the weight in kilograms divided by the 
square of the height in meters. 
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Table 3: Radionuclide Ventriculography at Rest and during Exercise: Early and Atrial  
Filling Characteristics and Systolic Function 
  Patient Control P value 
Heart rate (beats/min)    
Exercise 86 ± 12 98 ± 12 <0.001 
Systolic blood pressure (mmHg)    
Exercise 182 ± 27 168 ± 28 0.87 
Diastolic blood pressure (mmHg)    
Exercise 92 ± 11 93 ± 8 0.40 
Ejection Fraction (%)    
Rest 65 ± 9 64 ± 8 0.58 
Exercise 69 ± 9 73 ± 10 0.04 
Peak emptying rate (EDC/sec)    
Rest 371 ± 90 393 ± 102 0.48 
Exercise 380 ± 225 520 ± 168 0.06 
Time to peak emptying rate(msec)    
Rest 133 ± 66 159 ± 55 0.22 
Exercise 110 ± 67 138 ± 83 0.25 
Peak early filling rate (EDC/sec)    
Rest 347 ± 119 315 ± 123 0.43 
Exercise 390 ± 112 561 ± 156 <0.001 
Peak atrial filling rate (EDC/sec)    
Rest 213 ± 97 196 ± 94 0.59 
Exercise 361 ± 104 295 ± 74 0.14 
Time to peak early filling (msec)    
Rest 141 ± 59 151 ± 70 0.62 
Exercise 104 ± 48 86 ± 33 0.27 
Time to peak atrial filling (msec)    
Rest 99 ± 52 123 ± 112 0.29 
Exercise 74 ± 16 63 ± 12 0.02 
Early LV filling (%SV)    
Rest 66 ± 12 67 ± 10 0.85 
Exercise 55 ± 10 70 ± 9 <0.001 
Atrial contribution to LV filling (%SV)    
Rest 34 ± 12 33 ± 10 0.85 
Exercise 45 ± 10 30 ± 9 <0.001 
Total systolic period (%RR)    
Rest 40 ± 6 36 ± 9 0.06 
Exercise 46 ± 4 49 ± 6 0.05 
Total diastolic period (%RR)    
Rest 60 ± 6 64 ± 9 0.06 
Exercise 54 ± 6 51 ± 6 0.05 
Early component of diastolic period (%)    
Rest 66 ± 8 63 ± 12 0.33 
Exercise 59 ± 11 60 ± 8 0.97 
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Atrial component of diastolic period (%)    
Rest 34 ± 8 37 ± 12 0.33 
Exercise 40 ± 11 40 ± 8 0.97 
Relative change in EDVi    
Exercise 1.01 ± 0.31 1.10 ± 0.39 0.44 
Relative change in ESVi    
Exercise 0.98 ± 0.46 0.95 ± 0.59 0.91 
Relative change in SVi    
Exercise 1.06 ± 0.35 1.28 ± 0.46 0.11 
Relative change in COi    
Exercise 1.37 ± 0.44 1.97 ± 0.67 0.002 
 
Plus-minus values are means ± SD. EDC end diastolic count. SBP systolic blood pressure, DBP 
diastolic blood pressure. %RR - % of R-R interval,  
 
 
Figure 1: An example of a radionuclide ventriculography image with the activity-time curve 
for a healthy control. 
 
The image show the subject’s left ventricle and the corresponding activity-time curve 
demonstrating early and atrial contribution to LV filling. EDC – end diastolic count, ES – end 
systole. 
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Chapter IV 
 
Myocardial contractile inefficiency and dyssynchrony in Heart Failure with 
Preserved Ejection Fraction and narrow QRS complex 
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Chapter Four 
 
Myocardial contractile inefficiency and dyssynchrony in Heart Failure with 
Preserved Ejection Fraction and narrow QRS complex 
 
 
Introduction 
Many consider heart failure with preserved ejection fraction (HfpEF) to be a disorder of 
diastolic function (50), whilst others believe that it may be due to a combination of diastolic 
abnormalities with subtle disturbances of systolic function that are  insufficient to reduce 
LVEF (162). Studies using tissue Doppler imaging (TDI) have demonstrated the presence of 
diastolic and/or systolic dyssynchrony in patients with HfpEF (56, 57). Recently a novel 
technique known as speckle tracking imaging (STI), has been used to quantitatively evaluate 
myocardial strain patterns independent of cardiac translation and insonation angle (185), 
which are major limitations of TDI derived myocardial strain and velocities. (186) STI is also 
less time-consuming than TDI and has been validated in experimental and human studies. 
(185, 187). In addition, STI allows for an assessment of segmental synchronicity (188) and 
also longitudinal strain delay index (LSDi) (189).  
 
LSDi is derived from longitudinal strain (ε) patterns and is a strong predictor of responders 
to cardiac resynchronization therapy (CRT) in both ischaemic and non-ischaemic patients. 
(189) LSDi is an index that quantifies the wasted energy in dyssynchronous ventricles, which 
is brought about because delayed segments do not contribute fully to end-systolic (ES) 
function.  Furthermore, the wasted energy is greater in delayed segments with preserved 
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contractility compared to delayed segments with reduced contractility (i.e. scar or fibrotic 
myocardium). 
 
In this study, using STI, we aim to assess LV global and segmental synchronicity, and to 
determine which LV segments display delayed motion, which can therefore identify 
potential cardiac pacing sites for correction of LV dyssynchrony. In addition, we aim to 
quantify the wasted energy because of systolic dyssynchrony by determining LSDi.  
 
Method 
Study Participants 
HfpEF patients 
We studied 38 HfpEF patients, who were prospectively and consecutively recruited from 
heart failure clinics. All study participants had clinical examination, 12-lead ECG, a 
pulmonary function test, as well as an echocardiogram and a metabolic exercise test. All 
patients had signs and/or symptoms of heart failure with a LV ejection fraction >50% by 
transthoracic echocardiography and met the criteria of Yturralde and Gaasch for diastolic 
heart failure (19). Patients with severe pulmonary disease, significant valvular heart disease, 
atrial fibrillation, or evidence of hypertrophic cardiomyopathy were excluded. Patients with 
rhythm other than sinus and had QRS duration> 120ms were excluded. The study was 
performed at The University of Birmingham with approval of the Research Ethics 
Committee. Informed consent was obtained from all patients and controls.  
Healthy controls 
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We studied 33 healthy controls with no history of cardiac disease, hypertension or diabetes 
mellitus. Healthy volunteers from the community who responded to our advertisements 
were recruited on the basis that they were of similar age and gender as our patient group 
and had normal clinical cardiovascular examination, 12-lead electrocardiogram, 
echocardiogram and metabolic exercise testing. 
 
Metabolic Exercise Testing 
The metabolic exercise testing was performed on a Schiller CS-200 Ergo-Spiro exercise 
machine which was calibrated before every study. Subjects underwent spirometry and this 
was followed by symptom-limited erect treadmill exercise testing using incremental ramp 
protocol (speed and inclination was increased every minute) with simultaneous respiratory 
gas analysis (125, 126). Samplings of expired gases were performed continuously, and data 
were expressed as 30-second means.  Minute ventilation, oxygen consumption, carbon 
dioxide production, and respiratory exchange ratio (RER) were obtained.  Peak oxygen 
consumption (V02max) was defined as the highest value of oxygen consumption measured 
during the exercise period. Blood pressure and ECG were monitored throughout.  Subjects 
were encouraged to exercise to exhaustion with a minimal requirement of RER > 1. 
 
Resting Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position with 
a Vivid 7 echocardiographic machine (GE) and a 2.5-MHz transducer.  Resting scans were 
acquired in standard apical 4-chamber and apical 2-chamber views. All echocardiographic 
measurements were averaged from 3 heart beats. LV ejection fraction (LVEF) and left 
ventricular hypertrophy (LVH) was determined in accordance with the guidelines. (127) 
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From the LV-inflow pattern (measured at the tips of the mitral valve), peak early (E) and late 
(A) filling velocities, E/A ratio, and E-velocity deceleration time (DcT) were measured. The 
isovolumic relaxation time (IVRT) was determined using pulsed-wave Doppler velocity data 
of the LV inflow. Tissue Doppler was applied end-expiratory in the pulsed-wave Doppler 
mode at the level of the lateral mitral annulus from an apical 4-chamber view. The velocities 
of the mitral annular systolic wave (S’), early diastolic wave (E’), and late diastolic wave (A’) 
were noted. Lateral mitral annulus velocities were recorded to derive E/E’.  Parasternal 
circular short-axis images were taken at the papillary (identified by the papillary muscles 
present) similar to previous studies. (190) 
 
Speckle Tracking Imaging (STI)  
STI was measured using a commercially available speckle tracking system in an ECHOPAC 
(ver. 4.2.0) workstation.  Myocardial deformation measurements were performed using 
tissue speckle tracking. In this speckle tracking system, the displacement of speckles of 
myocardium in each spot were analyzed and tracked from frame to frame.  We selected the 
best-quality digital two-dimensional image cardiac cycle  and the left ventricle endocardium 
was traced at end-systole.(129).  The region of interest width was adjusted as required to fit 
the wall thickness.  The software package then automatically tracked the motion through 
the rest of the cardiac cycle.  The onset of QRS complex was taken as the beginning of 
systole. Adequate tracking was verified in real time.  A high frame rate between 70-100 Hz 
was used as in previous studies. (191)  For each subject, longitudinal strain values for all 12 
LV myocardial segments in each of the apical 4 and 2 chamber views were measured to 
derive the LV longitudinal strain, strain rates and velocity curves. In addition, radial and 
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circumferential strain values for all six LV myocardial segments in the short-axis view at the 
papillary level were measured to derive the radial and circumferential strain curves. 
 
Strain delay index and synchronicity assessment 
As described previously by Lim et al (189), in dyssynchronous ventricles, segments which are 
delayed do not contribute fully to global ES function. The energy wasted per segment 
because of dyssynchrony is expressed by the difference between peak (εpeak) and ES strain 
(εES). If all the LV segments were synchronous then the strain delay index would be zero 
which means all the myocardial energy during the systolic period is efficiently used to push 
blood out of the LV. However, as LV systolic dyssynchrony worsens the strain delay index 
(εpeak - εES) also increases. When the strain delay index is high, then whilst some LV segments 
are contracting others are still lagging behind and thus not all potential energy is efficiently 
used to move blood out of the LV during systole. The strain delay index is a mathematical 
representation of the sum of wasted energy because of systolic dyssynchrony across LV 
myocardial segments:  
 
The strain delay index was determined from the longitudinal strain curves derived from 2D 
speckle tracking (EchoPac version 4.2.0, GE).  The strain delay index proposed by Lim et al 
(189) is actually a magnitude of strain (%) and not of  time as suggested by the word ‘delay’. 
The onset of the QRS complex was used as the reference point for the start of systole. Strain 
curves derived from a single cardiac cycle were exported into DPlot graph software (Version 
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2.2.1.4, HydeSoft Computing, LLC, Vicksburg, USA) for analysis. The steps to determine LSDi 
were as follows: a) A global ε curve representing LV function was computed by averaging 12 
segmental LV ε curves. b) The time to peak of the global ε curve was ascertained to 
determine the time of ES and the strain at ES of each of the 12 segments (εES). c) Peak ε and 
time to peak ε were determined in the 12 segments as the ε curve reached its minimum 
value during the cardiac cycle. d) The difference (εpeak - εES) in each segment (12 segments) 
was summed to derive the strain delay index. (See figure 1) For segments that had positive 
strain or biphasic strain with the peak positive ε greater than the maximal absolute negative 
strain, the difference (εpeak - εES) was entered as zero. Radial and circumferential strain delay 
index was determined similarly but radial and circumferential ε curves from 6 segments 
were used (at papillary level).  
 
Time to peak longitudinal strain (Ts-LS), circumferential strain (Ts-Circ) and radial strain (Ts-
Rad) was also determined by STI. For the assessment of synchronicity, the standard 
deviation (SD) of Ts-LS, Ts-Circ and Ts-Rad was computed to derive Ts-LS-SD, Ts-Circ-SD and 
Ts-Rad-SD values respectively. Time to peak longitudinal velocity S (Ts), E (Te) and A (Ta) and 
peak longitudinal strain rate S (Ts-LSr), E (Te-LSr) and A (Ta-LSr) was also determined. For 
the assessment of synchronicity, the SD of Ts, Te and Ta were computed to derive Ts -SD, Te 
-SD and Ta -SD values respectively. The SD of Ts-LSr, Te-LSr and Ta-LSr was also determined 
to derive the Ts-LSr-SD, Te-LSr-SD and Ta-LSr-SD, respectively. For comparison, all time 
values were normalized for R-R interval, which was calculated by dividing the time period by 
the R-R interval. 
 
Statistics 
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Continuous variables are expressed as mean ± SD. Unpaired Student’s t-test (2-tail) was 
used to assess group differences. Categorical variables were compared using the Chi-Square 
test. A two-tailed p value of <0.05 was considered statistically significant. Variances of data 
sets were determined using Levene's test. Pearson correlation coefficient (r) was used to 
describe the relationship between two variables. All subjects were included into the model. 
SPSS (v15.0) was used to perform the statistical analyses. 
Results 
Characteristics of the Study Group  
HfpEF Patients were generally females (71%), overweight (BMI>25), aged 67±9 years old and 
hypertensive (Table 1).  Blood pressure was well treated (systolic BP 137±21mmHg vs. 
134±21mmHg; p=0.49, in patients vs. controls). The tissue Doppler E/E’ at the basal 
anterior-lateral segment (a measure of left ventricular end-diastolic pressure) (161), was 
significantly higher in patients than controls (11±4 vs. 7±2, p<0.001).  Patients with HfpEF 
also had significantly reduced VO2max compared to controls (21±5 ml/Kg/min vs. 34±7 
ml/Kg/min, p<0.001). The minute ventilation-carbon dioxide production relationship 
(VE/VCO2 slope) was also higher in patients with HfpEF than controls (33±6 vs. 28±3, 
p=0.001).  
 
Strain Delay Index 
LSDi was significantly higher in patients with HfpEF than controls (-14.36±8.24% vs. -
10.73±5.62%, p< 0.05). There was a non-significant trend towards a higher radial strain 
delay index and circumferential strain delay index in patients with HfpEF than controls 
(4.80±6.34% vs. 2.27±2.39%, p= 0.05 and -7.67±5.48% vs. -5.45±4.26%, p= 0.12, 
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respectively). (See Table 2) There were no significant correlation between LSDi and LVEF or 
stroke volume. 
 
Systolic and diastolic synchronicity  
The standard deviation of time to peak systolic velocity (Ts-SD) was significantly higher in 
HfpEF compared to controls (0.074±0.026 RR vs. 0.060 ± 0.023 RR, p< 0.05). The standard 
deviation of time to peak early diastolic longitudinal strain rate (Te-LSr-SD) was also 
significantly higher in HfpEF compared to controls (0.067 ± 0.031 RR vs. 0.054 ± 0.020 RR, p< 
0.05). There were no differences in Ts-LS-SD, Ts-Circ-SD and Ts-Rad-SD in patients with 
HfpEF vs. controls. (Table 3) There were no significant correlation between the parameter of 
diastolic dyssynchrony (Te-LSr-SD) and parameters of diastolic function such as E/E’, IVRT 
and MV DecT. 
 
Left ventricular segmental delay 
Time to peak systolic velocity was delayed mostly in the anterior wall in patients with HfpEF 
compared to controls (Anterior mid: 0.208±0.094 RR vs. 0.153±0.080 RR, p< 0.05). (Table 4). 
 
Subgroup analysis 
There were no significant differences in LSDi, Ts-SD, Te-LSr-SD and time to peak systolic 
velocity in the anterior wall between patients with and without left ventricular hypertrophy. 
Similarly there were no significances differences in these parameters between patients with 
and without ischaemic heart disease.  
 
Discussion 
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Whilst longitudinal dyssynchrony has been previously described in HfpEF using tissue 
Doppler imaging, to the best of our knowledge, this is the first study to use STI to investigate 
LV systolic and diastolic dyssynchrony, and to assess LV contractile efficiency in patients 
with HfpEF with narrow QRS complex. The principal findings are: a) patients with HfpEF 
exhibit a higher longitudinal strain delay index than control subjects i.e. increased 
myocardial energy wastage due to LV dyssynchrony b) HfpEF patients also exhibit both 
systolic and diastolic dyssynchrony compared to controls. c) the LV anterior wall displays the 
most delayed movement in patients with HfpEF.  
 
The presence of systolic and diastolic dyssynchrony in patients with SHF has been well 
evaluated over the years. (192) In recent years, a number of studies using conventional 
echocardiography and TDI have reported subtle myocardial systolic dysfunction in HfpEF 
(157). TDI based studies measuring time-delay to assess synchronicity have shown that LV 
diastolic and/or systolic dyssynchrony was present in 60% of patients with HfpEF. (57) 
Interestingly, the prevalence of systolic dyssynchrony or both systolic and diastolic 
dyssynchrony were commoner in SHF than in HfpEF; however isolated diastolic 
dyssynchrony was more prevalent in HfpEF than in SHF. (57) 
 
In this study using STI we have shown the presence of LV systolic dyssynchrony in HfpEF as 
evident by the higher LSDi and the higher Ts-SD (a marker of systolic dyssynchrony (57)). In 
addition, there was evidence of LV diastolic dyssynchrony as indicated by the higher Te-LSr 
(a marker of diastolic function and related to LV relaxation (τ) (193)) in HfpEF compared to 
controls. This is an important finding because systolic dyssynchrony in HfpEF is associated 
with reduced longitudinal function and lower stroke volume. (56) Indeed, in our study, 
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global longitudinal strain (derived by STI) and peak early diastolic velocities (derived by PW-
TDI) were reduced in HfpEF patients compared to controls indicating poor long-axis 
function. Our findings furthermore support the view that HfpEF is not solely a disorder of 
diastolic function but also of systolic function (although LVEF remains ‘normal) which is 
contrary to more traditional views that HfpEF is predominantly a disorder of diastole. (183) 
 
The significantly increased longitudinal and the trend (although non-significant) to increased 
radial strain delay index and circumferential strain delay index indicate energy wastage due 
to LV dyssynchrony in HfpEF patients. This might lead to a reduction in cardiac energetic 
reserves which we had previously shown to be reduced in this group of patients.(3) 
However, there are other factors which may play a part in lowering myocardial energetics 
reserves such as  insulin resistance (108) and impaired mitochondrial function as a result of 
ageing (113). Strain delay index can also be viewed as a marker of dyssynchrony in that if all 
the segments were synchronous and peaks at the same time, then strain delay index would 
be zero. This further reinforces the finding of systolic dyssynchrony in HfpEF. In the control 
group there was also evidence of systolic dyssynchrony which is reflected by the fact the 
LSDi was not zero. We believe that even in healthy controls there will be some degree of 
systolic dyssynchrony (or at least a distribution) especially in this age group with a mean age 
of 65 years as shown in previous studies (57).  
 
In a study involving SHF patients, longitudinal strain delay index was shown to be a stronger 
predictor of CRT response than SD of time to peak myocardial velocity (TDI derived). (189) 
Furthermore, in the PROSPECT trial (2008), twelve echocardiographic parameters of 
dyssynchrony, based on both conventional and TDI, were shown to be poor predictors of 
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clinical or volume response to cardiac resynchronization therapy (CRT). (194) Recently, 
radial dyssynchrony (as measured by STI) in patients with SHF have been shown to reliably 
predict immediate and long-term response to CRT. (195) And more recently, longitudinal 
strain delay index derived from longitudinal strain (ε) patterns by STI was found to be also a 
potential predictor of responders to CRT in both ischaemic and non-ischaemic patients. 
(189) Speckle tracking appear to be superior to TDI in evaluating intra-ventricular 
mechanical dyssynchrony, potentially due to less angle dependency as  well as better signal-
to-noise of the strain signal than TDI. 
 
From a clinical perspective, currently the management of HfpEF is primarily based on 
medical therapy. (196) What we have learnt from studies in SHF is that systolic 
dyssynchrony is a strong predictor of morbidity and mortality in these patients. (197) 
Indeed, CRT which aims to correct systolic dyssynchrony have been shown to improve 
symptoms (198) and prognosis (199) in patients with congestive heart failure. Systolic 
dyssynchrony is often found in patients with SHF associated with wide QRS complexes 
however in about 30-40% of patients with normal QRS complexes they also display evidence 
of systolic dyssynchrony. (192, 200) In a study on SHF, about a third of patients with QRS 
duration above 120 ms had the lateral wall most delayed which also means that that vast 
majority (two-thirds) of cases the most delayed segment is not the lateral wall. (192) This 
may explain why about 30% of patients with severe LVEF and wide QRS complex do not 
respond to CRT, as the LV lead is usually placed on the anterior-lateral wall. (199) Such 
patients may benefit more from multisite pacing. Interestingly, in patients with SHF and 
narrow QRS complex it is actually the anterior wall that displays the most delayed 
movement, occurring in about 25% patients. (192) In this study of patients with HfpEF with 
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narrow QRS complex we find that it is also the anterior wall that appears to be most delayed 
compared to controls.  
 
Study limitations 
Our study is limited by the relatively small sample size. Ideally we would have liked to 
recruit controls with similar co-morbidity as the patient group i.e. presence of coronary 
artery disease, hypertension etc in order to demonstrate the specificity of the findings of 
this study to patients with HfpEF. However, in practice we have found that even 
asymptomatic elderly subjects with hypertension usually have reduced peak VO2 – hence a 
clear-cut distinction in this age group between hypertension with and without HFpEF is not 
straightforward. Furthermore, our controls are not so dissimilar to controls used in previous 
HfpEF studies (56, 57). The p-values quoted were unadjusted for multiple comparisons. A 
small proportion of patients had coronary artery disease which may have affected LV 
mechanics however coronary artery disease is common in HfpEF and thus is considered to 
be part of the syndrome (12). A proportion of patients with HfpEF were on medications 
which may have affected LV function however they would be expected to affect all strain 
parameters not selective ones. Furthermore, any variation in heart rate was corrected by 
the normalization time duration by the respective R-R interval. 
 
Conclusions 
Patients with HfpEF exhibits increased myocardial contractile inefficiency. They also exhibit 
LV systolic and diastolic dyssynchrony with the LV anterior wall displaying the most delayed 
motion. 
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Table 1: Baseline characteristics of the study population 
Variables Patient Control p value 
n 38 33  
Age, years 67±9 65±6 0.20 
Female gender (%) 27 (71) 18 (55) 0.15 
BMI, kg/m2 30±4 26±4 0.003 
Race, Caucasian n (%) 38 (100) 33 (100) N/A 
CAD, n (%) 4 (11) 0 (0) N/A 
Diabetes mellitus, n (%) 2 (5) 0 (0) N/A 
Hypertension, n (%) 27 (71) 0 (0) N/A 
LVH, n (%) 19 (50) 0 (0) N/A 
Medication    
Loop diuretics, n (%) 12 (32) 0 (0) N/A 
ACEi or ARB, n (%) 24 (63) 0 (0) N/A 
Beta – blockers, n (%) 7 (18) 0 (0) N/A 
Nitrates, n (%) 3 (8) 0 (0) N/A 
Calcium antagonist, n (%) 12 (32) 0 (0) N/A 
Antiplatelet agents, n (%) 13 (34) 0 (0) N/A 
Statins, n (%) 20 (59) 0 (0) N/A 
Resting heart rate, b.p.m 79±15 79±14 0.87 
QRS duration, ms 90±16 94±14 0.25 
Resting SBP, mmHg 137±21 134±21 0.49 
Resting DBP, mmHg 82±11 81±11 0.67 
VO2max, ml/kg/min 21±5 34±7 <0.001 
RER 1.07±0.09 1.09±0.09 0.31 
VE/VCO2 33±6 28±3 <0.001 
Breathing reserve, L/min 36±15 40±15 0.29 
Peak SBP, mmHg 181±24 191±24 0.12 
Peak DBP, mmHg 82±13 88±11 0.07 
Peak heart rate, b.p.m 136±18 163±9 <0.001 
 
Data expressed as mean±SD. BMI - body mass index, CAD – coronary artery disease, DBP – 
diastolic blood pressure, RER – respiratory exchange 
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Table 2: Echocardiographic Measurements of Diastolic and Systolic function 
Variables Patient Control p value 
EF, % 64%±10% 63%±7% 0.62 
IVRT, ms 140±29 151±26 0.16 
MV E velocity, cm/s 0.71±0.17 0.64±0.12 <0.05 
MV A velocity, cm/s 0.83±0.18 0.66±0.15 <0.001 
E/A ratio 0.88±0.31 1.00±0.26 0.09 
Dct, ms 256±62 246±66 0.52 
TDI peak S' velocity, cm/s 0.08±0.02 0.09±0.03 0.06 
TDI peak E' velocity, cm/s 0.07±0.02 0.09±0.02 <0.001 
TDI peak A' velocity, cm/s 0.10±0.03 0.10±0.03 0.68 
E/E' 11±4 7±2 <0.001 
Global Longitudinal strain, % -17.6±3.3 -19.9±3.5 0.006 
 
Data expressed as mean±SD. Dct – Deceleration time of early mitral inflow EF – ejection 
fraction, IVRT – isovolumic relaxation time, MV A – peak Doppler late mitral inflow, MV E – 
peak Doppler of early mitral inflow and TDI – Tissue Doppler imaging of the lateral mitral 
annulus for systolic wave (S’), early diastolic wave (E’) and late diastolic wave (A’). 
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Table 3: Left ventricular strain delay index and synchronicity as measured by STI 
Variables Patient Control p Value 
Strain Delay Index      
Longitudinal (%) -14.36± 8.24 -10.73± 5.62 <0.05 
Circumferential (%) -7.67±5.48 -5.45±4.26 0.12 
Radial (%) 4.80±6.34 2.27±2.39 0.05 
      
Longitudinal, Circumferential and Radial strain      
      
Time to peak  longitudinal strain (Ts-LS), RR 0.403±0.116 0.400±0.040 0.86 
Ts-LS-SD 0.075±0.044 0.084±0.049 0.42 
Time to peak  circumferential strain (Ts-Circ), RR 0.435±0.071 0.453±0.093 0.43 
Ts-Circ-SD 0.064±0.026 0.053±0.027 0.14 
Time to peak  radial strain (Ts-Rad), RR 0.458±0.103 0.472±0.083 0.61 
Ts-Rad-SD 0.042±0.037 0.047±0.049 0.70 
     
Longitudinal velocity      
      
Time to peak systolic velocity (Ts), RR 0.169±0.041 0.159±0.034 0.31 
Ts-SD (RR) 0.074±0.026 0.060±0.023 <0.05 
Time to peak early diastolic velocity (Te), RR 0.589±0.055 0.575±0.067 0.37 
Te-SD (RR) 0.067±0.035 0.056±0.021 0.13 
Time to peak atrial diastolic velocity (Ta), RR 0.924±0.038 0.950±0.047 <0.05 
Ta-SD (RR) 0.051±0.055 0.042±0.022 0.44 
      
Longitudinal strain rates      
      
Time to peak systolic longitudinal strain rate (Ts-LSr), RR 0.182±0.040 0.176±0.034 0.56 
Ts-LSr-SD (RR) 0.071±0.021 0.063±0.025 0.16 
Time to peak early diastolic longitudinal strain rate (Te-LSr), 
RR 
0.578±0.055 0.560±0.061 0.22 
Te-LSr-SD (RR) 0.067±0.031 0.054±0.020 <0.05 
Time to peak atrial diastolic longitudinal strain rate (Ta-LSr), 
RR 
0.912±0.042 0.935±0.052 <0.05 
Ta-LSr-SD (RR) 0.050±0.055 0.043±0.024 0.55 
 
Data expressed as mean ± standard deviation (SD). Ts-LSr-SD - standard deviation of Ts-LSr, 
Te-LSr-SD - standard deviation of Te-LSr, Ta-LSr-SD - standard deviation of Ta-LSr, Ts-SD = 
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standard deviation of Ts, Te-SD - standard deviation of Te, Ta-SD - standard deviation of Ta, 
Ts-LS-SD - standard deviation of Ts-LS, Ts-Circ-SD - standard deviation of Ts-Circ and Ts-Rad-
SD - standard deviation of Ts-Rad. 
 
 
 
Data expressed as mean±SD. RR- R-R interval, Ts = time to peak systolic velocity, Te -LSr  = 
time to peak early diastolic longitudinal strain rate 
 
 
 
 
 
 
 
 
 
Figure 1 
Table 4:  Time to peak systolic velocity by segments in patients with HfpEF 
compared to controls 
Segments Patient Control P value 
Anterior, apical (RR) 0.221±0.106 0.170±0.102 0.05 
Anterior, mid (RR) 0.208±0.094 0.153±0.080 <0.05 
Anterior, basal (RR) 0.194±0.073 0.166±0.068 0.11 
Inferior, apical (RR) 0.126±0.056 0.164±0.064 <0.05 
Inferior, mid (RR) 0.134±0.043 0.141±0.047 0.53 
Inferior, basal (RR) 0.149±0.051 0.157±0.054 0.53 
Lateral, apical (RR) 0.217±0.104 0.177±0.092 0.11 
Lateral, mid (RR) 0.213±0.096 0.169±0.085 0.06 
Lateral, basal (RR) 0.209±0.104 0.189±0.080 0.38 
Septum, apical (RR) 0.100±0.034 0.139±0.066 <0.05 
Septum, mid (RR) 0.127±0.040 0.137±0.027 0.26 
Septum, basal (RR) 0.128±0.039 0.139±0.028 0.19 
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Figure 1: Longitudinal Strain delay index (LSDi) in a HfpEF patient and a healthy control: 
Demonstrating the sum of wasted energy (εpeak - εES) across 12 myocardial segments 
(colored curves) of the left ventricle. The black dotted line represents the average of all 12 
curves. There is more dispersion of each strain curve peaks in the HfpEF patient compared 
to the control, this leads to increased LSDi in HfpEF compared to control. In addition, the 
average longitudinal strain is lower in the HfpEF patient compared to the control. ES – end 
systole, εpeak – peak strain, εES – strain at end systole.  
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Chapter V 
 
Impaired Heart Rate Recovery and Chronotropic Incompetence in Patients 
with Heart Failure with Preserved Ejection Fraction 
 
Introduction  
Approximately 50% of patients with the clinical features of heart failure are found to have 
normal left ventricular ejection fraction and normal valvular function. The term heart failure 
with preserved LV ejection fraction (HfpEF) is applied to these patients. (77) They are 
typically elderly women who frequently have associated hypertension, diabetes, and/or 
coronary artery disease.  (14) They have similar hospital length of stay, admission rates (11, 
12) and mortality rate to that of patients with systolic heart failure (12). The prevalence of 
HfpEF appears to be increasing and in contrast to systolic heart failure the mortality rate of 
this disorder is not declining. (11) 
 
The pathophysiology of HfpEF has been a matter of considerable controversy. Impaired left 
ventricular relaxation, increased passive left ventricular stiffness and contractile dysfunction 
(despite the presence of a normal left ventricular ejection fraction) each appear to 
contribute to exercise limitation.  However one recent study in HfpEF reported an 
associated between an impaired heart rate (HR) response to exercise and exercise 
limitation. (77) However there are a number of important caveats. Firstly, the patients were 
mainly African American hypertensives and the relevance to HfpEF in a Caucasian 
population is unknown. Secondly, the patient numbers were relatively small. Thirdly, many 
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of the patients (and the hypertensive controls without breathlessness) were taking beta 
blockers. Although these were discontinued 24 hours prior to the study the potential of 
either ongoing beta blockade (chronotropic incompetence (201)) or of rebound effects (202) 
to have influenced the findings cannot be excluded. Thus, in this study we aimed to assess 
HR response to exercise and during recovery in a larger group of patients with HfpEF who 
were not taking beta-blockers using maximal symptom limited erect treadmill metabolic 
exercise testing.  
 
Methods 
Study Participants 
HfpEF patients 
We studied 41 HfpEF patients prospectively and consecutively recruited from heart failure 
clinics. All study participants had clinical examination, 12-lead electrocardiogram, pulmonary 
function test, echocardiogram and metabolic exercise test. All patients met the criteria of 
Yturralde and Gaasch for the diagnosis of diastolic heart failure. (19) They had (i) signs 
and/or symptoms of heart failure, (ii) objective evidence of exercise limitation on 
cardiopulmonary exercise testing (peak VO2 <80% of predicted) with a pattern of gas 
exchange indicating a cardiac  cause for limitation  exercise capacity, (iii) normal LVEF and 
chamber size, and (iv) LV hypertrophy and/or evidence of diastolic dysfunction on Doppler  
echocardiography. Patients with severe pulmonary disease, significant valvular heart 
disease, atrial fibrillation, or evidence of hypertrophic cardiomyopathy were excluded 
similar to previous studies (77). HfpEF patients on beta-blockers or non-dihydropyridines 
calcium blockers (e.g. verapamil and diltiazem) were also excluded in order accurately 
assess chronotropic response and HR recovery. The investigations were performed at The 
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University of Birmingham with approval of the Research Ethics Committee. Informed 
consent was obtained from all subjects. 
 
Healthy controls 
We studied 41 healthy controls with no cardiac history, hypertension or diabetes mellitus. In 
addition 16 newly diagnosed hypertensive controls from the community were studied to 
explore the possibility of hypertension per se as a cause of cardiac autonomic dysfunction. 
The vast majority of these hypertensive controls were studied prior to the commencement 
of any antihypertensive therapy. None was taking heart rate lowering medication.  All 
control subjects had a normal clinical cardiovascular examination, 12-lead 
electrocardiogram, echocardiogram and metabolic exercise test. Healthy controls were 
volunteers recruited prospectively from the community. 
 
Metabolic Exercise Testing 
The metabolic exercise testing was performed on a Schiller CS-200 Ergo-Spiro exercise 
machine which was calibrated before every study. Subjects underwent spirometry and this 
was followed by symptom-limited erect treadmill exercise testing using incremental ramp 
protocol (speed and inclination was increased every minute) as described previously by our 
group (124) with simultaneous respiratory gas analysis (125, 126). Samplings of expired 
gases were performed continuously, and data were expressed as 30-second means.  The 
minute ventilation − carbon dioxide production relationship (VE/VCO2 slope), maximal 
oxygen consumption, carbon dioxide production, and respiratory exchange ratio (RER) was 
used to verify objective effort adequacy.  Peak oxygen consumption (peak VO2) was defined 
as the average values of VO2 measured during the last 30 seconds. Blood pressure and ECG 
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were monitored throughout.  Subjects were encouraged to exercise to exhaustion with a 
minimal requirement of RER > 1.  
 
Chronotropic incompetence is defined as an inadequate HR response to exercise. Two 
methods were used to assess chronotropic response. The first, was percentage of the HR 
reserve used during maximal exercise (%HHR) which was determined as the change in HR 
from rest to peak exercise as a percentage of HR reserve (the difference between the 
predicted maximal heart rate and the resting heart rate). A failure to use 80 percent of the 
HR reserve was considered to be evidence of chronotropic incompetence, (203) which is an 
independent predictor of mortality. (204) The second method was to calculate the peak 
exercise HR as a percentage of predicted maximal HR (%Max-PPHR). In this case, 
chronotropic incompetence was defined as a peak exercise HR less than 80% of the 
maximum age predicted peak HR. (205) HR recovery post exercise was defined as the 
reduction in the HR from the HR at peak exercise to the HR at one minute after the 
cessation of exercise. Abnormal HR recovery was defined as a reduction of ≤12 beats per 
minute in the first minute of exercise. (206) Predicted maximal HR for an individual was 
calculated using the more recently determined formula of Tanaka et al (208 -  0.7 x age in 
years). (207) 
 
Resting Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position with 
a Vivid 7 echocardiographic machine and a 2.5-MHz transducer.  Resting scans were 
acquired in standard apical 4-chamber and apical 2-chamber views. All echocardiographic 
measurements were averaged from 3 heart beats. LV ejection fraction was calculated from 
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LV volumes (LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV)) by the 
modified biplane Simpson rule in accordance with the guidelines. (127) From the LV-inflow 
pattern (measured at the tips of the mitral valve), peak early (E) and late (A) filling velocities, 
E/A ratio, and E-velocity deceleration time (DcT) were measured.  
 
Statistics 
Continuous variables are expressed as mean ± SD. Variances of data sets were determined 
using Levene's test. Comparisons were performed with one-way ANOVA if the data were 
normally distributed. Categorical variables were compared using the Chi-Square test. 
Pearson correlation coefficient (r) was used to describe the relationship between variables.  
A two-tailed p value of <0.05 was considered statistically significant. SPSS (v15.0) was used 
to perform the statistical analyses. 
 
Results 
Characteristics of Patients 
HfpEF Patients were generally females (70%), overweight, aged 69±8 years old with a history 
of hypertension. Healthy controls were of similar gender (63% females) and age (67±6 years 
old). (Table 1) Patients with HfpEF had significantly reduced peak VO2 compared to healthy 
controls (20±4 ml/Kg/min vs. 31±6 ml/Kg/min, p<0.001). The minute ventilation--carbon 
dioxide production relationship (VE/VCO2 slope) was also higher in patients with HfpEF than 
healthy controls (33±6 vs. 29 ± 4, p<0.001). (Table 2) 
 
Chronotropic response to maximal exercise testing 
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HfpEF patients vs. matched healthy controls had similar resting heart rate and predicted 
maximal HR, 78±14 vs. 79±13 (p=0.99) and 160±6 vs. 161±4 (p=0.53), respectively. HfpEF 
patients had lower peak HR response and lower change in HR (the difference between peak 
HR and resting HR) during peak exercise compared to matched healthy controls, 139±22 vs. 
171±18, p<0.001 and 60±22 vs. 93±21, p<0.001, respectively. (Figure 1). Chronotropic 
incompetence was significantly more common in patients with HfpEF compared to matched 
healthy controls as measured by %HHR and %Max-PPHR. In addition, abnormal HR recovery 
1-minute post exercise was also significantly more common in patients with HfpEF 
compared to matched healthy controls. (See table 3 and figure 2). Peak oxygen consumption 
(peak VO2) correlated directly with peak exercise heart rate (r=0.57, p<0.001). (Figure 3) 
Chronotropic incompetence and impaired heart recovery remained highly significant in 
patients with HfpEF when compared with hypertensive controls. There were no significant 
differences between hypertensive controls and healthy controls with respect to 
chronotropic response during peak exercise and heart rate recovery following exercise. 
 
Discussion 
The principal findings of this study are: a) HfpEF patients had similar resting and predicted 
maximal HR compared to matched-healthy controls, but during peak dynamic exercise, 
HfpEF patients displayed significant chronotropic incompetence. b) Abnormal HR recovery 
1-minute post exercise was more common in HfpEF patients compared to matched healthy 
controls.  c) Hypertensive controls showed similar chronotropic response to peak exercise 
and heart rate recovery following exercise as healthy controls. 
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Chronic heart failure is characterised by impaired exercise tolerance often due to 
breathlessness and fatigue. Metabolic exercise testing is an objective tool to measure 
exercise limitation in patients with CHF as indicated by reduced maximal oxygen 
consumption (peak VO2) and an increase in the ventilatory response to exercise (the relation 
of ventilation (VE) to carbon dioxide production (VCO2) or VE/VCO2 slope). (208) In this 
study we found that patients with HfpEF have reduced peak VO2 and higher VE/VCO2 slope 
compared to older controls, which are supported by previous reports. (209)  Indeed, 
VE/VCO2 slope has been shown to have prognostic value in patients with diastolic heart 
failure with respect to both mortality and hospitalization. (179) 
 
In healthy subjects, the initial increase in HR during exercise results from a withdrawal of 
the physiological vagal tone present at rest and sympathetic tone is responsible for further 
increases in HR as exercise continues. (210) Post exercise sympathetic withdrawal 
contributes to early HR recovery and at a later stage parasympathetic reactivation plays a 
larger role in HR recovery. (211) 
 
In chronic heart failure (CHF) associated with LV systolic dysfunction there is impaired 
autonomic function (212) as a result of an  impaired vagal tone (164) as well as an over-
activity of sympathetic function which results in reduced responsiveness to beta adrenergic 
stimulation due to both reduced adrenoreceptor number and reduced downstream 
signalling (213). The clinical sequalae of these autonomic changes include an impaired HR 
response to exercise (chronotropic incompetence) which may contribute to exercise 
limitation. (214, 215) Indeed studies have shown that as the severity of systolic heart failure 
worsens the more common chronotropic incompetence during exercise becomes in patients 
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with CHF. (216) Nevertheless, even in asymptomatic patients with reduced LVEF and LV 
dilatation poor HR response has been reported. (217) An impaired heart rate recovery 
following exercise is also common in patients with systolic heart failure (218) and appears to 
be primarily due to low vagal tone (164). Impaired HR recovery following exercise also 
appears to be a powerful predictor of mortality not only in patients with systolic heart 
failure but also predicts cardiovascular mortality in apparently healthy subjects. (206) 
 
In this study, we found HfpEF patients had lower maximal HR response during maximal 
exercise than controls, which is important because maximal HR response is associated with 
coronary disease and cardiovascular mortality. Furthermore, we found that 34% of patients 
with HfpEF have chronotropic incompetence during maximal exercise when defined by, 
%Max-PPHR and 63% when defined by %HHR. These proportions are quite similar to 
findings in patients with CHF due to systolic dysfunction. (219) HR recovery was also found 
to be impaired in a significant proportion of patients with HfpEF, which suggest the 
presence of parasympathetic imbalance. 
 
Borlaug BA et al (77) showed in hypertensives (mainly African Americans) that chronotropic 
incompetence was a powerful predictor of the presence of symptoms of heart failure. 
However, this relationship between chronotropic incompetence and HfpEF may or may not 
be causal. Chronotropic incompetence in HfpEF may be an adaptation to improve diastolic 
filling, since increasing HR by atrial pacing has been shown to reduce supine resting stroke 
volume and cardiac output in patients with HfpEF. (2)  It will be important to undertake 
further studies to assess whether HR plays a causal role in exercise limitation in HfpEF, 
because if so, this may be amenable to rate responsive pacing. 
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The precise mechanism of impaired autonomic function in HfpEF is unclear, some have 
proposed a peripheral factor responsible rather than central. (77) Studies in CHF have 
revealed a blunted baroreflex control could play an important role (220) secondary to 
reduced arterial compliance (221), impaired central reflex integration, and a decrease in 
end-organ responsiveness (220). Increased sensitivity of muscle ergoreceptors and 
peripheral chemoreceptors has also been linked to autonomic impairment in CHF. (214, 222) 
A review on this topic has been discussed by our group elsewhere. (212) 
 
Conclusions 
Patients with HfpEF have chronotropic incompetence during maximal exercise and 
abnormal heart rate recovery post exercise. 
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Table 1: Baseline characteristics of the study population 
  Healthy 
Controls 
Hypertensive 
Controls 
HfpEF 
Patients 
P Value 
n=41 n=16 n=41 
     
Females no. (%) 26 (63) 7 (43) 29 (70) 0.17 
Age (years) 67±6 68±6 69±8 0.02 
BMI no. (%) 26±4 27±3 31±4*† 0.21 
Obesity no. (%) 21 (51) 13 (81) 35 (85%) 0.003 
Hypertension no. (%) 0 16 (100) 27(68) N/A 
Ischaemic heart disease no. (%) 0 0 1(2) N/A 
Diabetes no. (%) 0 0 3(7) N/A 
NHYA functional class no. (%)     
II   34(83) N/A 
III   7(17) N/A 
     
Medications     
Diuretic 0 2 (13) 9(22) N/A 
ACE inhibitor 0 1 (6) 18(44) N/A 
ARB 0 0 7(17) N/A 
Calcium blocker 0 1 (6) 14(34) N/A 
Alpha Blocker 0 0 4(10) N/A 
Spironolactone 0 0 1(2) N/A 
Nitrate 0 0 3(7) N/A 
          
 
Plus-minus values are means ± SD. NYHA denotes New York Heart Association, ACE 
angiotensin-converting enzyme, ARB angiotensin II receptor blockers. BMI body mass index. 
Obesity defined as BMI>25. 
*P<0.05 vs. Hypertensive controls 
†P<0.05 vs. Healthy controls 
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Table 2: Metabolic exercise test and Echocardiographic parameters  
  Healthy 
Controls 
Hypertensive 
Controls 
HfpEF 
Patient 
p 
value 
n=44 n=16 n=41 
Metabolic exercise test       
     
VO2 max (ml/Kg/min) 31 ± 6 29 ± 5 20 ± 4*† <0.001 
Respiratory Exchange Ratio (RER) 1.11 ± 0.10 1.12 ± 0.09 1.07 ± 0.09 0.04 
% Predicted VO2 max 93 ± 21 84 ± 13 60 ± 10*† <0.001 
VE/VCO2 29 ± 4 30 ± 3 33 ± 6† <0.001 
Breathing Reserve (L/min) 38 ± 14 34 ± 17 35 ± 14 0.58 
Heart rate (beats/min)     
Rest 79 ± 13 87 ± 13 78 ± 14 0.07 
Peak 171 ± 18 163 ± 11 139 ± 22*† <0.001 
Systolic blood pressure (mmHg)    
Rest 135 ± 20 153 ± 16†  139 ± 21 <0.01 
Peak 190 ± 20 193 ± 21 183 ± 26 0.29 
Diastolic blood pressure (mmHg)    
Rest 82 ± 9 87 ± 9 82 ± 11 0.16 
Peak 88 ± 10 93 ± 9 82 ± 11*† <0.01 
     
Echocardiography     
     
Left ventricular ejection fraction - % 64 ± 5 63 ± 7 64 ± 10 0.88 
Mitral E-wave velocity - m/sec 0.62 ± 0.14 0.68 ± 0.16 0.66 ± 0.14 0.30 
Mitral A-wave velocity - m/sec 0.71 ± 0.15 0.80 ± 0.17 0.85 ± 0.19† <0.001 
Ratio of E-wave: A-wave velocity 0.93 ± 0.25 0.88 ± 0.23 0.80 ± 0.18† 0.03 
Mitral E-wave deceleration - msec 237 ± 62 250 ± 44 265 ± 64 0.13 
          
 
Plus-minus values are means ± SD. The minute ventilation − carbon dioxide production relationship 
(VE/VCO2 slope)  
*P<0.05 vs. Hypertensive controls 
†P<0.05 vs. Healthy controls 
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Table 3: Chronotropic incompetence in patients with HfpEF compared to matched controls  
  Healthy 
Controls 
(N=41) 
Hypertensive 
Controls 
(N=16) 
HfpEF 
Patients 
(N=41) 
p Value 
Chronotropic incompetence using %Max-
PPHR method, No. (%) 
1 (2) 0 (0) 14 (34) <0.001 
Chronotropic incompetence using %HHR 
method, No. (%) 
1 (2) 0 (0) 26 (63) <0.001 
Abnormal heart rate recovery, No. (%) 1 (2) 1 (2) 9 (23) 0.01 
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Figure 1 
 
 
 
 
 
 
Figure 1: Differences in heart rate response during exercise and post exercise in patients 
with HfpEF, hypertensive controls and healthy controls. (Only significant differences are 
shown) 
*p<0.05  
†p<0.001  
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Figure 2 
 
 
 
Figure 2: Abnormal chronotropic response in patients with HfpEF compared to hypertensive 
controls and healthy controls during exercise. Panel A: chronotropic incompetence in HfpEF 
patients as measured by % of heart rate reserved used at peak exercise (%HHR). Panel B: 
chronotropic incompetence in HfpEF patients as measured by peak exercise HR as a 
percentage of predicted maximal HR (%Max-PPHR). 
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Figure 3 
 
 
 
Figure 3: Peak oxygen consumption correlating directly with peak exercise heart rate. Black 
dots – HfpEF patients, triangles – hypertensive controls and squares – healthy 
controls. 
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Chapter VI 
 
Left Ventricular Torsion and Strain patterns in Heart Failure with Normal 
Ejection Fraction are similar to Age-related changes 
 
Introduction 
Heart failure with normal ejection fraction (HfnEF) comprises approximately half of patients 
with clinical features of chronic heart failure (11) with hospital admission/readmission rates 
and length of stay similar to that of patients with systolic heart ‘failure’. (12) These patients 
are often overweight or obese elderly women who frequently have associated hypertension, 
diabetes, and/or coronary artery disease. (12) The prevalence of HfnEF appears to be 
increasing and mortality rate is only a little less than that of systolic heart failure. (11) Many 
patients with HfnEF have diastolic dysfunction, a feature that is also commonly found in 
normal aging. (223) No study has attempted to directly compare the physiological changes 
in LV torsion and untwist associated with aging and those found in patients with HfnEF. This 
is important because of the potentially significant overlap in the two processes especially 
when it comes to diagnosis and understanding the pathophysiology of HfnEF. In this study, 
we aim to investigate what features of LV biomechanics e.g. LV torsion and untwist as well 
as LV strains, are related to HfnEF and which are age-related changes. We used 2D 
ultrasound speckle-tracking echocardiography (STE) to noninvasively evaluate LV torsion 
and untwist in young and older healthy volunteers as well as in patients with HfnEF. STE 
estimation of LV torsion has been shown to be concordant with those analyzed by tagged 
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magnetic resonance imaging (MRI). (224) Metabolic exercise testing was used to objectively 
measure exercise capacity in patients with HfnEF and healthy controls. 
 
Method 
Study Participants 
HfnEF patients 
We studied 40 HfnEF patients prospectively and consecutively recruited from heart failure 
clinics. All study participants had clinical examination, 12-lead electrocardiogram, pulmonary 
function test, echocardiogram and metabolic exercise test. All patients had signs and/or 
symptoms of heart failure with a LV ejection fraction >50% by transthoracic 
echocardiography and met the criteria of Yturralde and Gaasch (19) for diastolic heart 
failure. Patients with severe pulmonary disease, significant valvular heart disease, atrial 
fibrillation, or evidence of hypertrophic cardiomyopathy were excluded similar to previous 
studies (77). Pulmonary function test was performed to identify patients with severe 
pulmonary disease. The investigations were performed at The University of Birmingham 
with approval of the Research Ethics Committee. Informed consent was obtained from all 
subjects. 
Healthy controls 
We studied 53 healthy controls with no cardiac history, no hypertension or diabetes 
mellitus. 27 healthy controls were under the age of 50 yrs and they were classified as young 
controls, the remainder were classified as older controls (n= 26). All healthy controls had a 
normal clinical cardiovascular examination, 12-lead electrocardiogram and metabolic 
exercise test. They were healthy volunteers from the community. 
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Metabolic Exercise Testing 
 
The metabolic exercise testing was performed on a Schiller CS-200 Ergo-Spiro exercise 
machine which was calibrated before every study. Subjects underwent spirometry and this 
was followed by symptom-limited erect treadmill exercise testing using incremental ramp 
protocol (speed and inclination was increased every minute) with simultaneous respiratory 
gas analysis (125, 126). Samplings of expired gases were performed continuously, and data 
were expressed as 30-second means.  Minute ventilation (VE/VCO2 slope), oxygen 
consumption, carbon dioxide production, and respiratory exchange ratio (RER) were 
obtained.  Peak oxygen consumption (V02max) was defined as highest value of oxygen 
consumption measured during the exercise period. Blood pressure and ECG were monitored 
throughout.  Subjects were encouraged to exercise to exhaustion with a minimal 
requirement of RER > 1. 
 
Resting Echocardiography 
Echocardiography was performed with participants in the left lateral decubitus position with 
a Vivid 7 echocardiographic machine and a 2.5-MHz transducer.  Resting scans were 
acquired in standard apical 4-chamber and apical 2-chamber views. All echocardiographic 
measurements were averaged from 3 heart beats. LV ejection fraction was calculated from 
LV volumes (LV end-diastolic volume (LVEDV) and LV end-systolic volume (LVESV)) by the 
modified biplane Simpson rule in accordance with the guidelines. (127) LVEDV and LVESV 
were indexed to body surface area (BSA). From the LV-inflow pattern (measured at the tips 
of the mitral valve), peak early (E) and late (A) filling velocities, E/A ratio, and E-velocity 
deceleration time (DcT) were measured. The isovolumic relaxation time (IVRT) was 
determined using pulsed-wave Doppler velocity data of the LV inflow. Tissue Doppler was 
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applied end-expiratory in the pulsed-wave Doppler mode at the level of the lateral mitral 
annulus from an apical 4-chamber view. The velocities of early diastolic wave (E’) was noted. 
Lateral mitral annulus velocities were recorded to derive E/E’.  Parasternal circular short-axis 
images were taken at three distinct levels: LV basal level with the cross section as circular as 
possible (identified by the mitral valve), papillary and apical (no papillary muscles present) 
similar to previous studies. (190) Area-length method was used to determine LV mass 
indexed to BSA. (127)  Left ventricular hypertrophy was defined as a left ventricular mass 
indexed to BSA that exceeded 88g/m2 for women and 102g/m2 for men.(127) 
 
Speckle Tracking Echocardiography (STE) 
STE was measured using a commercially available speckle tracking system in an ECHOPAC 
(ver. 4.2.0, GE, USA) workstation.  Myocardial deformation measurements were performed 
using tissue speckle tracking. In this speckle tracking system, the displacement of speckles of 
myocardium in each spot were analyzed and tracked from frame to frame.  We selected the 
best-quality digital two-dimensional image cardiac cycle  and the left ventricle endocardium 
was traced at end-systole.(129).  The region of interest width was adjusted as required to fit 
the wall thickness.  The software package then automatically tracked the motion through 
the rest of the cardiac cycle.  The onset of QRS complex was taken as the beginning of 
systole.  To adjust for intra- and inter-subject differences in heart rate, all time intervals 
were normalised to R-R interval by expressing the time interval as a percentage of the R-R 
interval (% RR). Adequate tracking was verified in real time.  Regarding adequate tracking 
quality, the system (ECHOPAC (ver. 4.2.0, GE, USA)) automatically generates an acceptable 
or unacceptable tracking quality. We systematically accepted only segments that received 
an acceptable tracking quality for analysis with visual control  of tracking quality to 
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ensure adequate automatic tracking. This was done by verifying adequate tracking quality of 
endocardial and epicardial borders by the system. To optimize speckle tracking, two-
dimensional gray-scale harmonic images were obtained at a frame rate of 70 – 100 
frames/s. For each subject, longitudinal strain values for all LV myocardial segments in each 
of the apical 4 and 2 chamber views were measured and averaged to derive the global LV 
longitudinal strain, strain rates and velocity. Circumferential strain values were obtained in 
all 18 segments of the three short-axis views. The average of peak systolic circumferential 
strain values from the three short-axis views was calculated to derive the global LV 
circumferential strain and strain rates. Similarly, peak radial strain values were measured in 
all 18 segments at the three short-axis views and averaged to derive the global radial strain 
and strain rates.  
 
In addition, cardiac rotation was computed using speckle tracking. Counter-clockwise 
rotation was marked as a positive value and clockwise rotation as a negative value when 
viewed from the apex. In order to calculate LV torsion, LV untwist and untwist rates, the 
rotation traces of the basal and apical LV cross-sections were exported into DPlot graph 
software (Version 2.2.1.4, HydeSoft Computing, LLC, Vicksburg, USA). The LV twist curve was 
generated by calculating the difference between apical and basal rotations at each 
corresponding time point. LV twist rates were derived from the first derivative of the LV 
twist curve. Peak LV torsion was derived from LV twist divided by LV diastolic longitudinal 
length as previously described. (130) Rotational deformation delay was also determined and 
defined as the magnitude of the time difference between time to peak basal rotation and 
time to peak apical rotation. (130) Peak untwist rate at the E wave was used to determine 
peak untwist rate as described in previous studies.  (190) Of the 93 subjects in the study, 63 
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(68%) subjects had both adequate LV basal and apical images for speckle tracking to 
complete analysis of all LV rotational parameters, which is comparable to previous studies. 
(130) 
 
Reproducibility of STE 
Inter-observer measurement variability was determined by two independent observers who 
measured LV torsion in 10 randomly selected controls. To obtain the intra-observer 
variability, the first observer performed the analysis at two separate occasions at 1 month 
apart.  We performed Bland-Altman plots to assess reproducibility of measurement. Our 
results showed that for LV torsion, intra-observer reproducibility was 0.24 ± 0.58 (bias ± 
1.96 standard deviation of the difference (STD)) with a mean of 3.06°/cm and 2.82°/cm. 
Inter-observer reproducibility was 0.15 ± 0.69 (bias ± 1.96 STD) with a mean of 2.82°/cm and 
2.67°/cm. 
 
Statistics 
Continuous variables are expressed as means ± SD. Comparisons were performed with one-
way ANOVA if the data were normally distributed. Categorical variables were compared 
with Pearson Chi-Square test. A P value of <0.05 was considered to indicate statistical 
significance. Variances of data sets were determined using F-test. Pearson correlation 
coefficient (r) was used to describe the relationship between variables. All subjects were 
included into the model. Bland Altman plot was used to assess data reproducibility using 
MedCalc (v9.2.1.0). Variables of interest that were found to correlate with the dependent 
variable on univariate analysis were included in a stepwise linear regression analysis to 
identify independent variables. SPSS (v15.0) was used to perform most of the statistical 
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operations. 
 
Results 
Patient characteristics 
Patients with HfnEF were generally females, overweight, mean aged of 67 ± 10 with a high 
prevalence of hypertension, which has been similarly described in previous large 
epidemiological studies (12). HfnEF patients also had significantly reduced VO2max and 
reduced peak HR on metabolic exercise testing compared to older controls (see table 1).  
The E/E’ at the lateral mitral annulus was significantly higher in patients than in older 
controls (see table 2).  
 
Longitudinal, radial and circumferential strains  
 Aging 
Global longitudinal, radial and circumferential strains were preserved with advancing age. 
However, longitudinal strain rate E was lower and longitudinal strain rate A was higher with 
aging. Longitudinal velocity (peak S and E) was also significantly reduced with aging (see 
table 3).  
 HfnEF 
Compared to older controls, global longitudinal and radial strains were preserved in patients 
with HfnEF. Longitudinal strain rates and velocity were also comparable to older controls. 
However, global circumferential strain was significantly increased in patients with HfnEF 
compared to older controls (-24.7 ± 4.7 and -20.0 ± 4.9, respectively, P= 0.003). Global 
circumferential strain rate peak S and E were significantly higher in HfnEF patients 
compared to older controls. 
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LV torsion and Untwist 
 Aging 
LV torsion is significantly increased with aging (table 4). This is in part due to the time to 
peak apical rotation occurring later during systole with aging with the resulting trend of 
peak rotational deformation delay decreasing with advancing age (p= 0.07), as well as a 
trend for increased LV basal rotation with aging (p=0.07). Peak LV untwist rate was 
preserved with aging and thus the times to 15%, 25%, 50% and 75% untwist were not 
significantly delayed with aging. 
  
HfnEF 
Compared to older controls, LV torsion and peak untwist rate were preserved in patients 
with HfnEF. Peak rotational deformation delay was similar in HfnEF and older controls. 
Furthermore, the times to 15%, 25%, 50% and 75% untwist were not delayed in HfnEF 
patients when compared to older controls. (See figure 1). 
 
Associations with LV torsion 
On univariate analysis, LV torsion was significantly correlated with age, BMI, Dct, E/A ratio, 
E/E’, LVEDV Index, LVESV Index, LV mass index, VO2max, global radial strain, global 
circumferential strain and rotational deformation delay. In the multivariate analysis, a 
linear-regression model was used to examine LV torsion as the dependent variable and 
found that rotational deformation delay, global circumferential strain, Dct and LVEDV Index 
were independent predictors of LV torsion (r2= 0.65, P= 0.010, P=0.004, P=0.004 and 
P=0.045, respectively).  
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Associations with LV Untwist rate 
On univariate analysis, LV untwist rate was significantly correlated with age, BMI, Dct, E/A 
ratio, E/E’, LVEDV Index, LVESV Index, LV mass index, VO2max, global radial strain, global 
circumferential strain, rotational deformation delay, peak LV torsion. In the multivariate 
analysis, a linear-regression model was used to examine LV untwist as the dependent 
variable and found that LV torsion and BMI were independent predictors of LV untwist rate 
(r2= 0.65, P<0.001 and P=0.013, respectively).  
 
Discussion 
The principal findings of the present study are: a) LV torsion increases with advancing age 
due to in part reduced rotational deformation delay and increased LV basal rotation. 
However, LV torsion is unchanged in HfnEF compared to older controls. b) LV untwist, peak 
untwist rate, LV longitudinal and radial strain are preserved with age and in patients with 
HfnEF. c) Circumferential strain and strain rate are enhanced in patients with HfnEF. d) LV 
torsion is independently predicted by rotational deformation delay, circumferential strain 
and MV deceleration time. e) LV untwisting rate is independently determined by peak LV 
torsion and by BMI.  
LV torsion is the net result of counter-clockwise rotation of the base with respect to 
clockwise rotation of the apex along the LV long axis. Normal LV torsion is a component of 
systolic function (225) and contributes to an energy-efficient ejection (226). The subsequent 
LV untwisting is a key determinant of diastolic function (227, 228) because it helps to 
generate the intra-ventricular pressure gradient (IVPG) during isovolumic relaxation (229)  
thus creating a suction effect to allow early diastolic filling to occur once the mitral valve 
opens. (230)  In this study, we found LV torsion increased with aging consistent with 
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previous STE studies (130, 231) and tagged MRI studies (232). The reason for this increased 
LV torsion is unclear but in patients with aortic stenosis (233) and hypertrophic 
cardiomyopathy (234) where LV torsion is also enhanced, the explanation appear to be 
related to under-perfusion of the sub-endocardium leading to reduce sub-endocardial 
myofibres function which normally counteracts the LV twisting generated by the sub-
epicardial myofibres. (235) In a tagged MRI study, aging was associated with a decrease of 
contractile function in the sub-endocardium relative to that in the sub-epicardium without 
changes in ejection fraction. (236) This impairment of sub-endocardial contractile function 
may be secondary to sub-endocardial fibrosis, asymptomatic sub-endocardial infarction 
(236) or reduced sub-endocardial perfusion (237). The net effect is increased LV torsion and 
the preservation of EF in the elderly and to reduce myocardial oxygen demand (238, 239).  
 
In addition, since LV torsion is determined by instantaneous basal and apical rotation, any 
changes in the magnitude of rotational deformation delay between apex and the base of the 
LV will affect LV torsion. Indeed we found that LV torsion is independently predicted by 
rotational deformation delay as well as circumferential strain. We found in young controls 
the peak apical rotation occurs earlier than peak basal apical rotation, which may be 
explained by the start of electrical activation sub-endocardially in the right-handed helix 
near the apical septum with subsequent spread of the electrical activity towards the base. 
(240) The reduction of rotational deformation delay with aging resulted in greater LV 
torsion. This appear to be primarily because time to peak apical rotation occurs later in 
systole and closer to the timing of peak basal rotation with advancing age. The reason why 
peak apical rotation occurs later in systole and close to the timing of peak basal rotation still 
remains to be investigated but some have postulated it may be due to an increase in elastic 
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and collagenous tissue in the conduction system with aging (241) and also due to prolonged 
contraction duration (prolonged active state) (242). Other studies have indicated that the 
increased in LV torsion with aging is related to significantly increased peak apical rotation. 
(232) 
 
In this study, we found patients with HfnEF had preserved LV torsion and untwisting rate 
compared to older controls, at least at rest, which is consistent with previous studies. (190, 
243) In a study involving a heterogeneous group of patients with diastolic dysfunction (e.g. 
hypertrophic cardiomyopathy, hypertension and amyloidosis), LV twist and untwist rate 
were found to be significantly increased in patients with mild diastolic dysfunction. 
However, in patients with advanced diastolic dysfunction with increased filling pressure, LV 
torsion was normalized or reduced. (244) In addition, we found LV torsion to be an 
independent predictor of LV untwisting rate.  This is perhaps not surprising, considering 
ventricular torsion during systole provides the potential energy for the later subsequent 
rapid untwisting recoil and so therefore the greater the LV torsion the more potential 
energy is stored for subsequent higher LV untwisting rate. Interestingly, peak LV untwisting 
rate has been found to be an independent predictor of the time constant of isovolumic 
relaxation (τ) and IVPG. (245) It is possible therefore for the observed increased LV torsion 
(therefore increase potential energy for subsequent LV untwisting recoil) to be a 
compensatory mechanism for reduced ventricular relaxation associated with aging. (246) In 
patients with HfnEF, ventricular relaxation is also impaired compared to matched controls. 
(1) In this study, we find untwisting rate to be preserved with HfnEF compared to older 
controls, which would suggest that LV untwisting becomes dissociated from LV relaxation 
rate in this population. Indeed, in patients with HfnEF, τ does not correlate with untwisting 
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rate. (190) Furthermore, we found that untwisting is not delayed with aging or in patients 
with HfnEF (compared to older controls), which is reflected by the lack of significant 
differences in LV untwisting rate. We also found LV longitudinal and radial strain to be 
preserved with aging and in patients with HfnEF (compared to older controls).  
 
In this study we found that patients with HfnEF have reduced VO2max and higher VE/VCO2 
slope compared to older controls, which are supported by previous reports. (209)  Indeed, 
VE/VCO2 slope has been shown to have prognostic value in patients with diastolic heart 
failure with respect to mortality and hospitalization. (179) Furthermore, we demonstrated 
that patients with HfnEF had increased circumferential strain  and strain rate compared to 
older controls and that this was an independent predictor of LV torsion.  It may be that 
circumferential strain is a marker of compensation to sustain LV torsion in order to preserve 
ejection fraction in these patients with HfnEF. 
 
What we learn from this study is that many of the changes in LV biomechanics (e.g. LV 
torsion and untwist) in HfnEF are also present in older controls at rest. The parameters that 
do separate the two groups (i.e. patients and older controls) are the enhanced 
circumferential strain and strain rate as well as marker of increased LV end-diastolic 
pressure such as E/E’. During exercise patients with HfnEF and similar age controls can be 
clearly differentiated by VO2max and VE/VCO2 slopes. It is possible that the pathophysiology 
of HfnEF is a dynamic process with marked changes occurring on exercise and that studying 
these patients at rest might not be informative. Thus, to fully appreciate the role of LV 
torsion and untwist in the pathophysiology of HfpEF we believe that patients with HfpEF 
need to be investigated under exercise conditions.  
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Study limitations 
Our study is limited by the relatively small sample size. There were a slightly greater 
proportion of females in the HfnEF group vs. the older control group, but the differences 
were relatively small and would not be expected to influence the results significantly. 
Statistically there were no differences in age between the HfnEF group and the older control 
group. A small proportion of patients had coronary artery disease which may have affected 
LV mechanics however coronary artery disease is common in HfnEF and thus is part of the 
syndrome. (12) A proportion of patients with HfnEF were on medications which may affect 
LV function however they would be expected to affect all strain parameters not selective 
ones. 
 
Conclusions 
Aging is associated with increased LV torsion secondary to reduced rotational deformation 
delay and increased peak basal rotation. LV untwist rate, longitudinal and radial strain are 
preserved with aging. LV torsion and strain patterns in patients with HfnEF are similar to 
age-related changes apart from circumferential strain, which is enhanced in patients with 
HfnEF. Independent determinant of LV torsion are rotational deformation delay, 
circumferential strain, LVEDV Index and MV deceleration time. And, LV untwisting rate is 
independently predicted by peak LV torsion and BMI.  
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Table 1: Baseline clinical characteristics and metabolic exercise parameters of the study 
population 
Variables Young Older HfnEF P-value 
n 27 26 40  
Age, years 30 ± 8 64 ± 7† 67 ± 10 <0.001 
Female gender (%) 7 (26) 14 (54)† 29 (73)* <0.001 
BMI, kg/m2 25 ± 3 26 ± 5 30 ± 4* <0.001 
LVH, n (%) 0 5 (19) 15 (38) <0.001 
CAD, n (%) 0 0 4 (10) na 
Diabetes mellitus, n (%) 0 0 2 (5) na 
Hypertension, n (%) 0 0 29 (73) na 
Medication, n (%)     
Loop diuretics, n (%) 0 0 13 (33) na 
ACEi or ARB, n (%) 0 0 26 (65) na 
Beta – blockers, n (%) 0 0 7 (18) na 
Nitrates, n (%) 0 0 3 (8) na 
Calcium antagonist, n (%) 0 0 12 (30) na 
Antiplatelet agents, n (%) 0 0 14 (35) na 
Statins, n (%) 0 0 21 (53) na 
Resting heart rate, b.p.m 78 ± 10 82 ± 16 79 ± 15 0.498 
Resting SBP, mmHg 114 ± 10 132 ± 22† 137 ± 21 <0.001 
Resting DBP, mmHg 72 ± 8 82 ± 11† 82 ± 11 0.002 
VO2max, ml/kg/min 44 ± 7 35 ± 8† 21 ± 5* <0.001 
RER 1.28 ± 0.11 1.12 ± 0.10† 1.07 ± 0.89 <0.001 
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VE/VCO2 28 ± 4 28 ± 7 33 ± 6* <0.001 
Breathing reserve, L/min 52 ± 6 44 ± 3 36 ± 15 0.001 
peak SBP, mmHg 169 ± 19 191 ± 27† 183 ± 26 0.012 
peak DBP, mmHg 74 ± 10 84 ± 10† 83 ± 13 0.004 
peak heart rate, b.p.m 178 ± 11 164 ± 11† 136 ± 19* <0.001 
Data expressed as mean  SD. BMI - body mass index, CAD – coronary artery disease, DBP – 
diastolic blood pressure, LVH - Left Ventricular Hypertrophy, RER – respiratory exchange 
ratio, SBP – systolic blood pressure.  
*P<0.05 vs. Older group  
†P<0.05 vs. Young group 
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Table 2: Echocardiographic Measurements on Diastolic and Systolic function 
Variables Young Older HfnEF P-value 
EF, % 62 ± 5 63 ± 6 63 ± 14 0.744 
IVRT, ms 72 ± 13 149 ± 26† 139 ± 29 <0.001 
MV E velocity, cm/s 78 ± 15 62 ± 11† 71 ± 17 0.001 
MV A velocity, cm/s 50 ± 10 65 ± 14† 82 ± 20* <0.001 
E/A ratio 1.6 ± 0.3 1.0 ± 0.3† 0.9 ± 0.4 <0.001 
Dct, ms 243 ± 65 263 ± 67 253 ± 64 0.533 
LVEDV indexed , ml/ m2 49 ± 12 37 ± 12† 30 ± 8 <0.001 
LVSDV indexed , ml/ m2 19 ± 6 13 ± 4† 11 ± 5 <0.001 
LV mass Index, g/m2 67 ± 10 85 ± 12† 97 ± 18* <0.001 
E/E' 5 ± 1 8 ± 2† 11 ±4* <0.001 
Data expressed as mean  SD. Dct – Deceleration time of early mitral inflow EF – ejection 
fraction, IVRT – isovolumic relaxation time, MV A – peak Doppler late mitral inflow, MV E – 
peak Doppler of early mitral inflow, LVEDV indexed – left ventricular end diastolic volume 
indexed to body surface area (BSA), and LVSDV indexed – left ventricular end systolic 
volume indexed to body surface area (BSA)   
*P<0.05 vs. Older group 
†P<0.05 vs. Young group 
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Table 3: Global longitudinal, radial and circumferential strains 
Variables Young Older HfnEF P-value 
Global Longitudinal Strain, % -18.4 ± 2.8 -18.2 ± 2.9 -17.8 ± 3.3 0.763 
Global Longitudinal Strain Rate 
peak S, 1/sec 
-1.16 ± 0.21 -1.11 ± 0.16 -1.16 ± 0.21 0.541 
Global Longitudinal Strain Rate 
peak E, 1/sec 
1.53 ± 0.29 1.24 ± 0.33† 1.32 ±  0.28 0.002 
Global Longitudinal Strain Rate 
peak A, 1/sec 
0.83 ± 0.25 1.23 ± 0.21† 1.30 ±  0.31 <0.001 
Global Longitudinal Velocity 
peak S, cm/sec 
4.54 ± 0.72 3.73 ± 0.90† 3.72 ± 0.85 <0.001 
Global Longitudinal Velocity 
peak E, cm/sec 
-5.26 ± 1.49 -3.02 ± 1.09† -3.05 ±  0.77 <0.001 
Global Longitudinal Velocity 
peak A, cm/sec 
-3.16 ± 0.96 -4.35 ± 0.94† -4.24 ±  1.09 <0.001 
Global Radial Strain, % 31.6 ± 9.5 28.3 ± 10.1 21.8 ± 10.5 0.006 
Global Radial Strain Rate Peak S, 
1/sec 
1.36 ± 0.30 1.4 ± 0.34 1.47 ± 0.28 0.518 
Global Radial Strain Rate Peak E, 
1/sec 
-1.41 ± 0.42 -1.39 ± 0.43 -1.71 ± 0.43 0.033 
Global Radial Strain Rate Peak A, 
1/sec 
-0.62 ± 0.23 -1.41 ± 0.50† -1.21 ± 0.39 <0.001 
Global Circumferential Strain, % -17.6 ± 3.6 -20.0 ± 4.9 -24.7 ±  4.7* <0.001 
Global Circumferential Strain 
Rate Peak S, 1/sec 
-1.46 ± 0.27 -1.53 ± 0.27 -1.80 ± 0.31* 0.001 
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Global Circumferential Strain 
Rate Peak E, 1/sec 
1.66 ± 0.39 1.77 ± 0.64 2.29 ± 0.40* <0.001 
Global Circumferential Strain 
Rate Peak A, 1/sec 
0.67 ± 0.20 1.39 ± 0.41† 1.52 ± 0.40 <0.001 
Data expressed as mean  SD.  
*P<0.05 vs. Older group 
†P<0.05 vs. Young group 
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Table 4: LV torsion and Untwist 
Variables Young Older HfnEF P-value 
peak Apical Rotation, ° 8.5 ± 4.6 8.8 ± 5.1 10.4 ± 5.4 0.380 
Time to peak Apical rotation %RR 33 ± 12 42 ± 6† 41 ± 8 0.002 
peak Basal Rotation, ° -4.7 ± 2.6 -7.5 ± 2.7 -7.4 ± 5.0 0.025 
Time to peak Basal rotation, %RR 43 ± 14 43 ± 11 34 ± 10 0.034 
Peak rotational deformation delay 
%RR 
19 ± 14 11 ± 9 10 ± 8 0.010 
peak Torsion, °/cm 1.4 ± 0.8 2.2 ± 0.9† 2.5 ± 1.2 0.001 
Time to peak Torsion, %RR 38 ± 8 39 ± 4 40 ± 7 0.870 
peak Twist rate S, °/sec 83 ± 41 111 ± 51 111 ± 46 0.066 
Time to peak Twist rate S, %RR 19 ± 12 17 ± 7 22 ± 9 0.222 
peak Untwist rate E, °/sec -79.5 ± 40 -110 ± 35 -129 ± 55 0.002 
Time to peak Untwist rate E, %RR 49 ± 7 54 ± 8 53 ± 9 0.154 
Time to 15% Untwist, %RR 45 ± 7 48 ± 7 45 ± 6 0.361 
Time to 25% Untwist, %RR 47 ± 7 51 ± 7 48 ± 7 0.184 
Time to 50% Untwist, %RR 53 ± 11 61 ± 14 56 ± 10 0.148 
Time to 75% Untwist, %RR 62 ± 16 75 ± 18 73 ± 18 0.032 
Data expressed as mean  SD. %RR – % of R-R interval.  
*P<0.05 vs. Older group 
†P<0.05 vs. Young group 
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Figure 1 
 
Figure 1: Profiles of apical rotation, basal rotation, LV twist and LV untwist rate. 
Profiles of apical rotation, basal rotation, LV twist rate and LV untwist rate in a young 
control, older control and a patient with HfnEF, over one cardiac cycle. Notice the longer 
rotational transformation delay in the young control resulting in a lower peal LV twist 
compared to the older control. Rotational transformation delay, LV twist and untwisting 
rate in the patient with HfnEF are comparable to the older control.  
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Conclusions 
 
About 50% of patients with the clinical features of chronic heart failure suffer from heart 
failure with preserved ejection fraction (HFpEF); (10, 11) Its prevalence is increasing and 
HFpEF causes as many hospitalizations and incurs similar morbidity and almost as high 
mortality as heart failure with reduced LVEF. (11, 12) Many consider HFpEF to be a disorder 
of diastolic function (50), whilst others believe that it may be due to a combination of 
diastolic abnormalities with subtle disturbances of systolic function that are  insufficient to 
reduce LVEF. (52, 162) In addition, studies using tissue Doppler imaging (TDI) have 
demonstrated the presence of diastolic and/or systolic dyssynchrony in patients with HFpEF 
(56, 57). The typical patient with HFpEF is an elderly female with systolic hypertension due 
to increased large artery stiffness.  
 
Diastolic function is influenced by the passive elastic properties of the LV and by energy 
dependent process of active relaxation. Increased myocardial mass or changes in extra-
myocardial collagen network (50)  can cause increased LV passive diastolic stiffness at rest 
(1). Recently, Zile et al reported that patients with HFpEF had abnormal LV relaxation and 
increased LV stiffness, and that the diastolic pressure-volume relationship was also shifted 
up and to the left. (1) These data suggest that left ventricular stiffness can modulate cardiac 
function in HFpEF patients. A study by van Heerebeek et al examined shifts in titin isoform 
expression between patients with systolic and diastolic heart failure. (67) Titin is a large 
cytoskeletal protein which contributes to resting stiffness of the myocardium. (59)   In this 
small, highly selected group (n=4 with DHF, n=5 with SHF) they demonstrated a shift 
towards the stiffer N2B isoform in the DHF group and a shift towards the longer N2BA 
Pathophysiology of HfpEF 
 
[163] 
 
isoform in the SHF group when compared with previously published results from healthy 
controls. (67) This may contribute to the observed high diastolic stiffness in HfpEF. A shift to 
expression of the shorter N2B isoform in response to increased arterial stiffness would 
increase ‘contractility’ (to compensate for increased aortic impedance) at the price of 
increased LV systolic stiffness   
 
The interaction between the heart and the systemic vasculature, termed ventricular-
vascular coupling (VVC) is essential for the heart to achieve maximal cardiac work, power 
and chamber efficiency while maintaining physiological blood pressures and cardiac 
outputs. (80, 81) VVC is indexed by the ratio arterial elastance/end-systolic elastance. LV 
end-systolic stiffness (Ees) is calculated from the slope of the end-systolic pressure-volume 
relation. Arterial stiffness (Ea) is a measure of impedance and is determined by the ratio of 
systolic pressure/stroke volume. Ventricular-vascular interaction is important in the context 
of HfpEF because of its important effects on diastolic filling. (247) In patients with HFpEF, 
the resting VVC is lower than  in  younger individuals (85) but similar to asymptomatic 
hypertensive elderly patients (45, 91) and falls within a range where cardiac work and 
efficiency are not compromised. (84)  
 
Recently, Borlaug et al found that although Ea and Ees were increased in hypertensive 
patients with or without compared to control patients, in hypertensive patients increased 
Ees was associated with increased myocardial contractility; this was not the case in HfpEF 
patients where myocardial contractility was depressed, (248) suggesting that Ees in HfpEF 
patients does not necessarily reflect LV contractility (i.e. muscle mass) but rather changes in 
extra-myocardial collagen (e.g. titin (67))  and fibrosis. Indeed, Martos et al recently 
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demonstrated in that there was marked serological evidence of active fibrotic processes 
HfpEF patients. (249)   
 
However, although the resting VVC ratio is within the physiological range in patients with 
HFpEF, the absolute values of Ees and Ea are considerably elevated indicating increased 
arterial and ventricular systolic stiffness and this becomes important during exercise. In 
young healthy subjects exercise is associated with an increase in contractility and in the rate 
of LV active relaxation, although the latter is attenuated with increasing age. (73) In HfpEF 
these physiological changes on exercise are profoundly deranged and this appears central to 
the pathophysiology of the disorder. Indeed, one of our study demonstrated that changes in 
LV torsion, untwist and LV strain and strain rate in patients with HfpEF at rest were actually 
quite similar to changes found as part of normal aging process. (6) However, during 
exercise, HfpEF patients had reduced systolic and diastolic function as well as evidence of 
delayed LV untwisting and LV suction. (250) 
 
In a small study by Kitzman et al, HFpEF patients underwent invasive cardiopulmonary 
exercise testing. They found HFpEF patients exhibited a shift of the LV end-diastolic pressure 
volume relation upward and to the left at rest, and during exercise increases in LV filling 
pressure during exercise were not accompanied by increases in end-diastolic volume index 
(EDVi), indicating limitation to LV filling during exercise and a failure of the Frank-Starling 
mechanism. (74) More recently a study conducted by Kawaguchi et al, reported a dynamic 
impairment of left ventricular active relaxation during isometric (handgrip) exercise in a 
group of HFpEF patients. (58) Ennezat et al (78) found that HFpEF patients had greater 
arterial elastance response to exercise which was accompanied by reduced systolic function 
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as measured by LVEF, stroke volume and cardiac output. Similar findings were reported by 
Wachter et al, (using pressure-volume loop analysis with atrial pacing) in a small population 
of HfpEF patients (n=17) a blunted frequency-dependent increase in cardiac output 
secondary to reduced LV relaxation reserve with increased LV passive stiffness. (251) 
 
In our own study, we found using radionuclide ventriculography that during cycle exercise 
HFpEF patients demonstrated marked disturbances of ventricular-vascular coupling and of 
both systolic and diastolic function that appeared to be responsible for exercise limitation. 
LV active relaxation was paradoxically slowed (measured by the time to peak filling from the 
time activity curve). Arterial elastance fell less and ventricular end systolic elastance 
increased much less during exercise than in age matched controls, the latter indicating a 
failure of contractile reserve. (3) The impaired LV diastolic filling during exercise  may be  
partly compensated by increased left atrial contribution during the final stages of diastolic 
filling, (4) until atrial failure and eventually atrial fibrillation supervene later in the natural 
history of the disease resulting in more severe diastolic dysfunction as well as increase 
hospitalization or death. (49)  
 
 These findings suggest a potentially attractive link between increased large artery stiffness 
and exercise-induced diastolic dysfunction. Animal studies have demonstrated that a large 
acute increase in afterload in the rabbit resulted in a marked slowing of active relaxation 
and impaired left ventricular LV diastolic filling (252). However, acute increase in afterload 
required to cause a slowing of active relaxation may be much less in a diseased compared 
with a healthy heart. However, the concept of relative load, which represents the ratio of 
systolic LV pressure to isovolumetric LV pressure (165) allows for the possibility that an 
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increase in afterload required to cause a slowing of active relaxation may be much less in a 
diseased heart compared with a healthy heart. A similar systolic LV pressure represents a 
higher relative load in the failing than in the normal heart. When relative load is low, 
afterload reserve is still available allowing the heart to face increased afterload without 
slowing of LV active relaxation. When relative load is high, afterload mismatch (99) occurs 
and a pronounced slowing of LV active relaxation is observed (98).  
  
A key coupler of this load dependent LV relaxation is Troponin I – Protein Kinase A (TnI-PKA) 
phosphorylation (95). This energy dependent process of phosphorylation of Troponin I by 
PKA decreases myofibrillar calcium sensitivity (96) and increases the rate at which calcium 
dissociates from Troponin C (97) which can lead to increase rate of LV relaxation by 
increasing the rate of thin filament deactivation. We demonstrated using magnetic 
resonance spectroscopy (MRS) that HfpEF patient had substantially reduced myocardial 
energetic reserve at rest compared to controls (decreased PCr/ATP ratio).The lower PCr/ATP 
ratio in patients indicates a reduction of high energy phosphates reserve at rest. (115, 166) 
This might explain why HfpEF patients are particularly prone to impaired LV active relaxation 
during exercise and impaired contractile reserve. (3) This is consistent with a previous 
smaller study which found a deficit in myofibrillar energy delivery could contribute to heart 
failure in patients with LVH. (253) The cause for this resting energy deficit may relate to 
insulin resistance  (108), to impaired mitochondrial function as a result of ageing (113), and 
to neuro-endocrine activation and aberrant substrate metabolism. (167)  In addition, 
increased myocardial fibrosis, as previously reported serologically in patients with diastolic 
heart failure (249), may also lead to reduced PCr/ATP ratio in HfpEF patients. This is relevant 
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because in patients with HCM, reduced PCr/ATP has been shown to correlate with the 
presence of fibrotic area in the myocardium of the LV. (169) 
  
 In addition, myocardial contractile inefficiency and dyssynchrony may also be a 
contributory factor. We showed that in HfpEF there was contractile inefficiency as a result 
of systolic dyssynchrony as measured by speckle tracking imaging. Which is similar to 
previous studies that shown using TDI that LV diastolic and/or systolic dyssynchrony was 
present in 60% of HfpEF patients.  (56, 57) Studies in CHF have shown that systolic 
dyssynchrony is a strong predictor of morbidity and mortality in these patients. (197) 
Indeed, CRT which aims to correct systolic dyssynchrony have been shown to improve 
symptoms (198) and prognosis (199)   in patients with CHF. In these cases, where patients 
have CHF and broad QRS complex, it is often the lateral wall that displays the most delayed 
movement. (192) In those patients with CHF and narrow QRS complex it is actually the 
anterior wall that displays the most delayed movement, occurring in about 25% patients. 
(192) In our own study we found that the LV anterior wall appears to be the most delayed 
segment.   
 
Another issue that we had addressed, a point often overlooked as a cause of exercise 
intolerance is autonomic dysfunction. An earlier study had demonstrated chronotropic 
incompetence in HfpEF, however the subjects were on rate-limiting drugs such as beta-
blockers which causes chronotropic incompetence. (77) We studied a relatively large 
number of patients with HfpEF who were not on heart rate (HR) limiting medication and 
found that patients with HfpEF demonstrated chronotropic incompetence during peak 
metabolic exercise testing and abnormal HR recovery following exercise compared to age-
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gender-matched healthy controls and hypertensive patients. There is no doubt that 
chronotropic incompetence plays a significant role in exercise limitation in HfpEF as peak 
VO2 is essentially determined by cardiac output (CO) which is in turn is defined by HR and 
stroke volume (SV). However, it is unclear whether chronotropic incompetence is adaptive 
(increasing diastolic filling time) or maladaptive. Further studies are required to resolve this 
matter. 
 
Ultimately the aim of understanding the pathophysiology of HfpEF is to propose a new 
therapy for condition that unlike systolic heart failure has no proven therapy that improves 
morbidity and mortality. Our group has previously demonstrated the beneficial short-term 
effects of perhexiline in patients with chronic heart failure (of both ischaemic and non-
ischaemic aetiology) in a phase 2 double-blind, randomized, placebo-controlled trial. (124) 
Perhexiline works by modifying myocardial substrate utilization from free fatty acids (FFAs) 
to carbohydrates. (254) Perhexiline inhibits both carnitine palmitoyl transferase-1 (CPT-1) 
and CPT-2, which are involved in mitochondrial uptake of long chain fatty acids. This results 
in a reduction in myocardial fatty acid β-oxidation, and an increase in glucose utilization at a 
reduced oxygen cost for energy production. (255) High levels of FFA can induce 
mitochondrial uncoupling that wastes energy. (256) We found in a multi-centre study that 
perhexiline therapy provides symptomatic relief in the majority of patients (chronic heart 
failure and/or refractory angina) with minimal side effects or toxicity. (257) Our studies 
indicate a myocardial energetic impairment in HfpEF and impaired LV relaxation during 
exercise. This has formed the scientific rationale for the potential use of perhexiline in 
HfpEF. Thus, we have successfully secured a project grant from the British Heart Foundation 
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for a randomized placebo-controlled trial looking at the effectiveness of perhexiline in 
HfpEF. This trial is currently underway and is recruiting. 
 
In addition, recently there has been much interest in the drug ‘Ranolazine’ which is a late 
sodium channel inhibitor (INa). (258, 259)  This agent has very interesting diastolic properties 
and has been shown to have therapeutic benefit in conditions of diastolic dysfunction due 
to elevated cellular Na+ and Ca2 concentrations by reducing these cellular Na+ and Ca2 
concentrations. (260)  What we understand is that HfpEF is a syndrome characterized by 
increased LV passive stiffness and impaired relaxation particularly during exercise. (1, 3, 58) 
In addition, Coronary artery disease and diabetes are highly prevalent in this population and 
there is evidence indicating abnormal calcium handling which may contribute to the 
impaired diastolic function such as relaxation and stiffness. In patients with ischaemic heart 
disease, Ranolazine has been reported to cause a downward shift of the LV pressure–
volume relationship, to increase peak filling rate and to increase wall lengthening during 
isovolumic relaxation of ischaemic regions of the LV. (261, 262) It is possible that Ranolazine 
can improve LV compliance and improve LV diastolic relaxation at rest and during exercise 
(when ischaemia induced diastolic dysfunction is most likely to occur).  
 
Future studies should focus on teasing out what the primary causes of HfpEF, what are 
primary and secondary effects of the HfpEF syndrome. Impaired chronotropic response may 
be a primary event contributing to HfpEF or it could be a secondary as a result of HfpEF. 
Impaired chronotropic response is typically present in systolic heart failure and is in part a 
manifestation of impaired vagal tone; (164) or it may be an adaptation to improve diastolic 
filling. Increasing HR by atrial pacing has been shown to reduce supine resting stroke volume 
Pathophysiology of HfpEF 
 
[170] 
 
and cardiac output in patients with HfpEF. (2)  But this is not be the normal physiological 
response since these patients were supine and at rest, the response might be different if 
they were undergoing physical dynamic exercise. Possible ways to address the issue 
whether chronotropic response is a primary or secondary event are: a) design a study 
involving the drug Ivabradine (263) (suppresses the sino-atrial node) then exercise HfpEF 
patients (metabolic exercise testing) to assess changes in peak VO2. If peak VO2 does not 
change with Ivabradine compared to without, this would suggest that chronotropic 
incompetence is not a primary event. However, peak VO2 is largely determined by cardiac 
output on exercise and the latter is determined by HR and SV. It is highly likely that that VO2 
will diminish with the use of Ivabradine. b) A failure to increase HR and peak VO2 in 
response to isoprenterenol (β1 and β2 agonist) might suggest chronotropic incompetence to 
be a primary event in HfpEF. However, chronotropic incompetence is not simply a function 
of beta receptor down regulation but also impaired resting vagal tone. The initial increase in 
heart rate during exercise is a result of vagal withdrawal and when resting vagal tone is low 
this effect is diminished. 
 
The specific limitations of each study of this thesis have been discussed in detail in the 
appropriate chapters. In general, we would have liked to study a larger group of patients 
and to have better matched cohort of controls with similar co-morbidities such as 
hypertension, diabetes and/or ishaemic heart disease undergoing MUGA and MRS scans. 
However such cohort of carefully matched controls without heart failure would be in 
practice quite difficult to attain. In addition, it would have been interesting if we had more 
invasive cardiovascular measurements (to measure actual intra-cavity pressures and 
volumes) such as pressure-volume loop analysis or Swan-Ganz catheter measurements at 
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rest and during exercise. However, of course this would be difficult to gain consent from 
sufficient number of patients and has major ethical implications especially with respect to 
the control cohort. What also potentially could have been very interesting was to 
investigate cardiac energetic using MRS during exercise in order to assess whether cardiac 
energetics in terms of PCr/ATP ratio reduces further during exercise. This currently is not 
possible because of the complexity of acquiring cardiac MRS spectra during exercise at 
higher HR and problems with localization due to the movements of the heart when 
respiration rate increases upon exercise with added interference from the liver and lungs. A 
small proportion of patients in the study had coronary artery disease which may have 
affected LV mechanics however coronary artery disease is common in HfpEF, making up a  
third of the population (12) and thus could be considered as part of the clinical syndrome. It 
is possible that myocardial ischaemia can lead to impaired LV filling during exercise in HfpEF 
patients with ischaemic heart disease. This is supported by some evidence suggesting that 
statins improves survivial in HfpEF patients (264), although this may be more related to 
statins’ beneficial properties on LVH, fibrosis and arterial compliance. (265) In addition we 
cannot completely exclude the effects of microvascular disease and how it may affect LV 
systolic and diastolic function during exercise. This is an important research question which 
we have plans to study further by using adenosine stress MRI scans to measure myocardial 
perfusion reserve index, which is an marker of coronary microvascular function as 
previously used by our group. (266)  
 
In summary, work from this thesis indicates that HfpEF is defined by a) reduced myocardial 
energetics reserves, b) impaired LV relaxation during exercise, c) failure of LV to increase 
contractile function during exertion, d) impaired chronotropic response during peak 
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exercise with impaired heart rate recovery, e) enhanced left atrial contribution to LV filling 
during exercise and f) LV contractile inefficiency with systolic and diastolic dyssynchrony at 
rest. (Figure 1) 
 
Our studies suggest that the pathophysiology of the HfpEF is one of a dynamic process with 
complex interaction between various processes such as increased LV stiffness, abnormal 
myocardial energetic, increased central arterial tree stiffness, abnormal autonomic 
functions and other factors such as cardiac dyssynchrony and contractility inefficiency. (3, 4, 
6) 
 
 
 
Pathophysiology of HfpEF 
 
[173] 
 
 
 
Figure 1: Pathophysiology of heart failure with preserved ejection fraction. 
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Abbreviations 
%HHR - % of heart rate reserve used at peak exercise  
%Max-PPHR - peak exercise HR as a percentage of predicted maximal HR 
A’ - the velocities of the mitral annular late diastolic wave  
ACE - angiotensin-converting enzyme 
ARB - angiotensin II receptor blockers 
ATC - activity-time curve  
BMI - body mass index 
BSA - body surface area  
CAD – coronary artery disease 
CRT - cardiac resynchronization therapy  
DBP - diastolic blood pressure 
DcT - E-velocity deceleration time  
E/E’ - mitral E-wave velocity-E’ tissue velocity (PW-TDI) 
E’ - the velocities of the mitral annular early diastolic wave 
Ea - arterial elastance 
EDC - End diastolic count 
EDC - end-diastolic count  
EDVI - end-diastolic volume index  
Ees - left ventricular end-systolic elastance 
ES - end-systole 
ESVI - end-systolic volume index  
HfpEF - Heart failure with preserved ejection fraction 
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HR – heart rate 
IVRT - isovolumic relaxation time  
LA - left atrial  
LSDi - longitudinal strain delay index  
LV - Left ventricular 
LVEDV - left ventricular end-diastolic volume  
LVEF – left ventricular ejection fraction 
LVESV - left ventricular end-systolic volume  
LVH - left ventricular hypertrophy  
MABP - mean arterial blood pressure 
MRS - Magnetic Resonance Spectroscopy 
MV A – peak Doppler late mitral inflow 
MV E – peak Doppler of early mitral inflow 
nTTPF - Time to Peak left ventricular Filling 
NYHA- New York Heart Association 
PCr – phosphor-creatine 
peakVO2 - peak oxygen consumption  
PER - peak emptying rate  
RER - respiratory exchange ratio  
RR – values normalised for R-R interval 
S’ - the velocities of the mitral annular systolic wave  
SBP - systolic blood pressure 
SD - standard deviation  
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STE - Speckle Tracking Echocardiography  
SV - stroke volume  
SVI - stroke volume index  
Ta - peak longitudinal velocity A 
Ta –SD – standard deviation of peak longitudinal velocity A 
Ta-LSr - longitudinal strain rate A 
Ta-LSr-SD – standard deviation of longitudinal strain rate A 
TDI - Tissue Doppler imaging  
Te - peak longitudinal velocity E 
Te –SD – standard deviation of peak longitudinal velocity E 
Te-LSr - longitudinal strain rate E 
Te-LSr-SD – standard deviation of longitudinal strain rate E 
Ts - peak longitudinal velocity S 
Ts –SD – standard deviation of peak longitudinal velocity S 
Ts-Circ - time to peak circumferential strain 
Ts-Circ-SD - standard deviation of Ts-Circ 
Ts-LS - time to peak longitudinal strain 
Ts-LSr - longitudinal strain rate S 
Ts-LSr-SD – standard deviation of longitudinal strain rate S 
Ts-LS-SD - standard deviation of Ts-LS 
Ts-Rad - time to peak radial strain  
Ts-Rad-SD - standard deviation of Ts-Rad 
VCO2 - carbon dioxide production  
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VE - minute ventilation 
VE/VCO2 slope - the minute ventilation − carbon dioxide production 
relationship  
VO2 - oxygen consumption 
VVC - Vasculo-ventricular coupling  
γ-ATP  - gamma peak adenosine triphosphate 
ε - longitudinal strain 
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